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ABSTRACT
MECHANISTIC AND CLINICAL STUDIES OF PLATELET RICH PLASMA:
A SIMPLE CLINICAL METHOD FOR ENHANCING BONE
AND SOFT TISSUE HEALING

By
James L. Rutkowski
December 2008

Dissertation Supervised by David A. Johnson Ph.D.
Platelet rich plasma (PRP) is a methodology of using a patient’s own platelets to
enhance bone and soft tissue healing following oral surgical procedures. Whole blood is
drawn from the patient by conventional phlebotomy techniques and then centrifuged with
the formation of a distinct middle layer that contains platelets and white blood cells
(WBCs). This layer of platelets and WBCs is then placed into the surgical site to enable
faster and more predictable healing. This technique has also found use in general
medical surgeries and is gaining in popularity.
Platelets contain growth factors and other cytokines that are beneficial for healing
following surgical trauma. This project uses both in vitro and in vivo studies to provide
the mechanistic basis for the continued and possible expanded clinical use of PRP.
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A simple and inexpensive technique for acquiring PRP is examined and provides
evidence that during the platelet harvesting steps the platelets are properly concentrated,
not altered, and that growth factors (GFs) critical to bone formation are present.
A retrospective clinical trial provides data that illustrate a significant decrease (p <
.0001) in the frequent complication of “dry socket” (alveolar osteitis, AO) formation
following mandibular tooth extractions. The study reveals that not using PRP is a risk
factor for AO formation.
The project also utilizes a molecular study utilizing human mesenchymal stem cells
(hMSCs) to provide a mechanistic basis for bone formation following PRP use.
Enhanced proliferation and inducement of differentiation of hMSCs were found to the
possible explanations for the clinical successes reported with PRP use.
A prospective clinical study provides radiographic evidence for increased
radiographic opacity (indicating bone formation) during the initial two weeks following
placement of PRP at the time of mandibular third molar removal.
This translational research offers scientific support for the use of PRP in osseous
surgeries. The use of this simple and inexpensive PRP technique could help patients
recover faster, with fewer complications and greater bone formation predictability
following surgeries involving bone manipulation.
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Introduction
Literature Review of Platelet Rich Plasma

Improved rate and predictability of healing is a goal for various medical and dental surgical
procedures. It has become increasingly common in the clinical practice of dentistry to use
autologous platelet-rich plasma (PRP) to facilitate soft and hard tissue healing following surgical
procedures (1-8). PRP has been found to accelerate bone formation and induce healing in nonhealing wounds (8-14). These referenced techniques involve expensive techniques that require
60 to 480 mL of whole blood to be drawn from the patient, however the method examined in this
dissertation uses an inexpensive technique that requires only 5 to 10 mL of whole blood. PRP is
a generic term that has some specific variations. These variations include: platelet concentrates
(PC), concentrated platelet rich plasma (cPRP), gelled platelet rich plasma (PG), and the “buffy
coat” (BC). The terms are often erroneously interchanged and many clinicians are unaware of the
differences. Although one common aspect of all variations is a higher than normal baseline
concentration of platelets (10, 15), there are subtle, but often clinically significant, differences
between each of these blood products. The reason PRP (and its variants) is of interest is because
platelets contain growth factors (GF), which are released upon activation. The literature
pertaining to the role of growth factors in soft and hard tissue regeneration is abundant (8). PRP
was approved for clinical use in 1998 (16). Since that time several PRP variants have been used.
Review of the medical and dental literature supports (with some discrepancies) the use of
1

autologous PRP in clinical practice (16). Clinical uses of PRP are as a healing adjuvant for soft
tissue injuries, chronic diabetic foot ulcers, injuries to muscles, tendons or ligaments, distraction
osteogenesis of extremities in patients with achondroplasia/hypchondroplasia, and for increased
predictability following urologic, dental, ophthalmic, and plastic surgery procedures (17-31).
The studies of this dissertation examine a simple, cost-effective method of obtaining PRP.
The studies provide evidence of suitable platelet concentration, platelet viability, growth factor
content, positive effects on human mesenchymal stem cell (hMSC) proliferation, and positive
effects on bone development in third molar tooth extraction sites, in addition to decreased
alveolar osteitis (AO) following mandibular molar tooth removal in patients. In vitro molecular
studies also suggest that this technique may have a positive effect on hMSC differentiation down
the osteoblastic lineage. This project provides the necessary scientific basis to prove the efficacy
of a simple BC method and therefore its suitability for use in a clinical setting.

A. Platelets
Histology
Platelets are anuclear, void of genomic DNA and discoid in shape (32). They are
produced during hematopoiesis by budding off from megakaryocytes (33). Each
megakaryoctye undergoes controlled cellular fragmentation that produces 5,000 to
10,000 platelets (34). Platelets are rapidly depleted and must be replaced every 7 to 10
days (15). Unless activated, platelets circulate normally in a resting state for
approximately 7 to 9 days and are destroyed by the spleen and Kupffer cells in the liver.
Platelets contain high concentrations of cytoskeleton, signaling, membrane-bound,
protein-processing, and cytoskeletal regulatory proteins. These presynthesized proteins
are made in the megakaryocytes and packaged into granules through vesicle-trafficking
2

processes. There are other proteins synthesized from platelet mRNA during platelet
activation (35). Platelets contain RNA, mitochondria, a canalicular system (similar to an
endoplasmic reticulum), and several different types of granules. There are three main
storage compartments in platelets: lysosomes, dense granules, and α-granules. The
lysosomes contain acid hydrolases; the dense granules contain ADP, ATP, serotonin,
histamine and calcium; and the α-granules contain fibrinogen, factor V, vitronectin,
thrombospondin, von Willebrand factor (vWF) and several growth factors. Platelets
release the contents of intracellular granules in response to activation (15).

Morphology
Platelets appear in stained blood film as small, blue or colorless bodies with several
purple-red granules (34). They average about 0.5 to 3 µm in diameter, although there is a
wide variation in shape, from round to elongated, cigar-shaped forms (15, 36).

Platelet Count
Platelets are counted by enumerating particles in the unlysed whole blood sample
within a specific volume window (e.g., 2-20 fL), where volume may be measured by
electrical impedance or light scattering. Accurate platelet quantification is difficult and
presents with variation because of their small size, predisposition to aggregation and
potential overlap of platelets with more numerous red blood cells. Contemporary platelet
quantifying instruments typically create a platelet volume histogram based upon the
measured platelet size within the platelet volume window, and mathematically
extrapolate the histogram to account for platelets whose size overlaps with debris of

3

small red cells. Platelet counts show substantial ethnic variation (37). The normal
platelet count is lower in individuals of African ethnic origin (38). See Table 1 for ethnic
difference in normal leukocyte and platelet count values

4

Gender

Nationality

Men

European

Afro-

Descent

Caribbean

Women

African

European

Afro-

Descent

Caribbean

n=100

n=51

n=65

Leukocyte

n=100

n=51

5.7(3.6-9.2)

5.2(2.8-9.5)

4.5(2.8-7.2)

count*

Neutrophil

African

n=50

6.2(3.5-

5.7(3.3-9.9)

5.0(3.2-7.8)

10.8)

3.2(1.7-6.1)

2.5(1.0-5.8)

2.0(0.9-4.2)

3.6(1.7-5.5)

3.0(1.4-6.5)

2.4(1.3-4.2)

1.7(1.0-2.9)

1.9(1.0-3.6)

1.8(1.0-3.2)

1.8(1.0-3.5)

2.0(1.2-3.4)

2.0(1.1-3.6)

Monocyte

0.34(0.18-

0.33(0.18-

0.29(0.15-

0.30(0.14-

0.31(0.16-

0.28(0.15-

count

0.62)

0.52)

0.58)

0.61)

0.59)

0.39)

Eosinophil

0.12(0.03-

0.13(0.03-

0.12(0.02-

0.13(0.04-

0.10(0.03-

0.10(0.02-

count

0.48)

0.58)

0.79)

0.44)

0.33)

0.41)

Platelet count

218(143-

196(122-

183(115-

246(169-

236(149-

207(125-

332)

313)

290)

358)

374)

342)

count

Lymphocyte
count

Table 1. Ethnic Differences in Normal Leukocyte and Platelet
Count Values
All counts expressed in thousands per μL. Geometric mean and 95% reference range are
in parentheses (15).
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Function
Platelets have two distinct physical states.

Figure 1. Two States of Platelets
Platelets in their resting form (A) and at the beginning of activation (B) (39).

At rest, the platelets circulate through the vasculature as small discs of
reproducible structure having an elegant, actin-based cytoskeleton.

In response to

vascular damage or when blood flow ceases (becomes stagnant), the platelets enter a
second stage where they rapidly convert

into their active form with filopodia and

lamellipodia that derive from a remodeled actin skeleton and a sophisticated assembly of
new actin filaments (36). This change in physical state allows platelets to interact with
each other and adhere to, the injured vessel, specifically with the subendothelium. This
process is mediated by von Willebrand factor (vWF), collagen, fibrinogen,
thrombospondin, and different platelet membrane glycoproteins (Figure 2) (15, 40).

6

Figure 2. Platelet Shapes
Top-resting platelets shown as small discs. Middle - platelets increasing in size due to
vascular damage. Bottom-active platelets showing filopodia (36).

Aggregation
As platelets change their shape, they begin to aggregate which results in a hemostatic
plug (clot). Platelet aggregation is stimulated by thromboxane and α2 adrenergic
receptor-activation. Platelets adhere to each other via adhesion receptors or integrins and,
in conjunction with fibrin, to endothelial cells in the wall of the blood vessel forming the
hemostatic plug. Myosin and actin filaments within the platelets are stimulated to
contract during aggregation, further reinforcing the plug. The most abundant platelet
adhesion receptor is glycoprotein (GP)IIb/IIIa. This is a calcium-dependent receptor for
fibrinogen, fibronectin, vitronectin, thrombospondin and vWF. Activation of the
GPIIb/IIIa receptor facilitates the aggregation process, which helps generate thrombin.

7

Thrombin leads to the activation of other platelets. The GPIIb/IIIA receptor action is
further augmented by other elements secreted by platelets, such as ADP, 5-HT, collagen,
and thromboxane A2. Two other receptors involved are GPIb-V-IX complex (VWF) and
GHPVI (collagen) (40). Epinephrine is a weak platelet agonist (α2 adrenergic receptor),
but probably plays a significant role by enhancing the platelet’s response to other
agonists (15, 40).
Several inhibitory factors prevent excessive platelet aggregation. The endothelial cells
synthesize three anti-aggregation products: PGI2 (prostacyclin), PGD2, and nitric oxide.
Other important inhibitory factors include platelet-leukocyte interactions and the speed of
blood flow (15, 40).

Platelet Activation
Activation follows the aggregation process and occurs when platelets experience
several biochemical changes before secreting their active components. Platelets are
activated when brought into contact with collagen, thrombin, fibronectin, laminin,
thromboxane A2, epinephrine, ADP, a negatively charged surface (e.g. glass), and
platelet-activating factors. If whole blood is collected in a glass tube, it must contain an
anticoagulant (heparin or tri-sodium citrate) to prevent coagulation. Activation involves
specific extracellular membrane receptors that transduce the signal via G-proteins or
other mechanisms that induce intracellular signaling. Figure 3 illustrates the steps
involved in platelet activation.

8

Figure 3. Schematic Representation of Platelet Activation by
Extracellular Factors (40)
Several platelet membrane receptors bind with extracellular factors in response to platelet
adhesion and aggregation, resulting in platelet activation. GPIb in the platelet membrane
binds von Willebrand factor (vWF) and mediates adhesion. Not illustrated is a second site
on vWF that binds to GPIIb/IIIa. GPIIB-IIIa in the membrane binds fibrinogen and
mediates platelet-platelet interactions. ADP and thrombin receptors are illustrated to
show the relationship between ADP stimulation and arachidonic acid pathway (AA), with
release of thromboxane A2 (TXA2), which further stimulates aggregation. (40)
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Upon activation, granules contained within the platelets release coagulation factors,
platelet activating factors, adhesion molecules, cell-activating molecules, cytokines,
integrins, inflammatory molecules, and GFs. The release process is mediated by
molecular mechanisms homologous to other secretory cells, uniquely coupled to cell
activation by intracellular signaling events (41). Platelets in the resting state do not
expose negatively charged phospholipids on the surface. However binding to collagen
initiates a sequence of biochemical reactions that results in the activation of the
membrane protein scramblase. Scramblase transports negatively charged phospholipids
from the inner leaflet of the membrane to the outer leaflet. The presence of negatively
charged phospholipids allows the binding and the formation of a prothrombinase
complex. These phospholipids provide a catalytic surface (with the charge provided by
phosphatidylserine and phosphatidylethanolamine) for tenase and prothrombinase
complexes. The tenase complex is formed by the activated forms of the blood coagulation
factors, factor VIII and factor IX. It forms on a phospholipid surface in the presence of
calcium and is responsible for the activation of factor X. Prothrombinase is the protein
complex which consists of negatively charged phospholipid (phosphatidylserine),
prothrombin, Factors Va and Xa. The prothrombinase complex converts the inactive
protease prothrombin into thrombin, which has proteolytic activity to convert fibrinogen
into fibrin.
Some of the substances released by platelets – in particular adenosine diphosphate,
serotonin, and thromboxane, can act in an autocrine and paracrine manner to further
10

enhance platelet activation and aggregation (39). In addition, thrombin also stimulates
platelet activation producing a positive feedback loop (41).

Role of Platelets in Inflammation
Platelets, the chief cellular effectors of hemostasis, are also deployed to sites of injury
or infection to modulate inflammatory processes by interactions with leukocytes through
the secretion of cytokines, chemokines and other inflammatory mediators (42-45).
Cytokines particularly involved with healing include: transforming growth factor- 1
(TGF 1), platelet derived growth factors (PDGFs), and insulin-like growth factor
(ILGF). These cytokines and others of significance will be discussed in detail in the
discussion of α-granules.

Plasma Membrane
The platelet plasma membrane consists of a phospholipid bilayer in which cholesterol,
glycolipids, and glycoproteins are embedded (46, 47). Platelets have more intramembranous
particles embedded in the outer platelet membrane leaflet than in the inner leaflet. The greater
number of particles in the outer membrane most likely reflects the many external receptors that
mediate platelet interactions. The plasma membrane contains sodium- and calcium-adenosine
triphosphatase (ATPase) pumps that control the platelet’s intracellular ionic environment. It is
estimated that slightly over half of platelet phospholipids are contained in the plasma membrane.
When platelets are in the resting state, negatively charged phospholipids are almost exclusively
present in the inner leaflet, whereas other phospholipids are more uniformly dispersed (48).
When platelets are in the resting state the negatively charged phospholipids, including
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phosphatidylserine, are capable of initiating several steps of the coagulation sequence. Therefore,
the presence of phosphatidylserine in the inner leaflet of resting platelets sequesters them from
circulating plasma coagulation factors thereby preventing inappropriate coagulation (49, 50).
When agonists induce platelet activation, the aminophospholipids become exposed on the
platelet surface or on the surface of microparticles associated with the activation cascade (4952). The location of phospholipids in quiescent platelets is maintained by an ATP-dependent
aminophospholipid translocase that actively moves phosphatidylserine and
phosphatidylethanolamine (PE) from the outer leaflet to the inner leaflet (49, 53).

The asymmetry of the negatively charged phospholipids may also be maintained by
interactions that occur with cytoskeletal or other cytoplasmic elements (49, 50, 54, 55).

Platelet Membrane Receptors
Platelet receptors, some of which are expressed only on activated platelets (41), are
comprised of glycoproteins that receive signals from outside the platelet and transduce
them to the interior. Receptors are also activated by signals orginating inside the platelet
that affect surface domains. Membrane receptors determine the reactivity of the platelets
with a wide range of agonists and adhesive proteins.

Platelet receptors are derived from several different receptor families including
integrins, leucine-rich glycoproteins, immunoglobulin (Ig) cell adhesion molecules,
selectins, quadraspanins, and seven transmembrane (7TM) domain receptors (15). A
single member of the integrin family, αIIβ3, is thought to be exclusive to platelets, as is
GPVI. The leucine-rich glycoproteins GPIb-IX and GPV appear to have a limited
expression that includes platelets and cytokine-activated endothelial cells (56-58). The
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αIIbβ3 integrin receptor mediates interactions between platelets and between proteins and
platelets (15, 59).
αIIbβ3 (GPIIb/IIIa; Fibrinogen Receptor; CD41/CD61) Receptor
The integrin αIIbβ3 (Figure 4) is among the most densely expressed
adhesion/aggregation receptors present on any cell type, (15) and is necessary for platelet
aggregation (59). It is a heterodimeric receptor composed of an alpha chain and a beta
chain that binds fibrinogen, vWF, fibronectin, and vitronectin. Expression of the receptor
is thought to be limited to cells of the megakaryoctye lineage (59-61). The genes for the
αIIb (α chain) subunit are encoded by the gene designated ITGA2B. The β3 portion (β
chain) is encoded from the ITGB3 gene (15, 34). The αIIb chain undergoes posttranslational cleavage to yield disulfide-linked light and heavy chains that join with beta
3 to form the receptor.
The αIIbβ3 receptor not only plays a crucial role in coagulation, but is also significant
in cell-surface mediated signaling, resulting in activation. Upon activation, these
receptors are able to join the plasma membrane and undergo the release of the GFs
contained within the α-granules (62-64). On quiescent platelets, αIIbβ3 has low affinity
for fibrinogen. However when platelets are activated by ADP, epinephrine, thrombin, or
other agonists, αIIbβ3 binds fibrinogen with higher affinity (65-67). Platelet activation
induces changes in the αIIbβ3 integrin receptor that are responsible for the change in
fibrinogen-binding affinity (68-70), although changes in the environment surrounding
αIIbβ3 may also be involved. αIIbβ3 receptors in α-granules appear to cycle to and from
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the plasma membrane (70). This recycling explains the capacity of αIIbβ3 to take up
fibrinogen from plasma and transport it to α-granules, where it is concentrated (71, 72).

α2β1(GPIa-IIa; Collagen Receptor; CD49b/CD29) Receptor
Unlike the integrin αIIbβ3, α2β1 (Figure 4) is widely expressed in many cell types and
can mediate adhesion to collagen (73-79). The GPVI receptor activates α2β1, as well as
other integrins. α2β1 promotes firm adhesion of the platelet to collagen, stabilizes
thrombus growth on collagen, and promotes procoagulant activity (15, 80, 81). It is
linked to the membrane skeleton and is competent to mediate adhesion of resting platelets
(15, 82). Interestingly, activation of α2β1 can initiate protein synthesis in platelets (15,
83).

Cytoskeletal Elements
A planar network of thin, elongated spectrin tetramers interconnected by the ends of
actin filaments is present immediately below the plasma membrane of the platelet and the
membranes of the open canalicular system (15). Filamin-A (actin-bonding protein) can
interact with both the transmembrane glycoprotein (GPIbα) and the actin immediately
below the plasma membrane. This interaction connects these components to the
cytoskeleton protein spectrin (on the intracellular side of the plasma membrane) forming
a scaffolding cytoskeleton that possibly stabilizes the membrane’s discoid shape. In
addition, the association of GPIbα with the membrane skeleton restricts the expansion of
the spectrin network and probably helps to organize receptors into linear arrays on the
platelet surface, thus enhancing receptor cooperation (84).
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Figu
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Figure 4: Platelet Membrane Transmembrane Glycoproteins
Depiction of selected platelet transmembrane glycoprotein connections to the
cytoplasmic skeleton (15, 85).

Talin is another protein found in the membrane skeleton and is implicated in the
control of αIIbβ3 activation by virtue of binding to the cytoplasm domains of αIIbβ3 (61,
84, 86-89). When platelets are activated, receptors αIIbβ3 and α2β1 may bind to the
cytoskeleton as well. Therefore, the cytoskeleton may affect whether receptors are free to
move in the plane of the membrane have a role in moving certain receptors from the
surface to the interior of platelets and vice versa, via the canalicular system (84, 90).
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Microtubules
The circumferential band of microtubules present underneath the plasma membrane in
all probability plays a significant role in platelet formation from megakaryocytes and
contributes to the platelet's discoid shape (15, 34, 91-93). Microtubules are hollow
polarized polymers (25 nm diameter) that contain 13 protofilaments consisting of α, β, βtubulin dimers (15, 34, 61, 84). Four tubulin isoforms (β1, β2, β4, β5) are found in
platelets. β1 is dominant and is megakaryoctye- and platelet-specific. Approximately 50
to 60 percent of platelet tubulin is utilized in microtubules, with an equilibrium
maintained between polymerized and free tubulin subunits (34, 94). Motor proteins
associated with the microtubules contribute to the development and function of platelets
(15).

Organelles
Peroxisomes, mitochondria, lysosomes, dense bodies, exosomes, α-granules, and
ribosomes (with mRNA) are all found in platelets. Alpha-granules and ribosomes are of
particular importance to this project and are discussed below.

α-Granules
The majority of secretory substances found in platelets are localized in α-granules,
numbering approximately 50 to 80 per platelet (15, 34, 95). The α-granules are
approximately 200 nm in diameter and demonstrate internal variation in electron density,
often with an eccentric area of accentuated electron density, termed a nucleoid, in which
β-thromboglobulin, platelet factor 4 (PF4), and proteoglycans are concentrated (46). The
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less dense electron areas include tubular elements in which vWF, multimerin, and factor
V are preferentially contained (96). Table 2 lists some of the most important proteins
relevant to this research that are present in α-granules.
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Category

Term

Biological activities

Adhesive proteins

vWf + propeptide, Fg, Fn, Vn,
TSP-1, laminin-8

Cell contact interactions,
clotting, extracellular matrix
composition

Clotting factors and
associated proteins

Factor V/Va, factor XI,
multimerin, gas6, protein S,
high-molecular weight
fibrinogen, antithrombin, tissue
factor pathway inhibitor (TFPI)

Thrombin production and its
regulation, angiogenesis

Fibrinolytic factors and
associated proteins

Plasminogen, PAI-I, u-PA,
osteonectin, α2-antiplasmin,
histidine-rich glycoprotein,
TAFI, α2-macroglobulin

Plasmin production and
vascular remodeling

Proteases and anti-proteases

Tissue inhibitor of
metalloprotease-4 (TIMP-4),
metalloprotease-4, platelet
inhibitor of FIX, protease
nexin-2, C1 inhibitor, α1antitripsin

Angiogenesis, vascular
modeling, regulation of
coagulation, regulation of
cellular behavior

Growth factors, cytokines, and
chemokines

PDGF, TGFβ1,and 2, EGF,
IGF-1, VEGF (A and C), bFGF,
and FGF-2, hepatocyte GF,
RANTS, IL-8, MIP-1α, growth
regulated oncogene-α, ENA78, MCP-3, angiopoietin-1, Il1β,IGF BP-3, neutrophil
chemotactive protein

Chemotaxis, cell proliferation
and differentiation,
angiogenesis

Basic proteins and others

PF4, β-thromboglobulin,
platelet basic protein,
connective tissue activating
peptide III, neutrophil
activating peptide-2,
endostatins

Regulation of angiogenesis,
vascular modeling, cellular
interactions

Anti-microbial proteins

Thrombocidins

Bactericidal and fungicidal
properties

Others

Chondroitin 4-sulfate, albumin,
immunoglobulins

Diverse

Membrane glycoproteins

αIIbβ3, αβ3, GPIb, PECAM-1,
most plasma membrane
constituents, receptors for
primary agonists, CD40L,

Platelet aggregation and
adhesion, endocytosis of
proteins, inflammation,
thrombin generation, platelet-
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Category

Term

Biological activities

tissue factor, P-selectin

leukocyte interactions

Table 2. Contents of the Platelet α-granules
Platelet α-granule contents by category (39, 97).

Small quantities of nearly all plasma proteins are nonspecifically taken up into granules. Platelet levels of these proteins are determined by their plasma concentrations
(98, 99). This is especially significant for the -granule pool of immunoglobulins (Ig),
because the majority of total platelet Ig is affected by plasma Ig levels, rather than by
changes in platelet surface Ig (15, 98, 99).
The concentrations of the platelet-specific proteins, PF4 and the β-thromboglobulin
family members, in -granules are on the order of 20,000 times higher than their plasma
concentrations. These proteins also share amino acid sequence homology with each other
and with other members of the "intercrine-cytokine" family of molecules. Once PF4 is
released from platelets, it inhibits angiogenesis, perhaps through inhibition of endothelial
cell proliferation (100).
The α-granules also contain platelet-derived growth factor (PDGF). PDGF is a
disulfide-linked dimeric molecule of the tyrosine kinase receptor family (101). PDGF is
mitogenic for smooth muscle cells (102). After PDGF was discovered in platelets and
was given its name, other tissues were found to produce the same factor; thus, the name
platelet-derived growth factor is misleading because its presence is not limited to
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platelets. The PDGF in platelet -granules contains a mixture of a homodimer PDGFBB (30%) and a heterodimer PDGF-AB (70%). These two isoforms appear to have
different functional activities (103). Platelet-derived growth factors PDGFs (PDGF-AA,
PDGF-BB) are essential regulators for migration, proliferation and survival of
mesenchymal cell lineages. (104-106) PDGF’s function in regulating mesenchymal cell
lineages is of great importance for bone development, remodeling (104, 107) and
cicatrization (fibrous scar formation) (104, 108). PDGF may also be instrumental in
normal cell proliferation and in the development of atherosclerosis, tumor growth, wound
repair, and fibroproliferative responses (pulmonary and renal fibrosis) (109-111).

Vascular endothelial growth factor (VEGF), an important stimulator of angiogenesis,
is also found in high concentrations in α-granules. VEGF is released after platelet
stimulation during the hemostatic response to a bleeding wound (112-114). Platelets and
megakaryocytes express the gene transcript for a VEGF receptor termed KDR (115).
VEGF is the most prominent and ubiquitous of the known vascular growth promoters
(116, 117). It is instrumental in the control of endothelial cell proliferation, migration,
specialization, and survival (116, 118, 119). The singular presence of VEGF is enough to
initiate angiogenesis and the availability of different isoforms VEGF makes it possible to
direct and refine the development plan for tissue growth (46, 116, 120).

Insulin-like growth factors (ILGFs) I and II are positive regulators of proliferation
and differentiation for most cell types, including tumor cells. ILGF also is important in
the regulation of apoptosis regulation by inducing survival signals and inhibiting pro-
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apoptotic stimuli (104, 121). ILGF is released during platelet degranulation and is also
ubiquitous in circulating blood (104).
Platelet α-granules contain high concentrations of the growth factor TGF-β1. TGFis a large superfamily with more than 30 members. TGF-β is of great importance for
bone formation and is the isoform of greatest abundance not only in platelet α-granules,
but is also, important for intercellular signaling (104, 122). In vitro, the effects of TGF-β
are varied depending upon the concentration, the matrix environment and cell type.
TGF-β1 has been shown to stimulate the proliferation of osteoblasts as well as causing
their inhibition (104, 123). Despite TGF- 1’s variable effects on proliferation, for the
great majority of cell types, it represents the most powerful fibrosis inducing agent
among all cytokines (104, 124). Therefore, TGF-

1

can be considered an inflammation

regulator because of its ability to induce fibrous wound healing leading to scar formation.
Depending on the cell type being affected, TGF-β1 can promote or inhibit the growth
of cells (125). TGF-β1 can increase thrombopoietin production by bone marrow stromal
cells. Thrombopoietin, in turn, induces megakaryoctye expression of TGF-β1 receptors.
This enables TGF-β1 to arrest the maturation of megakaryoctye colony forming units
(126). TGF-β1 also promotes synthesis of extracellular matrix proteins, plasminogen
activator inhibitor-1 (PAI-1), and metalloproteinases. TGF-β1 has been implicated in
wound healing, malignancy, and tissue fibrosis (125). TGF-β1 acts as a chemoattractant
for monocytes and fibroblasts, but inhibits the migration of endothelial cells. There are
three isoforms-TGF-β1, TGF-β2, and TGF-β3- with a wide tissue distribution, but platelets
contain only TGF-β1. TGF-β1 released from platelets can stimulate smooth muscle cells
to express and release VEGF, thus supporting re-endothelialization after vascular injury
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(127). TGF-β1 is released from platelets in an inactive (latent) form that is complexed
with a portion of the precursor protein (latency-associated peptide, LAP). A fraction of
LAP is covalently coupled to another protein latent TGF-β–binding protein (LTBP),
which localizes the complex to the extracellular matrix (128). Activation of latent TGFβ1 is a multifaceted process that is thought to involve a conformational change in LAP
that unmasks the active site of TGF-β1 (128). Activation of latent TGF-β1 can be
achieved by several different mechanisms, including acidification, proteolysis by
plasmin, interaction with the integrin αVβ6, or interaction with thrombospondin-1 (TSP1) or a small peptide derived from TSP-1. However, the physiologic activator(s) remains
unclear (15, 128-130). The ability of TSP-1 to activate TGF-β1 is of special interest
because both TGF-β1 and TSP-1 are present in -granules. Only a small percentage of
the TGF-β1 released from platelets with thrombin stimulation becomes activated, but the
amount is sufficient to activate synthesis of plasminogen activator inhibitor-1(PAI-1)
(130-132). Active TGF-β1 can bind to three different cell surface proteins- a
proteoglycan (β-glycan), and two serine/threonine kinases (125, 133).
Epidermal growth factor (EGF) has also been observed in platelet α-granules, but the
kinetics of its release differs from that of other granule proteins (134).

Platelets also contain endothelial cell growth factor which stimulates endothelial cell
proliferation and angiogenesis (135). It is thought to be present in the cytoplasm of
platelets but not the α-granules. Therefore, it is released only at the time of platelet
disintegration--not stimulation.
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Ribosomes and Messenger RNA
Platelets contain a relatively small number of ribosomes and remnants of a Golgi
apparatus. Platelets also have a small amount of mRNA on platelet polysomes carried
over from megakaryocytes but cannot synthesize mRNA due to the lack of a nucleus
(136-138).

Although mRNA is present in platelets where it corresponds with

constitutively expressed factors, mRNA undergoes progressive decay due to the absence
of any new gene transcription (138, 139). Platelets contain a plethora of mitochondria,
with each containing multiple copies of its own genome that can be actively transcribed
(138, 139). Regulated synthesis of new proteins by platelets has been reported upon
thrombin activation as a result of redistribution of the eukaryotic initiation factor 4E.
Signaling produced by ligand engagement of αIIbβ3 appears to be necessary to initiate
the process of protein synthesis (83, 140, 141). One of the translated proteins is pro–ILIβ, which provides a link between thrombosis and inflammation (142). Signaling through
α2β1 (GPIa-IIa) also can initiate platelet protein synthesis (83).

Membrane Systems
The open canalicular system is an intricate series of conduits that originate as
indentations of the plasma membrane and course throughout the interior of the platelet
(91, 143). Electron microscopy of sectioned platelets demonstrates that the open
canalicular system is contiguous with the exterior of the platelet, even though elements of
the open canalicular system may appear as closed vesicles or vacuoles (91, 143, 144).
The open canalicular system serves several functions. It provides a point for entry of
external elements into the interior of the platelet and a potential means for the release of
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granule contents to the outside, eliminating the need for granule fusion with the plasma
membrane itself (144, 145). This latter purpose is particularly significant because, under
most circumstances, platelet granules move to the center of the platelet upon platelet
activation, rather than to the periphery (91, 146). However, the degree to which α
granule secretion occurs via the open canalicular system, versus direct fusion with the
plasma membrane remains unclear (91, 147). The open canalicular system is contiguous
with the platelet plasma membrane. Platelet spreading after adhesion requires a
significant increase in the surface area of the plasma membrane. New membrane cannot
be synthesized quickly enough to accommodate this phenomenon, therefore, the
membrane of the open canalicular system contributes to the suface plasma membrane
following platelet activation. The membrane of α-granules also may contribute, but only
if the stimulus is sufficient to induce the fusion of these organelles with the plasma
membrane (also known as release reaction). Lastly, the membrane of the open canalicular
system may serve as a storage site for plasma membrane glycoproteins. For example,
platelet activation by thrombin can lead to a predictable, selective loss of GPIb-IX from
the membrane surface. Electron microscopy analysis indicates the GPIb-IX becomes
sequestered into the open canalicular system (90, 148, 149). Plasmin may stimulate a
similar event (90, 150). Platelet activation leads to an increase in surface αIIbβ3, and
although much of this αIIbβ3 is thought to derive from α-granule, some may come from
αIIbβ3 in the membranes of the open canalicular system (15, 90, 151).

Platelet Secretion
Granule secretion is thought to be mediated by a contractile mechanism involving
actin and myosin, but the details remain obscure (152, 153). After an initial platelet
24

shape change, actin becomes centrally organized into thick filamentous masses, where it
most likely associates with myosin filaments (96). The contractile reaction is initiated by
an increase in cytosolic calcium, which results in the formation of a calcium–calmodulin
complex that activates myosin light-chain kinase. Phosphatases and cyclic adenosine
monophosphate (cAMP) kinase modulate the reaction. The centralization of organelles in
a contractile ring correlates with secretion (15, 91). However, as stated earlier, it is
unclear if platelets secrete the contents of their granules by fusion with the open
canalicular system in the center of the platelet or by direct fusion with the plasma
membrane (91, 147). A complex multistep model for granule secretion has been
suggested in which granules tether and dock to the inner leaflet of the plasma membrane
and then additional molecular interactions lead to fusion of the lipid bilayers (15, 34, 152,
154-163).

Platelet Growth Factors in Treating Wounds and Soft-Tissue Injuries
Platelets are not only critical for hemostasis, but also in promoting tissue repair,
angiogenesis, and inflammation by releasing growth factors. Tissue repair begins with
the formation of a clot and subsequent platelet activation and degranulation that releases
inflammatory and mitogenic substances that are involved in all aspects of wound-healing
(164). The released substances include growth factors (GFs) that are necessary for
wound repair. These GFs are proteins that enhance tissue repair mechanisms including
chemotaxis, cell proliferation, angiogenesis, extracellular matrix deposition, and
remodeling (39, 165).
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More than 60 biologically active substance groups are found in platelets that are
involved in tissue-repair mechanisms such as chemotaxis, cell proliferation and
differentiation, angiogenesis, intracellular matrix deposition, immune modulation,
antimicrobial activity, and remodeling (39). Of all these substances, GFs are the most
important (Table 3).

26

Growth Factor

Function

EGF (epidermal growth factor), β-Urogastron

Stimulates the proliferation of
epidermal and epithelial cells,
fibroblasts, and embryonic cells
Chemoattractant for fibroblasts and
epithelial cells
Stimulates re-epithelialization,
augments angiogenesis
Influences the synthesis and turn-over
of extracellular matrix

PDGF (platelet-derived growth factor)

A and B isoforms are potent mitogens
for fibroblasts, arterial smooth muscle
cells, chondrocytes, and epithelial and
endothelial cells
Potent chemoattractant for
hematopoietic and mesenchymal cells,
fibroblasts, and muscle cells, stimulates
chemotaxis toward a gradient of PDGF
Activates TGF-β, stimulates neutrophils
and macrophages, mitogenesis of
fibroblasts and smooth muscle cells,
collagen synthesis, collagenase
activity, and angiogenesis

TGF-α (transforming growth factor alpha)

Resembles EGF, binds to the same
receptor
Stimulates mesenchymal, epithelia,
and endothelial cell growth, endothelial
chemotaxis, controls the epidermal
development
Stimulate the proliferation of endothelial
cells, more potent than EGF
Promotes the generation of
osteoblasts, influencing them to lay
down bone matrix during osteogenesis
Affects bone formation and remodeling
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Growth Factor

Function

TGF-α (transforming growth factor alpha)
(cont’d)

by inhibition of the synthesis of
collagen and release of calcium

TGF-β1 (transforming growth factor beta)

Stimulates fibroblast chemotaxis and
proliferation and stimulates collagen
synthesis
Decreases dermal scarring
Growth inhibitor for epithelial and
endothelial cells, fibroblasts, neuronal
cells, hematopoietic cell types, and
keratinocytes
Antagonizes the biological activities of
EGF, PDGF, aFGF and bFGF

KGF or FGF-7 (keratinocytes growth factor)

Most potent GF for skin keratinocytes,
playing a role in tissue repair following
skin injuries
Promotes wound healing via
proliferation, differentiation,
angiogenesis, and cell migration
Mitogens for many epithelial cells but
not for fibroblasts and endothelial cells

aFGF or FGF-1 (fibroblast growth factor;
acidic)

Participates in proliferation,
differentiation, angiogenesis, and cell
migration
A mitogens for skin-derived
keratinocytes, dermal fibroblasts, and
vascular endothelial cells

bFGF or FGF-2 (fibroblast growth factor; basic)

Stimulate the growth of fibroblasts,
myoblasts, osteoblasts, neuronal cells,
endothelial cells, keratinocytes, and
chondrocytes
Stimulates angiogenesis, endothelial
cell proliferation, collagen synthesis,
wound contraction, matrix synthesis,
epithelialization, and KGF production
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Growth Factor

Function

VEGF/VEP (vascular endothelial growth factor)

Stimulates the proliferation of
macrovascular endothelial cells
A strong angiogenic protein, induces
neovascularization
Induces the synthesis of
metalloproteinase, which degrades
interstitial collagen type 1,2,and 3

CTGF (connective tissue growth factor)

Induces the proliferation, migration, and
tube formation of vascular endothelial
cells and angiogenesis
A potent stimulator for the proliferation
ad differentiation of osteoblasts,
stimulates the matrix mineralization

GN-CSF or CSF-α (granulocyte/macrophage
colony-stimulating factor)

Stimulates proliferation and
differentiation of osteoblasts
Synergizes with Epo in the proliferation
of BM progenitor cells
Strong chemoattractant for neutrophils

IGF (insulin-like growth factor)

Growth factor for normal fibroblasts,
mitogenic in vitro for a number of
mesodermal cell types
Promotes the synthesis of collagenase
and prostaglandin E2 in fibroblasts
Stimulates collagen and matrix
synthesis by bone cells, regulating the
metabolism of joint cartilage

TNFα (tumor necrosis factor alpha)

Growth factor for fibroblasts
Promotes angiogenesis

IL-1βI (interleukin-1β)

Inhibits the growth of endothelial cells
and hepatocytes
Activates osteoclasts, therefore
suppresses the formation of new bone,
but in low concentrations it promotes
new bone growth
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Growth Factor

Function
Enhances inflammatory reactions and
collagenase activity

IL-8 (interleukin 8)

Supports angiogenesis mitogenic for
epidermal cells

NGF (nerve growth factor)

Responsible for the survival and
differentiation and the functional
activities of sensory and sympathetic
neurons in the peripheral nervous
system.
Play an important role in the
development and functional activities of
cholinergic neurons in the central
nervous system.
Induces the synthesis of specific
transmitter like peptides in sensory
neurons, including substance P

Table #3: Growth Factors Contained Within Platelets.
The growth factors of interest found in platelets and their function (166).

Leukocyte Cytokines of Interest
The various PRP techniques, with the exception of the leukocyte poor method, contain
concentrated white blood cells (WBCs). The WBCs contain many cytokines that are
instrumental in the inflammatory and healing processes. The BC method examined in
this project includes WBCs and therefore has an effect on the various cells types involved
in tissue injury and healing. The cytokines of relevance to bone formation are described
below.
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Interleukin-1
IL-1 is produced by activated macrophages and neutrophils. It is also produced by
endothelial cells, fibroblasts, keratinocytes, and Langerhans cells. IL-1 is a significant
mediator of inflammation (116, 167-169). It exists as 2 isoforms, α and

with IL-1

being the prevalent form. IL-1 synthesis is mediated by TNF-α, Interferons (IFN) α, ,
and , and bacterial endotoxins (116). The principle action of IL-1 is to stimulate Thelper lymphocytes. TNF-α and IL-1 are also present in the platelets and their
combination is known to activate osteoclasts and inhibit bone formation (116, 170).

Interleukin-6 (IL-6)
IL-6 is an inflammatory cytokine associated with the IL-1 /TNF-α pathway (116,
171). It is found in activated monocytes, macrophages, T and B lymphocytes,
granulocytes, fibroblasts, endothelial cells, mastocytes, chondrocytes, and osteoblasts
(116). IL-6 secretion is stimulated by IL-1, bacterial endotoxins, TNF-α, and PDGFs. It
is also self-regulating in that it can stimulate or inhibit its own synthesis (116, 172). IL-6
increases the rate of antibody secretion by 120 to 400 times and in vitro is known to
promote hematopoietic stem cell proliferation (116). IL-6 constitutes an important
amplification pathway for signaling immune cells and therefore supports the reaction
chains leading to inflammation, destruction, and remodeling of tissues (116, 173, 174).
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Tumor Necrosis Factor-α (TNF-α)
TNF-α is released during the inflammatory response induced by bacterial endotoxins.
Once stimulated by bacterial antigens, TNF-α is secreted by monocytes/macrophages,
neutrophils, polymorphonuclear leukocytes, and T lymphocytes. The production of TNFα is down-regulated by IL-6 and TGF- (116, 175). TNF-α activates monocytes,
stimulates the remodeling ability of fibroblasts, increases phagocytosis, neutrophil
cytotoxicity and modulates the expression of key mediators such as IL-1 and IL-6 (116,
176, 177).

Interleukin-4 (IL-4)
IL-4 is produced principally by the subpopulation of activated T cells (TH2, CD4+),
which also secrete IL-6 (116, 178). It supports proliferation and differentiation of the
activated B cell, but its effects are completely dependent upon the cytokine environment
(116, 179, 180). IL-4 supports the healing response by modulating inflammation. IL-4
increases fibrillary collagen synthesis by fibroblasts and inhibits stimulation of MMP-1
and MMP-3 by IL-1 (116, 181). It opposes transduction pathways mediated by IL-1 ,
such as stimulation of PGE2 synthesis (116, 182). When macrophages are treated with
IL-4 there is diminished production of IL-1 , TNF-α, and prostaglandins in response to
bacterial endotoxins or IFN- (116, 183, 184).
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B. History of PRP Use
Autologous PRP was first developed in the early 1970s as a byproduct of multicomponent apheresis. Various GFs from platelets had been discovered by that time, but
the clinical use of PRP was rarely reported in the 1980s. Historically it was principally
used in an activated gel state. PRP gel is made by the addition of thrombin and excess
calcium, which promotes both platelet activation and the coagulation cascade, resulting in
the formation of a thrombus-like gelatinous substance (platelet gel, PGEL). Activated
platelets are trapped within the fibrin network, where they secrete bioactive substances
that slowly diffuse into the surroundings tissues (39, 185-192). The use of thrombin has
recently been questioned because of the possible auto-immune responses to bovine
thrombin (193). PRP was introduced to the dental community by Whitman et al. who
hypothesized that the activation of platelets and the subsequent release of GFs would
enhance surgical wound healing (39, 194). Autologous PRP GFs had been proposed as a
treatment option for enhancing wound healing of chronic cutaneous ulcers by promoting
the formation of granulation tissue. This hypothesis was confirmed by a randomized
prospective double-blind study which demonstrated improved wound healing compared
to standard treatments (39, 195). Since the publication of the initial studies, the use of
PRP by the medical and dental communities has increased, but has often been costprohibitive for individual practitioners. Anecdotally, it is now generally accepted that the
best procedure for promoting wound healing by PRP is to prepare an autologous PRP or
PRP platelet gel (PRP/PGEL) that contains relevant GFs and to administer it directly to
the site of the surgical intervention or wounds (39, 196). The various methods for
collection of PRP are discussed elsewhere in this manuscript.
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Clinical Use of Platelet-Gel or PRP Growth Factors
PRP (and PRP/PG) use is widespread in dentistry and oral-maxillofacial surgery. It is
routinely used in conjunction with dental implant placement and bone regeneration
techniques (197, 198). It is also used in cardiovascular, renal, opthalmological,
orthopedic, and plastic surgeries. Moreover, several wound clinics use PRP or
recombinant GFs to promote healing for patients with chronic diabetic ulcerations and
other slow healing wounds. Treatment of diabetic wounds with PRP was more effective
in patients with deeper wounds than superficial lesions (39, 199). In a study of 54
diabetic patients with 86 wounds, treatment with PGEL significantly improved healing
efficacy and reduced the incidence of amputations (39, 200). Surprisingly Crovetti et al.
(201) found that patients experienced less pain when PGEL was applied to diabetic
ulcers.

It has also been reported that the use of PRP in 14 patients with skin and soft-tissue
losses caused by acute trauma or chronic pathology led to fewer infections and a
shortened length of hospital stays (202). This finding highlights the significance of the
WBCs contained in PRP and their possible role in decreasing or preventing infection.
Man et al. (27) demonstrated decreased capillary bleeding in the surgical flaps of 20
patients undergoing various cosmetic surgical procedures (face lifts, breast size changes,
or neck lifts.) PGEL or PRP is currently being used in the treatment of tendonitis, and
tendon/muscle repairs (203). A study of 100 patients who received calcified autologous
PRP matrix in the surgical treatment to reconstruct the anterior cruciate ligament had
enhanced attachment of the new articular cartilage graft (204). PGEL used in the
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treatment of chronic elbow tendonitis improved function and decreased pain when
compared to conservative standardized physical therapy protocols (205).

Each of the above studies used variants of PRP that were prepared with expensive and
time consuming techniques that limited the use and benefits of PRP use to larger
sophisticated medical centers. This dissertation examines a less expensive and time
efficient method of obtaining a variant of PRP so the benefits will be readily available for
multiple procedures in smaller out-patient clinics.

Soft Tissue Wound Healing
Soft tissue-healing is a complex process that includes coagulation, inflammation,
ground substance/matrix synthesis, angiogenesis, fibroplasias, epithelialization, wound
contraction, and subsequent remodeling. The physiological process begins immediately
upon tissue injury and includes four distinct, yet overlapping, phases: a) hemostasis, b)
inflammation, c) proliferation, and d) remodeling (164).

Hemostasis Phase
Immediately following tissue injury that includes a vascular injury, intracellular
calcium is released activating coagulation factor VII and inducing the extrinsic
coagulation cascade. Concurrently with the coagulation cascade, the arachidonic acid
pathways, and the release of GFs and cytokines work jointly to initiate and sustain the
inflammatory phase including the sequencing of cells involved in the process. Locally, a
reflex vasoconstriction occurs to facilitate hemostasis. Hemostasis is ultimately achieved
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by the formation of a fibrin plug composed of a provisional wound matrix that functions
as a lattice network upon which platelets aggregate (39, 164).

Inflammation Phase
During the early post-injury period platelets provide an abundance of GFs. These
GFs act on inflammatory cells, fibroblasts, and endothelial cells to orchestrate wound
healing including chemotaxis of neutrophils, monocytes, and fibroblasts into the wound
(39, 164, 206, 207). In the first two days of healing, the inflammatory process is initiated
by the migration of neutrophils. Neutrophils are responsible for debris scavenging,
complement-mediated opsonization of bacteria, and bacteria destruction via
myeloperoxidase (MPO)-driven oxidative burst mechanisms (i.e. superoxide and
hydrogen peroxide formation) (39). Neutrophils destroy bacteria and decontaminate the
wound by removing lymphocytes and macrophages (monocytes). The macrophages
secrete multiple enzymes including collagenases, which lead to wound debridement. The
macrophages also secrete additional GFs, which in turn stimulate fibroblasts to produce
collagen and promote angiogenesis. This step marks the transition from the
inflammatory phase to the proliferation phase of tissue reconstruction (39).

Proliferation Phase
The proliferative phase begins approximately 2 to 3 days after wounding. This phase
begins with the arrival of fibroblasts into the wound site. Fibroblasts migrate from the
wound margins by means of the fibrin-based interim matrix established during the
inflammatory phase. During the first week of healing, fibroblasts are driven by a
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macrophage-derived fraction, TGF-β, and PDGF to proliferate and synthesize
glycosaminoglycans and proteoglycans. The glycosaminoglycans and proteoglycans
become the foundation for a new extracellular matrix of granulation tissue and collagen.
(39, 164, 206) Angiogenesis and fibroplasias begin after day three, followed by the
initiation of collagen synthesis on days three to five (39, 208).

Remodeling Phase
During the remodeling phase, macrophage numbers diminish in the wound,
therefore fibroblasts become the primary source for TGF-β, PDGF, keratinocytes growth
factor (KGF) and IGF-1. Fibroblasts are the dominant cell type, reaching peak numbers
at 7 to 14 days. Once fibroblasts have secreted collagen molecules, fibroblasts then
gather them extracellularly to form collagen fibers. These collagen fibers then become
cross-linked and assembled into a bundle form. Collagen is the most important
component of acute wound connective tissue, and production continues for the next 6
weeks. Increasing amounts of wound collagen correlates with greater tissue tensile
strength (39, 206, 207). The increased tensile strength is the most significant step in
wound-healing, followed by epithelialization and finally wound remodeling (39).

During the wound-healing process, platelet GFs regulate the time-critical and
multifaceted mechanisms involved in cell-cell and cell-matrix interactions (39, 189, 206,
209). Therefore, the local application of PRP or PGEL to enhance repair of surgically
induced wounds has the benefit of providing numerous synergistically working
autologous GFs to induce proliferation of mesenchymal and other stem cells at the wound
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site (39, 210, 211). Bone formation is covered in the section titled: Osteogenesis –
Developmental Pathways for Bone Formation.

Platelet Concentrate Storage
Occasionally it is necessary to collect whole blood and process the PRP for use at a
later time point. This may be due to the complexity and extensive nature of the pending
surgery or that the patient may have difficult veins to access and the end-user facility may
not have the adequate personal to obtain the whole blood. In these situations, it becomes
necessary to store PRP for this future use. The storage of PRP for clinical use with
surgical procedures has only recently been studied. Liu et al. (212) in 2008 found that
levels of GFs in PRP that had been activated with calcium and thrombin and stored for 2
to 10 days resulted in TGF-β1 and PDGF-AB concentrations that decreased rapidly when
stored at various temperatures. When stored at -20°C and -70°C the levels declined but
were significantly higher than when stored at 4°C. Therefore if PRP is to be stored it
appears that lower temperatures (<-20°C) are preferred. The optimal storage conditions
for platelets differ from that of other blood cell types. The isolation of platelets from
other blood cells allows for the storage of the PC under optimal conditions. This
dissertation examines the effect of short-term storage (6 hours or less) at room
temperature. PRP is often collected prior to commencing the surgical procedure. The
time to final use of the PRP is dependent upon the time requirements for the intended
procedure. This may vary from as little as 15 minutes to more than 4 to 6 hours.
Therefore, it is important that clinicians have a guideline as to how long PRP (processed
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by the investigated technique) and its constituents are stable for at room temperature after
processing.

Platelet Collection for Surgical Site Application
Two major techniques are used to concentrate autologous platelets from whole blood
in the medical or dental office setting. Each method has several variations, but they can
be summarized as concentrated platelet-rich plasma (cPRP) and the buffy coat (BC)
methods (34, 213). This dissertation investigates the BC method of acquiring PRP
because it can be achieved in a time-efficient manner and with a standard clinical table
top centrifuge that creates a force of 1150 x g.

Concentrated Platelet Rich Plasma (cPRP) Collection Technique
The cPRP technique has widespread popularity in the United States (15). The cPRP
collection technique involves collecting whole blood that is anti-coagulated and is
separated by centrifugation. The separation is based on the physical properties of cells
(specific gravity, size, and deformability) in addition to the viscosity of the plasma (34).
Steps for this technique are as follows:
1. Initially 20 - 450 mL of whole blood is subject to a low g force “soft” spin that
allows for separation of the blood into 3 layers. The bottom of the tube contains
red blood cells (RBCs-55% by volume), the middle contains platelet rich plasma
(PRP-5% by volume) and the top contains platelet poor plasma (PPP-40% by
volume). This low-speed centrifugation results in a PRP layer that contains the
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majority of suspended platelets, 30 to 50% of the original total white blood cells,
and some red blood cells.

The PPP and PRP layers are transferred to a satellite container and centrifuged at
a higher g force referred to as a “hard” spin for a longer time period. This allows
for platelets to be concentrated at the bottom of the tube and to subsequently
obtain, once again, 3 distinct layers (some residual RBCs will be trapped at the
bottom of this 2nd tube).

Figure 5: Schematic Showing Concentrated PRP Collection (214).
2. It is recommended that the platelet pellet should be left undisturbed for 1 hour
prior to the next step to minimize platelet aggregation and damage (215).
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3. At this stage, it becomes easy to collect the PRP. The major portion (50 to 80%)
of the supernatant serum is now removed. Enough serum is left behind to allow
for suspension of the PRP and any remaining RBCs by gentle shaking. This now
provides concentrated PRP (cPRP), which has a rosy aspect due to the presence of
some RBCs.
4. Most techniques call for making a platelet gel (PGEL) from this suspension by the
addition of calcium and bovine thrombin. This can be achieved with the use of a
mixing syringe. Gelling of platelet concentrate will then occur quickly.
Fibrinogen is also concentrated during the cPRP preparation, and its
polymerization will constitute a fibrin matrix with hemostatic and adhesive
properties.

This cPRP technique followed by gelling is a technology that is deemed new, but in
reality is similar to conventional fibrin adhesives (214, 216-232). The potential for
platelet cytokines and growth factors being released en masse during platelet activation
with bovine thrombin appear to be dependent on the time of activation and the
mechanical and biological properties of the final fibrin matrix (214, 233). Unfortunately,
many studies indicate that the clinical effects of PGEL are very near those observed with
conventional fibrin adhesives (204, 214, 216-232). Concentrated PRP gelling with
bovine thrombin and calcium chloride begins during the final stages of coagulation and
results in sudden fibrin polymerization. This mode of polymerization will considerably
influence the mechanical and biological properties of the final fibrin matrix (214, 233).
The fibrin network is a condensed tetra-molecular or bilateral junction with high
thrombin concentrations that forms a rigid network not favorable to cytokine
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enmeshment and cellular migration (Figure 6). Although PGEL should support cytokine
action, cytokines may be released too quickly to be incorporated into the fibrin.
Therefore, the released cytokines will be extrinsic, that is, trapped in the colloidal
suspension during the gelling process. Therefore, cytokine/fibrin synergies may be lost
because of rapid elimination (104). This could explain the modest clinical effects
observed with PGELs (214).

Figure 6. Rigid Fibrin Junctions
Theorectical computer model of rigid condensed tetramolecular or bilateral fibrin branch
junctions (214).

Buffy Coat Technique
The buffy coat technique is more common in Europe and is similar to the technique
studied in this project. Steps involved in the BC technique are as follows:

1. The desired quantity of whole blood is drawn and is centrifuged for 7 to 10
minutes at 3000 x g. This creates a “buffy coat” (BC) of platelets and
leukocytes. During high speed centrifugation WBCs initially sediment with
RBCs while platelets remain in the plasma supernatant. Next the RBCs become
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packed closely together and rapidly fall to the bottom of the collection vessel.
This process forces WBCs upwards to the plasma interface. The platelets in the
supernatant plasma then settle and accumulate on this interface. Interestingly,
this settling of platelets on the red cell interface may explain the lesser degree of
platelet activation when platelets are prepared in this manner as compared to the
cPRP method (234). The BC consisting of platelets and WBCs is removed
along with a small portion of the lower plasma layer and the upper red cell layer.
2. The BC is then centrifuged at low speed to separate the platelets from leukocytes
and any remaining RBCs. Collection vessel systems that have a top/bottom
separation partition facilitate separation by allowing the platelets in the BC to
remain undisturbed in the initial separation bag (with plasma and RBCs removed
from the top and bottom ports, respectively) (235).
3. The collection of platelets, now referred to as platelet rich plasma (PRP), is
transferred to a delivery device for immediate use.

Platelet rich plasma acquired by other methods are referred to generically as PRP. In
this dissertation, the technique under investigation is referred to as the “buffy coat” or BC
method and steps 2 and 3 is not followed during platelet processing. Our technique also
uses a g force of 1150 rather than 3000. Therefore, the “platelet rich plasma” of this
investigated technique is actually a combination of platelet concentrates and WBCs.

The two PRP methods (cPRP and BC) used in dental/medical offices are summarized
in the figures 7 and 8. PRP techniques that include the addition of exogenous bovine
thrombin and excessive calcium are added at the completion of the “hard” centrifugation
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seen in figure 7. One-third to one-half of the platelet poor plasma (PPP) is also added
back into the cPRP. The BC technique examined here is similar to that shown in figure
8, but does not include the “soft” centrifugation (2nd centrifugation).

Anticoagulated
whole blood
“Soft”
centrifugation

Red blood cells

Platelet-rich plasma
“Hard” centrifugation

Platelet Poor
Plasma (PPP)

Platelet-concentrate
cPRP

cPRPR

Figure 7: Preparation of cPRP
Concentrated Platelet-rich plasma (cPRP) preparation from anticoagulated whole blood
(34). To make gelled PRP at the completion of the above steps, one-third to one-half of
the platelet poor plasma (PPP) is added back into the cPRP, followed by the addition of
bovine thrombin and excess calcium.
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Anticoagulated
whole blood

“Hard” centrifugation

Plasma

Red Blood Cells

Buffy Coat (BC)

“Soft” centrifugation

Platelet concentrate – “Leukocyte
poor or depleted”

White Blood Cells and residual

Figure 8: Preparation of Buffy Coat From Anticoagulated Whole
Blood
Buffy coat (BC) preparation from anticoagulated whole blood (34). The technique
investigated in this dissertation utilizes the “hard”centrifugation at 1150 x g and does not
include the “soft” centrifugation (2nd centrifugation).

Concerns of Residual WBCs in Platelet Concentrates:
When platelets are obtained from one individual for transfusion into another
individual the presence of WBCs is of concern. WBCs from the donor can theoretically
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induce the rare, incurable, and often-fatal degenerative neurological disorder CreutzfeldJacob disease. Another benefit of using leukocyte poor PRP is a decrease in the risk of
common febrile non-hemolytic transfusion reactions such as cytomegalovirus (CMV)
transmission, and HLA alloimmunization (34, 236, 237). These complications are only
of concern if the recipient of the PRP differed from the donor. When the PRP donor and
recipient is the same individual, the presence of WBCs in the PRP is of no concern.

Zimermann et al. (238) examined whether the presence of leukocytes had an
effect on PDGF-AB, PDGF-BB, and TGF-β1 levels. The mean absolute levels of PDGFAB and PDGF-BB showed differences between leukocyte rich and leukocyte poor
preparations. Leukocyte rich PRP had significantly higher levels of PDGF-AB, PDGFBB, and TGF- β1 than leukocyte poor PRP did (P < .05). Stepwise regression analysis
revealed that platelet concentration was the most significant variable and the presence of
monocytes was a significant co-variable for predicting the variance in PDGF-BB and
TGF-β1 measurements (238).

Platelet Rich Fibrin (PRF): A Second –Generation Platelet Concentrate
A new family of platelet concentrates has recently been developed that is a cross
between an autologous fibrin glue and classical platelet concentrates. This new
biomaterial, referred to as platelet-rich fibrin (PRF), is similar to an autologous cicatricial
matrix (214). Study 2 of this dissertation examined the effect of the BC method on dry
socket formation following mandibular tooth extraction using a gelled BC technique that
is similar to PDF. The BC had been prepared as described previously and followed by
the addition ½ of the obtained PPP layer and 0.5 mL calcium chloride 10% and allowed
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to set for 10 minutes. This resulted in a fibrin gelled clot similar to this PRF platelet
concentrate described in this section. The gelled BC method collected the blood in a
glass tube containing the anti-coagulant tri-sodium citrate and the PRF method uses a
glass tube that does not contain an anti-coagulant.

Fibrin adhesives have been used for the past 30 years as adjuncts for regulating
inflammation and increasing healing following surgical procedures (214, 239). Use of
PRF has been limited due to the complexity of the production protocols for autologous
adhesives and the risk of cross-infection from commercial adhesives.
Fibrinogen is present in platelet α-granules and is instrumental in platelet aggregation
during hemostasis (214). Fibrinogen is the final substrate for all coagulation reactions
and is cleaved by thrombin to yield insoluble fibrin. The result is a polymerized gel that
constitutes the scar-like matrix for the injured site (214, 240-242). Just as in PGELs,
combining the advantages of a fibrin adhesive with the advantages of concentrated
platelets may have greater benefits to the healing process. However, since 1978 many of
the commercial fibrin adhesives have been removed from the commercial market due to
the risk of hepatitis. To avoid this complication Tayapongsak et al. (243) developed an
autologous fibrin adhesive technique in 1994 (214, 243). Due to the time and expense
commitment, this methodology never gained widespread acceptance for simple
procedures but did find a place in cardiothoracic, vascular, and plastic surgeries (214,
243, 244). The possibility of obtaining autologous growth factors from PRP or BCs
sparked interest in combining a fibrin adhesive with PRP treatment. The PRF protocol is
similar to the BC technique examined in this dissertation.
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PRF Protocol
Blood is drawn into 10 mL tubes without anticoagulant and then immediately
centrifuged in a table top centrifuge at 3000 x rpm (approximately 400 x g) for 10
minutes. Since there is no anticoagulant present, platelet activation will begin once the
blood comes in contact with the tube walls and subsequently initiate the coagulation
cascade. Fibrinogen is initially concentrated in the top and middle portions of the tube,
before circulating thrombin transforms it into fibrin. This leads to the development of a
fibrin clot in the middle of the tube, just between the red blood cells at the bottom and the
acellular plasma at the top of the tube. Platelets will theoretically be trapped in the fibrin
clot (Figures 9 and 10) (214).

Figure 9. Centrifuged Whole Blood
Result of centrifugation of whole blood by PRF protocol. The fibrin clot is shown in the
middle with the red blood cells below and the acellular plasma layer above (214).
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Figure #9 Reference:(214)

Figure 10. Protocol for Platelet Rich Fibrin Processing
A. Clinical centrifuge used for PRF protocol. B. Results of centrifugation showing fibrin
clot as PRF. C. Removal of the clot from the tube. D. Resistant autologous fibrin
membranes obtained by driving out the serum from the clot (214).
The success of the technique depends entirely upon promptly centrifuging the whole
blood after collection. Without anticoagulant the collected whole blood begins to
coagulate immediately upon coming in contact with the glass wall of the collection tube.
It takes a minimum of a few minutes of centrifugation to concentrate fibrinogen in the
middle and upper part of the tube. Efficient handling is essential to obtaining a clinically
usable PRF clot. If the time required to collect blood and to begin centrifugation is
prolonged, the fibrin will polymerize in a dispersed manner in the tube and only a small
blood clot without consistency will be obtained (214).
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PRF is different from PGELs in that it polymerizes naturally and slowly during
centrifugation.

Thrombin acts on fibrinogen to produce a fibrin mesh that has tri-

molecular or equilateral fibrin junctions.

These connected junctions allow the

establishment of a fine and flexible fibrin network capable of supporting cytokine
enmeshment and cellular migration. The trimolecular fibrin organization (Figure 11)
gives greater elasticity to the fibrin matrix in comparison to PGELs tetra-molecular or
bilateral fibrin architecture (Figure 6). This results in a flexible, elastic, and strong PRF
membrane (214).

Figure 11. Flexible Fibrin Junctions
Theorectical computer model of flexible trimolecular or equilateral fibrin branch
junctions (214).

It should also be noted that the PRF matrix enmeshes glycosaminoglycans (heparin
and hyaluronic acid) from the blood and platelets. The fibrillary architecture of fibrin is
followed, meaning that the glycanic links are incorporated within fibrin polymers.
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Glycosaminoglycans have high affinity for small circulating peptides including platelet
cytokines and therefore support cell migrations and the healing processes (104, 240).

This PRF technique has relevance to this dissertation, because Study 2 uses a gelledBC methodology that is very similar to this technique. The findings of a flexible fibrin
junction and the trapping of GFs in this matrix may explain why the results of Study 1
show stable or increasing levels of growth factors over bench set time after BC
preparation.

Bovine Thrombin
Many clinicians believe that PRP must have the platelets activated for the growth
factors to be released and made available for healing benefits to be achieved (7). The
most common method to achieve this platelet activation is with the addition of bovine
thrombin to the PRP. The BC PRP technique examined in this dissertation does not
utilize bovine thrombin for platelet activation because it may not be necessary to
exogenously activate the platelets. Activation will occur spontaneously due to the high
calcium molar concentration that is available endogenously in plasma (approximately 2
mM) plus the many other activating agonists found at the site of injury such as collagen,
thrombin, thromboxane A2, ADP, serotonin, vasopressin, thrombospondin, von
Willebrand factor, fibrinogen, PAF, immune complexes, and plasmin. (15).
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Bovine thrombin is utilized in surgical procedures because of its biological ability to
convert fibrinogen into fibrin. Thrombin is a naturally occurring enzyme that has been
widely characterized for its roles in hemostasis, inflammation, and cell signaling (193). It
has been purified from multiple sources and used as a clinical adjunct for topical
hemostasis for more than 60 years in nearly all types of surgical procedures. Thrombin is
used routinely in cardiovascular, orthopedic, neurologic, general, gynecologic, oral
surgical and dental procedures. Thrombin is also used to aid in the thrombosis of
vascular pseudo-aneurysms and for topical application at bleeding cannulation sites of
dialysis access grafts (193, 245-247). A conservative estimate is that at least 1 million
patients in the United States are treated with topical thrombin each year. Currently, the
only FDA approved stand-alone hemostatic product is a derivative from bovine sources.
Bovine-derived thrombin has potent biological activity that converts fibrinogen to fibrin,
activates platelets, and induces vascular contraction. Thrombin can also induce a robust
immune response in humans (193). There are several reports in the medical literature that
document multiple clinical events following exposure to bovine thrombin in surgical
settings (193, 248-261). These events included the development of antibodies against
thrombin, prothrombin, factor V, and cardiolipin (193). In some cases, these antibodies
cross-react with the analogous human coagulation proteins, specifically factor V,
resulting in hypocoagulopathies (256, 262, 263). Bovine thrombin is extremely
immunogenic in cardiac surgical patients, and greater than 90% of the patients who are
exposed to bovine thrombin develop a significant immunologic response. It is of even
greater concern that a significant number of these patients also develop cross-reacting
antibodies to their own endogenous coagulation proteins with associated hematologic
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abnormalities in more than 30% of these patients (193, 256). The process of breaching
self-tolerance through molecular mimicry can lead to autoimmunity (264-268). It has
been hypothesized by Lawson et al. (193) that the consequences of applying
immunologically disparate, yet biologically active, thrombin at physiologically extreme
concentrations (1000U/mL) into surgical sites may lead to direct immune recognition and
other biologic cascades, resulting in deleterious complications.

Zimmermann et al. (238) compared the effect of the adding bovine thrombin and
calcium gluconate 10% in a 1:1 mixture with PRP to untreated PRP. They found the
addition of the thrombin/calcium did not have an effect on PDGF-AB or PDGF-BB
levels when compared with untreated PRP samples. However, the addition of bovine
thrombin and calcium gluconate did cause a significant decrease in TGF-β1 levels when
compared with the untreated group (238). This finding might explain reports that PRP
mixed with bovine thrombin and calcium do not improve bone healing, but do improve
soft tissue healing (269). These reports may be explained by the following: PDGF-AB
and PDGF-BB are significant to soft tissue healing and only contribute to bone formation
when in the correct ratio with TGF-β1 levels. PDGF-AB and PDGF-BB concentrations
are unaltered by the addition of bovine thrombin, therefore the soft tissue healing
benefits would be present. However, the addition of bovine thrombin does decrease
concentrations of TGF-β1. Therefore, one could expect that bone healing maybe
diminished with the bovine thrombin formulation.

Most dental PRP procedures use a 1:10 (bovine thrombin/PRP) ratio (upwards of
1000+ units) for converting cPRP to PGEL. Because the use of bovine thrombin is
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associated with a significant risk of immunologic side effects and a potential decreased
TGF-β1 levels, its use for the production of PGELs should be questioned. The BC PRP
technique examined in this dissertation does not utilize bovine thrombin and may offer an
alternative for clinicians. If this technique is able to provide the necessary growth factors
to facilitate healing, then the continual use of bovine thrombin with its potential
autoimmune responses and decreased TGF- β1levels can be avoided.

C. Cellular Aspects of Bone Formation
Genetic Markers of Osteoblast Differentiation
Osteoblasts synthesize the macromolecules responsible for forming and
mineralizing bone matrix including type I collagen, osteocalcin, osteonectin, osteopontin,
proteoglycans I and II, bone sialoprotein, matrix gla-protein, bone glycoprotein 75, and
other proteins including growth factors (270). Additionally, osteoblasts have high levels
of the membrane-bound enzyme alkaline phosphatase, which is important in matrix
mineralization, and receptors for tissue-specific hormones, such as parathyroid hormone,
cytokines and growth factors. These molecules act in concert to regulate bone growth,
cell differentiation and metabolism. Although these proteins are not exclusive to
osteoblasts, together they characterize bone phenotype (270).

The differentiation process of osteoblasts, originating from mesenchymal
precursors, involves a complex process of timely activation of specific transcription
factors that regulate the expression of certain genes. The genes Runx2/Cbfa1 and Osterix
(Osx) are master controllers of the osteoblastic lineage, and the absence of any of these
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genes results in a complete lack of a mineralized bone (271-274). The expression of
these genes during osteoblast differentiation occurs in a stepwise fashion involving
multiple regulatory factors. Type I collagen and alkaline phosphatase are expressed early
during differentiation while osteopontin and osteocalcin appear later during
differentiation (270). The gene for bone sialoprotein (IBSP) is expressed in newly
formed osteoblasts (275). Osteocalcin gene expression follows the expression of IBSP
(276). Osteoblasts pass through many phases in the differentiation process and the geneexpression profile varies widely depending upon the stage of differentiation. Therefore,
changes in gene expression must be interpreted in a way that accounts for hMSC culture
diversity with respect to the mixture of cells that may be in various stages of
differentiation.

There are several osteoblastic cell culture models available to study the
expression of osteoblast-related genes in vitro. These models include primary cultures
from calvaria or trabecular, osteosarcoma-derived cell lines, and experimentally
immortalized cells (270). The current investigation uses a line of commercially available
human mesenchymal stem cells.

Osteocalcin Gene [BGLAP bone gamma-carboxyglutamate (gla) protein]
[Homo sapiens]
This dissertation used the osteocalcin gene as a marker of hMSC differentiation
into a mature osteoblast because it is known to be a late marker of this differentiation
(276). Osteocalcin is bone γ-carboxyglutamic acid-containing protein thought to be
produced exclusively by relatively mature osteoblasts (276, 277). Serum levels of
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osteocalcin correlate well with histomorphometric parameters of bone formation.
Osteocalcin controls hydroxyapatite crystal growth and signals osteoclast induced bone
resorption. In vitro experiments demonstrate that osteocalcin is a chemoattractant for
monocytes, which are osteoclast precursors (276-278). Osteocalcin gene expression has
been used to study cell type-specific gene expression for osteoblasts (276, 279). This
study uses the osteocalcin gene (BGLAP-Homo sapiens) as a marker of late osteoblast
differentiation.

Bone Sialoprotein Gene (IBSP: integrin-binding sialoprotein (bone
sialoprotein, bone sialoprotein II) [Homo sapiens]
This dissertation used the bone sialoprotein gene as a marker of hMSC
differentiation down the osteoblast lineage because it is known to be a middle to late
marker of this differentiation (280). Bone sialoprotein (IBSP) is a bone extracellular
matrix glycoprotein that represents 8 to 12% of the total noncollagenous proteins
associated with mineralized tissues (281-285). IBSP expression correlates with terminal
osteoblastic differentiation and the onset of bone matrix mineralization. Expression of
high levels of IBSP coincides with de novo bone formation. Bone formation results from
IBSP’s biophysical and chemical properties that include high binding affinity for calcium
and for the ability to initiate hydroxyapatite formation (275, 281, 286-291). It is well
accepted that IBSP plays a major role in bone formation and remodeling and is
considered one of the primary markers of terminally differentiated osteoblasts (288).
IBSP has cell attachment and cell signaling properties that are utilized in bone
remodeling and may also play a role in various pathologies (288).
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Bone sialoprotein mRNA is highly expressed in newly formed cuboidal
osteoblastic cells that form bone matrix (287) and is readily detectable in osteoblasts of
embryonic bone, indicating that IBSP is induced when osteoblasts are generated (275,
282). IBSP gene expression is up-regulated by hormones and cytokines that promote
bone formation and down-regulated by factors that suppress bone formation (275).

There are few cell lines that constitutively synthesize IBSP. Rat osteosarcoma
cell lines ROS17/2.8 and UMR 106-01 cells have recognized characteristics of
osteoblasts and they both express IBSP. The high levels of IBSP mRNA and the absence
of osteocalcin expression suggest that UMR 106-01 cells model newly formed
osteoblasts, whereas the lower expression of IBSP and high osteocalcin in ROS cells
model a more mature osteoblast phenotype (288, 292). The investigator examined both
osteocalcin and IBSP gene expression in this study.

Glycoprotein IIb [ITGA2B integrin, alpha 2b (platelet glycoprotein IIb of
IIb/IIIa complex, antigen CD41) [Homo sapiens]
The glycoprotein IIb gene (ITGA2B) was chosen as a marker of platelet presence
and expression would hopefully diminish with time. The PRP treatments done in this
dissertation were for a 24-hour period only and therefore should be removed with
aspiration of the PRP medium after 24 hours and what did remain would be removed
with successive growth medium changes. The ITGA2B gene encodes for the protein
integrin α-chain 2b portion of the glycoprotein IIb/IIIa. This integrin α-chain 2b is part of
a heterodimeric integral membrane protein receptor composed of an alpha chain and a
beta chain. The α-chain 2b undergoes post-translational cleavage to yield disulfide57

linked light and heavy chains that join with beta 3 to form the fibronectin receptor
expressed in platelets that plays a crucial role in coagulation. In addition to adhesion, the
glycoprotein IIb/IIIa receptor is known to participate in cell-surface mediated signaling
(293). The glycoprotein receptor and its expression are discussed in detail in the platelet
membrane glycoprotein section of this paper.

In the mouse and murine embryo, Cd41 is the initial and most explicit surface
marker that distinguishes cells that are committed to the hematopoietic lineage from
endothelial and other mesodermal cell types (294-299). However, Cd41 is expressed
only in nascent hematopoietic mouse stem cells (HMCs), whereas mature HMCs lose
Cd41 expression, with the exception of megakaryocytes and platelets which maintain it
(294, 300-302). In humans, ITGA2b gene expression is thought to be limited to
megakaryocytes and platelets (293).

GAPDH (glyceraldehyde-3-phosphate dehydrogenase; G3PD; GAPD)
Glyceraldehyde-3-phosphate dehydrogenase was chosen as the “housekeeping”
gene for this study because it is not regulated by PRP treatment. Glyceraldeye-3phosphate dehydrogenase catalyzes an essential energy-yielding step in carbohydrate
metabolism, the reversible oxidative phosphorylation of glyceraldehyde-3-phosphate in
the presence of inorganic phosphate and nicotinamide adenine dinucleotide (NAD+).
GAPDH is a tetramer of four identical chains. GAPDH is expressed in hMSCs,
differentiating osteoblasts, mature osteoblasts, leukocytes, and platelets (303-306).

Osteogenesis – Developmental Pathways for Bone Formation
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Osteogenesis is the process of bone formation. Bone is an organ that is
comprised of mineralized calcium phosphate matrix and a variety of cell types that
provide structural support for the body and play a role in bone metabolism. Bone
develops as osteoblasts - cells that produce and secrete mineralized matrix - mature and
then differentiate into osteocytes or bone lining cells or undergo apoptosis. Maturation of
osteoblasts is coupled with the breakdown of damaged bone by osteoclasts. Bone is
therefore a continually remodeled structure. The site of remodeling is the mineralized
matrix, which is also the location of the osteoclasts and osteoblasts.
Osteoclasts are large, multi-nucleated cells that are of hematopoietic origin,
differentiating from the monocyte-macrophage lineage (307). These cells are responsible
for bone resorption at sites within the osteiod of microdamage. The maturation and
differentiation of osteoclasts is directly linked with that of osteoblasts, as a balance
between bone resorption and matrix production must exist.
Osteoblasts develop from mesenchymal stem cells (MSCs) and are responsible for
secreting the calcium phosphate matrix, or osteiod found in bone (308). There are four
stages in the osteoblast life span (309, 310). The first stage is the preosteoblast, which is
located within bone one or two cell layers apart from mature bone forming osteoblasts.
For preosteoblasts to become active, they must locate to the bone surface. This is
achieved by osteoclast-induced bone breakdown. Once in position, the preosteoblast
begins to produce and secrete bone matrix proteins and is identified as an osteoblast.
After an osteoblast has ceased synthesis and mineralization of new bone, it is fated to one
of three states: osteocyte, bone-lining cell, or apoptosis. A small fraction of the
osteoblasts are ultimately embedded in the mineralized matrix of the bone and termed
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osteocytes. Osteocytes represent the final differentiation stage of the osteoblast lineage
(309, 311). Osteocytes regulate bone turnover by detecting microdamage of the bone
(309). Inactive bone surfaces are covered with post-proliferative osteoblastic cells known
as bone-lining cells. It is thought that bone-lining cells are not involved in matrix
formation, but play a role in initiating remodeling and other functions (312).
Interestingly, the total population of osteocytes and bone-lining cells does not equal the
total population of once active osteoblasts, thus suggesting that the third fate, apoptosis,
may be of importance (309, 313-316).
Other cell types that develop from mesenchymal stem cells include chondrocytes
and adipocytes (317). The osteogenic protein BMP-2 and the cytokine TGFβ1 are
examples of regulatory molecules that help mediate the commitment of the progenitor
cells to the osteoblast lineage (317). Osteoblasts are under the control of many factors
including paracrine, autocrine, and endocrine compounds that influence cell replication,
recruitment, and differentiation. These factors include bone morphogenetic proteins
(318), cell growth factors and cytokines (IGF-I, TGF-β, others) (319), hormones (GH,
insulin, glucocorticoids, 1,25 (OH)2-vitamin D3) (320), and biomechanical forces (321).

Genetic Aspects of Bone Development
Bone formation is directed by multiple genes (322). The transcriptional cascade that
regulates osteoblastogenesis is initiated by developmental signals that recruit MSCs to
organize embryonic bone via osteoblast differentiation (intramembranous bone), or MSC
condensation into a cartilage template for endochondral bone formation (323). Primary
intramembranous bone is formed from mesenchymal cells that develop directly into
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osteoblasts and is responsible for the formation of the cranial vault, facial bones, and, in
part, the clavicle and mandible (324, 325). Endochondral bone formation is responsible
for the formation of the axial and appendicular skeleton (325, 326). Endochondral bone
development is a complex process that involves a highly specific temporo-spatial pattern
in which undifferentiated MSCs differentiate into chondrocytes, and then undergo wellordered and controlled phases of proliferation, hypertrophic differentiation, death, blood
vessel invasion, and finally replacement of cartilage with bone. Fibroblast growth factors
(FGF) and parathyroid hormone/parathyroid related protein (PTH/PTHrP) are regulators
of proliferation for expansion of progenitor cell populations and growth plate maturation
during bone development (323, 324, 326). Secreted factors that have a significant impact
on bone development include the BMP/TGFβ type factors.
Several members of the TGF-β superfamily, the bone morphogenetic proteins
(BMP 2, 4, and 7) have potent osteogenic effects. It should be noted that PRP contains
TGF-β1 and BMP2 (327). Graziani et al. (328) found that various concentrations of
leucodepleted PRP activated with calcium gluconate and autologous thrombin had an
effect on hMSC proliferation and osteoblast expression of, osteocalcin, and
osteoprotegerin. In 2005, Kanno found that bovine thrombin activated PRP enhanced
both osteoblast cell proliferation and differentiation (329). This dissertation differs from
these two works because the BC PRP used in this technique was not activated with
thrombin.
The mechanism for BMP signaling is through heteromeric formation of BMP
transmembrane receptors that phosphorylate specific receptor Smad proteins resulting in
translocation to the nucleus with DNA binding Smad4 (figure 12) (323, 330-332). While
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BMP-Smad signaling is a major pathway for induction of osteoblast differentiation, it
should be noted that BMPs induce other kinase-dependent signaling pathways (e.g., p38,
MAPK, PKC, and JNK) that also contribute to Smad phosphorylation and mediate the
effects of BMP on bone formation (323, 333-340).

Figure 12. Bone Morphogenetic Protein Signaling Cascade
Bone morphogenetic protein (BMP) ligands bind to the BMP receptors BMPRI and
BMPRII. Once binding has occurred, BMPRI becomes phosphorylated and activated.
Phosphorylated BMPRI in-turn phosphorylates receptor-activated Smad proteins (RSmads), which combine with common mediator-Smad (co-Smad) and enter the nucleus.
Once in the nucleus they regulate gene expression by either transcriptional co-activators
or co-repressors (332).
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Human Mesenchymal Stem Cells (hMSCs)
Human mesenchymal stem cells (hMSCs), also referred to as marrow stromal
cells, mesenchymal progenitor cells, or colony forming-unit fibroblasts, are multipotent
cells with a long columnar or fibroblastic appearance that are present in bone marrow.
They can replicate as undifferentiated cells and then differentiate to lineages of
mesenchymal tissues that include bone, nerve, cartilage, fat, tendon, muscle, and marrow
stroma (341-344). Human MSCs’ non-hematopoeitic adult stem cells have the capacity
for renewal after trauma, disease, or aging and can be expanded ex vivo (341-344).
Expanded culture populations of hMSCs are comprised primarily of a single phenotypic
population (95% and 98% homogenous at passages 1 and 2 respectively) that can be
differentiated with high fidelity into the various tissue cell types (341, 342). These cells
can also be obtained via culture from other tissues, such as the periosteum, fat and skin
(345).
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Figure 13. A hypothesized lineage progression for MSCs from
Caplan et al. (346)
Typically, various supplements are added to stimulate the differentiation of MSCs
into the various cell types. For osteogenic differentiation, the supplements ascorbate-2
phosphate, dexamethasone, and β-glycerophosphate are added to the cell culture medium
(343). Following treatment, within 21 days the cultured cells form alkaline phosphatase
(ALP)-positive granules. Osteoblast specific genes such as Runx2, bone morphogenic
protein-2 (BMP-2), BMP-6, osteocalcin (BGLAP), bone sialoprotein (IBSP) and
osteoprotegerin are expressed as the osteoblasts mature (309).
Pittenger (341) has extensively analyzed the expression of cell-surface receptors
on hMSCs by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of
mRNA and confirmed the results by fluorescent antibodies and flow cytometry (342).
Table 4 provides examples of some hMSC surface markers.
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hMSC Surface Markers
Receptor Type

Receptors

Cytokine

IL-1R, IL-3R, IL-4R,
IL-6R, IL-7R
ICAM-1, ICAM-2,
VCAM-1, ALCAM,
Endoglin, Hyaluonate ,
Integrins α1, α2, α3, αA,
αV, β1, β2, β3, β4
BFGFR, PDGFR

Extracellular Matrix

Growth Factor
Others

Thy-1, IFNγR, TGFβR,
TNFR

Table 4. Human Mesenchymal Stem Cell Surface Markers (342).

Dissertation Outline
This dissertation includes both in vitro and clinical studies. It is divided
into 4 studies.
Study 1 is an in vitro study that validates the use of a simple clinical
table top centrifuge that creates 1150 x g. Platelet and white blood cell
concentrations with optimal centrifugation times are tested.

Platelet

morphology changes with centrifugation and bench set time are examined.
The presence of key growth factors PDGF-BB, VEGF, EGF, and TGF-β1
are confirmed and the effect bench set time has on their presence is studied.
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Study 2 examines the effect of a gelled BC has on the incidence of dry
socket formation with mandibular molar tooth extractions.

Individual

patient factors for AO formation are considered and the effect PRP
application has on each of them. Combination of factors is considered and
the effect PRP had on these combinations.
Study 3 is an in vitro analysis of the effect BC PRP application has on
hMSC proliferation and differentiation.
Study 4 is a blinded prospective clinical trial that examines the effect of
BC PRP on bone density changes following the removal of bilateral
mandibular 3rd molars.
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Study I: Preparation and Characterization of PRP
A. Introduction
Review of the medical and dental literature supports the use of autologous PRP in
clinical practice (347, 348). There are a number of procedures by which platelets can be
concentrated to produce PRP in a clinical office setting by dental personnel for
immediate post-operative use (7, 197). However, techniques that ensure the production
of large quantities of autologous PRP can be time- and labor-intensive, and expensive. In
contrast, techniques that produce small quantities of PRP can be time- and cost-efficient
and easily accomplished by dental auxiliaries.
A variety of systems are available for use by dental practitioners that involve basic
protocols for blood collection, platelet concentration via centrifugation, and delivery to
the surgical site via a syringe. One such generic system utilizes a single speed (1150 x g)
clinical centrifuge known as the Clinaseal Centrifuge™ (Salvin Dental Specialties,
Charlotte, NC). Use of this type of clinical centrifuge is a simple and cost-effective
method of concentrating platelets and the desired growth factors contained within them.
While Eby reported an average platelet yield increase of 356% versus whole blood using
this method (349), there is only limited analysis on the use of this centrifuge for
concentrating intact platelets that also includes confirmation of the presence of GFs. If
this research can provide scientific evidence that supports this technique as a method for
enhancing soft and hard tissue healing and provide mechanistic reasoning for its success,
then patients and clinicians will benefit.
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In this section of the dissertation, results of our investigation into the use of the
clinical centrifuge to obtain PRP are reported. Platelet and WBC enrichment as a
function of centrifugation time are evaluated. Western blot analysis reveals that three key
GFs are present after centrifugation for 10 minutes at 1150 x g. The effect of benchsetting time on PRP platelet enrichment, platelet microscopic morphology, and GF
content (PDGF-BB, EGF, VEGF, NGF, and TGFβ1) using enzyme-linked
immunosorbent assays (ELISAs) are also reported. Collection of this data and its
analysis will answer the question if this technique can effectively concentrate platelets,
WBCs, GFs, and does bench set time affect the concentration of GFs.

B. Materials and Methods
Collection of PRP
For platelet and WBC concentration studies seven different subjects (4 male, 3 female)
were used and values were done in triplicate. For the GF studies there was an N of 3 with
each sample run in triplicate. Whole blood was drawn using a 21 gauge 1.5 inch latexfree needle (EXELINT Int. Co., Los Angeles, CA), and 4.5 mL BD Vacutainer™ tubes
containing 0.45 mL of the anticoagulant trisodium citrate (9:1) (Becton Dickinson & Co.,
Franklin Lakes, NJ) to prevent clotting of the blood in the Vacutainer™ tube. For each
experiment, one Vacutainer™ tube was used to acquire baseline whole blood platelet and
WBC values as a reference. Dependent upon the experiment, the required number of
additional Vacutainer™ tubes were centrifuged for various times at 1150 x g to assess
the optimal spin time for the recovery of platelets in PRP. After centrifugation, the tubes
were removed and placed in a test tube rack on the bench for various time intervals to
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ascertain whether bench set time affected the recovery of platelets in PRP. The red blood
cell/plasma interface was allowed to set for 3 minutes. Pre-made labels were placed on
the outside of the tube to reproducibly delineate the PRP layer to be harvested. Labels
possessed a center dotted line positioned at the blood cell/plasma interface, a solid line 3
mm above the dotted line, and a second solid line 2 mm below the dotted line (Figure
14). Figure 13 displays the label used during the course of this study on a Vacutainer™
tube filled with water (for illustration purposes only).

Figure 14: Placement of Custom Label for Consistent Retrieval
of PRP (Buffy Coat, BC).
The dotted line is placed at the interface of the RBCs and the PPP – between these two
layers is the PRP layer. The PPP is removed down to the top solid line. The PRP layer is
between the top solid line and the bottom solid line.
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Figure 15. Anticoagulated Whole Blood After Centrifugation
Close-up of pelleted anticoagulated whole blood separated into the 3 layers. Note the
placement of the label on the outside of the tube is dictated by matching the dotted line to
the plasma/cell pellet interface.

The upper plasma layer (platelet poor plasma, PPP) was aspirated to the 3 mm mark
(top solid line) using a sterile aluminum blunt end 20 gauge 1.5 inch needle (Monoject #
8881202363, TYCO Healthcare Group LP, Mansfield, MA) attached to a 3 mL B-D
latex-free syringe (Becton Dickinson & Co., Franklin Lakes, NJ). The PRP was collected
from between the upper 3 mm mark and the lower 2 mm mark using a beveled 20 gauge
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1 inch B-D Precision Glide™ needle (Becton Dickinson & Co., Franklin Lakes, NJ)
attached to a 3 mL B-D latex-free syringe.

Platelet Concentration Determination
Platelets were counted using a Cell Dyn 1600™ cell counter (Abbott Laboratories,
Abbott Park, IL). Due to the viscosity of PRP it was necessary to dilute the PRP 1:10
with Streck Diluent™ (Streck Laboratories, Omaha, NE) prior to introducing the sample
into the cell counter. The diluted sample was gently mixed by inversion to obtain a
uniform suspension before aspiration and analysis using the cell counter.

Platelet Morphology in PRP
Smears of PRP were stained with Wright-Giemsa stain, and then examined by oil
immersion brightfield microscopy at 1000X magnification using a Nikon Eclipse 600
microscope. Several fields were examined for each sample, and representative
photomicrographs were obtained using the SPOT RT-Slider camera and SPOT Advanced
Digital Image Analysis software (Fryer Co. Inc., Huntley IL).

Partial Purification of Platelets from PRP
In order to remove red blood cells from PRP, the Histopaque 1077 cell separation
medium was used. Briefly, PRP was diluted ten-fold with Hank’s Balanced Salt Solution
(HBSS); Mediatech, Inc. Herndon, VA) and overlaid onto 5 mL Histopaque 1077 density
gradient medium (Sigma-Aldrich St. Louis, MO). The overlaid PRP was then
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centrifuged at 1150 x g for 20 minutes. The band containing platelets, lymphocytes and
monocytes was aspirated using a sterile polypropylene pipet, then, diluted with HBSS,
and centrifuged for 20 minutes at 1150 x g. Platelet-rich pellets were then resuspended
and washed two times in HBSS for 5 minutes at 1150 x g and platelet counts performed
as before. To lyse platelets, the washed pellets were suspended in 0.5% Triton X100, and
gently rocked on an Ocelot shaking platform (Fisher Scientific, Pittsburgh PA) for 40-60
minutes. Lysis was verified by microscopic examination and by subjecting the lysate to
centrifugation as before, with no visible pellet observed. The lysate was then used for
analysis by immunoblotting to indicate the presence of specific growth factors (GFs), or
by ELISA to quantify specific GFs.

Western Blotting
Pre-cast 5-20% polyacrylamide gradient gels (Jule Biotechnologies, Inc. Milford, CT)
were loaded with either Kaleidoscope molecular weight standards (Bio-Rad, Chicago,
IL), positive control purified human recombinant growth factors (US Biologicals,
Swampscott, MA), or partially purified PRP platelet samples. The samples were
subjected to electrophoresis for approximately 75 minutes at 150 v, 35 mA, and 8 watts.
Transfer of proteins to nitrocellulose paper was performed at 100 v at 3 oC for 1 hour.
Blots were then placed in Tris-buffered saline (20mM Tris, 150 mM NaCl, TBS) with
0.5% v/v Tween 20 (TBST) and 3% BSA to block nonspecific binding for 8 hours or
overnight. The blots were then removed and washed three times with TBST and placed
in a sealed storage bag with the appropriate primary antibody (US Biologicals
Swampscott, MA) at the manufacturer’s specified concentration for Western blotting (20
ng/mL TGF-β1, 0.2 μg/mL PDGF, 0.2 μg/mL NGF) in TBST for 4 hours at 3 oC. The
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blots were removed and washed three times with TBST, then placed in anti-rabbit IgG
alkaline phosphatase conjugate (US Biologicals, Swampscott, MA) as the secondary
antibody for one hour. The blots were then removed, washed three times with distilled
water, and placed in a solution of 5-bromo-4-chloro-3-indolyl phosphate nitro blue
tetrazolium (Sigma Fast Tablets, Sigma Aldrich, St. Louis MO). Color development was
allowed to proceed until positive control growth factor bands were readily apparent, then
stopped by immersing the blot in distilled water. The blots were then photographed using
a Sony Digital Mavica™ camera (Sony Corporation, NY, NY).

ELISAs
Enzyme-linked immunosorbent assays (ELISAs) were employed to determine the
quantity of various growth factors. Lysed platelet samples were prepared for ELISA with
Quantikine kits (R&D Systems Minneapolis, MN). The manufacturer’s protocol was
followed with the following modifications. To fully release TGFβ, it was necessary to
use a 3-fold higher volume (600µL) of 1 N HCl with incubation of lysates at room
temperature for the specified time. This change required that the lysate was subsequently
neutralized using 600µL 1.2 N sodium hydroxide. It was also necessary to dilute samples
10-fold before adding to the anti-TFGβ1-coated wells because the residual 0.5% Triton
X-100 used for lysis interfered with the ability of TGF-β1 to bind to the wells. PDGFBB samples were diluted 5-fold to ensure that the absorbance was in the range of the
standard curve. After color development, quantification was performed using a BIOTEK Kinetic Microplate Reader Model EL312E (Winooski, VT).
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Statistical Analysis
Statistical analysis was performed using one-way ANOVA with post-hoc NewmanKeuls analysis for the platelet and white blood cell concentrations, effect of bench set
time on platelet concentration, and effect of bench set time on growth factor content per
105 platelets data. Analysis was performed using GraphPad Prism® 3.0 (La Jolla, CA)
computer software.

C. Results
The first objective was to determine the optimum time of centrifugation in a table-top
clinical centrifuge to obtain the most consistent and greatest enrichment of the PRP. The
enrichment of platelets in PRP over whole blood using this centrifuge is displayed in
Figure 16. A greater than 6-fold enrichment of platelet concentration was obtained
consistently using a 6, 8, or 10-minute centrifugation time. Newman-Keuls analysis
showed that compared to whole blood baseline platelet counts, a 2- and 20-minute
centrifugation time did provided a significant increase (p < .05) in platelet concentration,
but there was greater significance (p < .001) for 6, 8 and 10 minutes. There was no
significant (p > .05) difference in platelet concentrations between 2- and 20-minute
centrifugation times. Newman-Keuls analysis also found no significant difference (p >
.05) in platelet concentrations between the 6, 8, and 10 minute centrifugation times.
Centrifugation times greater than 20 minutes were not considered because these longer
times would not be time efficient in the clinical setting and there was concern that too
long a centrifugation time (> 20 minutes) might cause complicating factors such as
damage to the platelets. The value of these findings is that centrifugation times between
6, 8, and 10 minutes do provide significant (p < .001) concentration increases in
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comparison to whole blood, yet there is no significant difference (p > .05) in platelet
concentrations between 6-, 8-, and 10-minute centrifugation times. These data suggest
equivalent platelets would be harvested between 6- and 10-minute centrifugation times.

Platelet Fold Increase
Over Whole Blood
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a,d,f

7.5

5.0

b

b

2.5

0.0
0

2

6

8

10

20

Centrifugation Time (minutes)

Figure 16. Platelet Concentration Fold Increase
Over Whole Blood By Centrifugation Time
The effect of various centrifugation times on platelet concentration in comparison to
whole blood that had not been centrifuged (0 minutes). Each bar represents the ± S.E.M.
of 7 different specimens performed in triplicate. All data were analyzed with a one way
ANOVA followed by a Newman-Keuls post-hoc test where significance was defined as p
< .05, where a = p < .001when 6, 8, and 10 centrifugation times compared with 0
centrifugation time (whole blood); b = p < .05 when 2 and 20 centrifugation times
compared with 0 centrifugation time; c = p < .01 when 6 minute centrifugation time
compared with 2 minutes; d = p < .05 when 8 and 10 minute centrifugation times
compared with 2 minutes; e = p < .001when 6 minutes is compared with 20 minutes; f =
p < .05 when 8 and 10 minutes are compared with 20 minutes. The importance of these
findings is that centrifugation times between 6, 8, and 10 minutes do provide significant
(p < .001) concentration increases in comparison to whole blood, yet there is not a
significant difference (p > .05) between 6, 8, and 10 minutes.
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In the second study, WBC counts for various centrifugation times were determined.
As seen in Figure 17, there was a slight increase in WBC counts even with a 2 minute
centrifugation but the concentration continued to rise, peaking at 10 minutes before
declining. One-way ANOVA with a Newman-Keuls post-hoc statistical analysis verifies
that there is a significant difference (p < .001) in WBC concentrations when 2 through 20
minute centrifugation times are compared with whole blood that has not been centrifuged
(0 time). Newman Keuls post-hoc analysis did not reveal a significant difference (p >
.05) between any of the centrifugation times (2- through 20-minutes).
When considering that platelets contain the wanted GFs and WBCs contain
macrophages plus factors such as thrombin that are involved in clotting, the 10-minute
centrifugation time was chosen as the optimal time and used for the duration of the study.

76

WBC Fold Increase
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Figure 17. White Blood Cell Fold Increase Over
Whole Blood by Centrifugation Time
The effect of various centrifugation times on white blood cell (WBC) concentration in
comparison to whole blood that had not been centrifuged (0 minutes). Each bar
represents the ± S.E.M. of 7 different specimens performed in triplicate. All data were
analyzed with a one way ANOVA followed by a Newman-Keuls post-hoc test where
significance was defined as p < .05, where a = p < .001when 2 – 20 centrifugation times
are compared with 0 centrifugation time (whole blood). There was no significant
difference in WBC concentration when 2-20 minute centrifugation times are compared
with each other. The importance of these findings is that centrifugation times between 2
and 20 minutes do provide significant (p < .001) concentration increases in comparison to
whole blood, yet there is not a significant (p > .05) change in WBC concentrations with
centrifugation times from 2-20 minutes.

The final objective of this investigation was to determine whether bench set time (time
between centrifugation of the whole blood and application in the patient) at room
temperature affected the recovery and enrichment of platelets in PRP. Figure 18 shows
that after a 10-minute centrifugation, the enrichment did not vary as a function of bench
set time for up to 6 hours. One-way ANOVA with a Newman-Keuls post-hoc test
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showed that the fold enrichment of platelets vs. baseline platelet count of whole blood
was statistically significant (p < .001) for all times examined. When comparing all bench
set times (0 through 360 minutes) with each other there was not a significant difference
(p > .05) in platelet enrichment as bench set time progressed. This confirmed that PRP

Platelet Fold Increase
Over Whole Blood

still contained platelets even if the blood was collected up to 6 hours prior to application.
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Figure 18. Platelet Fold Increase of Centrifuged Blood
Over Whole Blood with Bench Set Time
The effect of various bench set times at room temperature on platelet concentration when
compared to whole blood that had not been centrifuged or experienced bench set time.
Bench set time began after the whole blood was centrifuged and before removal of the
PRP layer. At completion of the prescribed bench set time the PRP layer was removed
and analyzed. Each bar represents the ± S.E.M. of 7 different specimens performed in
triplicate. All data were analyzed with a one way ANOVA followed by a Newman-Keuls
post-hoc test where significance was defined as p < .05, where a = p < .001when 0 – 360
minute bench set times are compared with whole blood that did not experience bench set
time. There was no significant difference between the 0 to 360 minute bench set times.
The importance of these findings is that bench set times of centrifuged whole blood
between 0 and 360 minutes did maintain significant (p < .001) platelet concentration
increases in comparison to whole blood, yet there is not a significant (p > .05) change in
platelet concentrations with bench set time up to 360 minutes.
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While the number and concentration of platelets did not appear to change as a
function of bench set time, platelets in the PRP may change in other ways and, thereby,
become less active in promoting healing. The fourth objective was to determine whether
the morphology of platelets changed as a function of bench set time. Figure 18A shows
the components of a typical stained whole blood smear. Figure 18B-F shows the changes
that occurred in platelet morphology from 0-6 hours bench set time. From 0-2 hours,
platelets appeared to be normal, much as they appear in whole blood: discoid and lightly
stained with the blue Giemsa dye. The platelets displayed little to no aggregation.
However, after 2 hours of bench set time, platelets began to appear smaller, and more
densely stained, forming small clusters. These effects were more dramatically evident by
6 hours, indicating a change in their morphology as a function of bench set time.
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Figure 19. PRP Platelet Morphology with Bench Time.
The morphology of platelets in platelet-rich plasma (PRP) changed as a function of
bench set time. Centrifuged blood was allowed to set on the bench for up to 6 hours, and
then PRP was harvested at various times. Samples were smeared, stained with WrightGiemsa, and viewed/photographed using brightfield microscopy. All fields are x1000
magnification. (A) Whole blood; note that very few platelets were present relative to the
number of red blood cells (RBCs). (B) A 0-time bench set time; note that the platelets
are higher in number relative to the RBCs, indicating that platelets have been enriched
using the procedures described previously. Also note that the platelets possess a normal
morphology (discoid, light blue staining, with little to no adherence to one another
(aggregation). (C) A 30-minute bench set time: concentrated platelets continue to appear
intact and healthy. (D) A 1-hour bench set time; platelets begin to aggregate but they are
still ovoid and lightly stained. (E) A 2-hour bench set time; platelets form larger
aggregates and have begun to lose ovoid shape developing bleb-like structures on the
plasma membranes. (F) A 6-hour bench set time; note the aggregation that occurred with
prolonged bench set time and more than 100 platelets per aggregate. Platelets appear
shrunken and distorted, suggesting aggregation, possible activation and a loss of
functional capacity.
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PRP's effectiveness in wound healing and other responses is thought to be due to the
presence of GFs present in the platelets. Western blots shown in Figure 19 demonstrated
that the PRP obtained using the above protocol contains growth factors, including PDGFBB, TGF-β1, and NGF.

Figure 20. Platelets in Platelet-Rich Plasma (PRP) Prepared
using the Clinaseal CentrifugeTM Method Contained Intact
Growth Factors.
Western blotting was used to qualitatively assess whether platelets in PRP prepared using
the methods described contained platelet-derived growth factor-BB (PDGF-BB),
transforming growth factor-β1 (TGFβ1), or nerve growth factor (NGF). Lane 1:
molecular weight markers that flank the growth factor protein bands of interest. Lane 2:
purified recombinant human growth factors that serve as positive controls. Lane 3:
lysates from 5-7 X 106 partially purified platelets contained within the PRP. Note the
presence of bands in Lane 3 that correspond in migration and immunoreactivity to the
standard growth factors in Lane 2. Also note that the bands in Lanes 2 and 3 migrate to
the known molecular weight range for each growth factor monomer (PDGF-BB = 15kD,
TGF-β1 = 12. kD, nerve growth factor =14 kD).
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Since GFs are small proteins (5-30 kDaltons) and their structure and activity may be
sensitive to hydrolytic or proteolytic degradation over time, the next objective was to
investigate whether the platelet morphological changes that occurred with increasing
bench set time were accompanied by changes in GF content of the PRP. ELISAs were
used to measure the content of TGF-β1, EGF, VEGF, and PDGF-BB in PRP as a function
of bench set time. Table 5 shows that levels of these GFs were comparable to the levels
reported by others who used more complicated techniques for preparation of the PRP
(238, 350, 351). While there was some variation observed in the data collected, the effect
of bench set time did not have a significant effect (p > .05) on the concentration of select
growth factors found in the platelets. These findings suggest that platelets, even when
they undergo morphological changes and possible activation, retained significant growth
factor concentrations over time.
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Bench Set Time (hours)
0

3

6

Mean (SE)

Mean (SE)

Mean (SE)

PDGF-BB

2.877 (±0.6492)

2.135 (±0.8093)

2.432 (±0.8932)

EGF

0.1865 (±0.1440)

0.2826 (±0.2085)

0.2930 (±0.2659)

TGFβ1

5.257 (±0.5959)

4.043 (±0.6095)

4.525 (±1.024)

VEGF

2.474 (±0.5702)

3.052 (±0.5845)

3.202 (±0.9860)

OPG

BDL

BDL

BDL

Growth
Factor
Content*
5

(pg/10
platelets)

Table 5: Growth Factor Content of Platelets with Bench Set
Time

Growth factor content pg per 105 platelets after 10-minute centrifugation time at 1150 x g
force as measured by enzyme linked absorbant assay (ELISA). All samples were run in
triplicate. PDGF-BB N=4, EGF N=3, TGF-β1 N=4, VEGF N=3, OPG N=3. BDL =
below detectable limits. All data were analyzed with a one-way ANOVA followed by a
Newman-Keuls post-hoc test where significance was defined as p < .05. There was not a
significant change in GF content over a 6-hour bench set time when compared with a 0
bench set time (p > .05)
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D. Discussion
The goal of this study was to determine whether a simplified, inexpensive procedure
to obtain platelet-rich plasma (PRP) by the buffy coat (BC) method would yield intact
platelets and GFs in concentrations similar to those reported in the literature to facilitate
clinical healing.
The investigation showed that platelet recovery and enrichment in PRP prepared using
a clinical centrifuge creating 1150 x g force was optimal, consistent and significant (p <
.001) between 6 and 10 minutes of centrifugation (Figure 16). This is of importance to
the clinician because if time were limited in the clinical setting, then a centrifugation time
of 6 minutes will provide optimal platelet concentrations. WBC concentration was also
significantly (p < .001) increased with a 10-minute centrifugation time using the clinical
centrifuge. It was also shown that platelet recovery and enrichment did not change
significantly after centrifugation for up to six hours of bench set time at room temperature
(Figure 18). Thus, this method of PRP preparation provides platelet concentrations and
recoveries that match or exceed the PRP preparations obtained through more expensive
and elaborate methods (178, 238).
However, it was found that platelet morphology did change over a period of six hours
bench set time (Figure 18). Even with two hours of bench set time, platelets in PRP
began to appear less normal and as an example, small aggregates formed indicative of
platelet activation and possible growth factor release. In western blots, at 0 hour bench set
time, detectable levels of the growth factors PDGF-BB, TGF-β1, and NGF were present
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in partially purified platelets using this BC method of PRP preparation. PDGF-BB, EGF,
TGFβ1, and VEGF levels did not significantly change over 6 hours of bench set time
(Table 5).
There are a variety of explanations for why the time between blood draw and PRP
harvest might exceed two hours. One obvious reason is that different methods of PRP
collection vary in the length of time required to obtain the PRP for use; another is that if
the blood is drawn from the patient upon arrival at the practice, some simple dental
surgical procedures may require less than 30 minutes until PRP application while other
more complex surgeries may require more than 3-4 hours. In practice, it is easiest to
draw blood from the patient initially, centrifuge the Vacutainer™ immediately after draw,
but then harvest the PRP layer just prior to administration. The centrifuged blood
therefore will vary in the length of time it remains on the bench top prior to collection of
PRP and use. The results suggest that bench set time does not influence the activity of
PRP and therefore its effectiveness in promoting bone formation and wound healing,
despite there being platelet morphology changes.
It is known that TGF-β1 stimulates osteogenesis (7, 352, 353), therefore the loss of the
bioactivity of TGF-β1 in PRP preparations may account for the disparity among
clinicians concerning the effectiveness of PRP. The current results suggest that TGFβ1concentration in PRP prepared by the BC method is not affected by bench set times of
up to 6 hours.
A decrease in TGF-β1 concentration in PRP prepared with bovine thrombin and excess
calcium has been noted (238). The loss of this factor over time with when bovine
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thrombin is added could be due to three factors including: 1) natural hydrolysis, 2)
degradation by proteases, or 3) specific irreversible binding by molecules that may be
present in the PRP. TGF-β1 is normally found in a latent form within platelets. When
TGF-β1 is in the latent form it is either bound to latency associated peptide (LAP) or
latent TGF-β binding protein (LTBP) and release from these proteins is required before it
can bind to receptors on target stem cells and trigger the formation of osteoblasts and
ultimately new bone tissue (354). If TGF-β1 were released from LAP or LTBP before
reaching its receptor, it could be rapidly degraded by hydrolysis (354, 355). Therefore,
hydrolysis is one explanation for the loss of TGF-β1 over time in the bovine thrombin
induced PGEL (gelled PRP).
Another explanation for the potential loss of TGF-β1 with these other methods is via the
action of proteases. If thrombin and Ca2+ are used in conjunction with PRP, the clotting
cascade and platelets will become activated resulting in the secretion of a variety of
granule components and growth factors. Two types of proteases found within platelet
granules are matrix-metalloproteinase-2 (MMP-2) and thrombospondins-1 and -2 (TSP2,
TSP2). One effect of these proteases is the release of TGF-β1 from its bound form
rendering it active (355, 356). MMP-2 is found as a constituent of PRP, but MMP-2
must be activated in order to proteolytically cleave its substrates (357). Activation of
MMP-2 depends upon other enzymes (MMP-14, -16) that are found in monocytes, also
present in PRP preparations. Monocytes may be triggered to release MMP-2 activating
proteases by platelet factors released during the clotting cascade initiated by thrombin
and Ca2+ (355). Interestingly, monocytes and neutrophils, also found in PRP, contain
TSP1 and 2, protease 3, and cathepsin G that may be released during the clotting cascade.
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These proteases could act in concert with active MMP-2 to release TGF-β1 resulting in
its rapid degradation (358). Zimmermann et al. (359) found that when thrombin and
calcium were added to platelets prepared by plateletpheresis and leukaphoresis under
various conditions and bench set times, the concentration of TGF-β1 decreased by
approximately 60-65%. This study found that by not activating the platelets, TGF-β1
concentrations did not significantly change over six hours. Since the PRP in this current
study was not used in conjunction with thrombin and Ca2+ hydrolysis of TGF-β1 via a
protease cascade may not have occurred, this may explain why higher levels of TGF-β1
were detected when using the current protocol compared with the others (238, 269).
Recent evidence suggests another route whereby osteogenic TGF-β1 can be lost from
PRP preparations. Alpha-2-macroglobulin (α2M) a protein that can bind active TGF-β1
is found in high concentrations (2-4 mg/mL) in PPP. Initially, active TGF-β1 noncovalently associates with α2M but this loose association leads to the formation of a
covalent bond between the molecules (356). Once the TGFβ1/α2M complex is
irreversibly formed, TGF-β1 becomes inactive, and incapable of binding to receptors.
Therefore, the less PPP is present in PRP preparations, the greater the free TGF-β1 is
available to bind to receptors triggering osteogenesis.
Growth factor levels in this PRP preparation were generally higher than those reported
by other researchers (238). These findings may result from diluting the 0.5% Triton X100 (TX-100) platelet lysates prior to adding the samples to the ELISA plate. Preliminary
experiments showed that concentrations greater than 0.05% TX-100 interfered with
stoichiometric measurement of this growth factor using the manufacturer's protocol.
Diluting the TX-100 lysates allowed for lower binding interference by this detergent and
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allowed the maximal TGF-β1 signal from the samples during ELISA analysis. Also, the
ELISA kit for TGF-β1 analysis employed a monoclonal capturing antibody, whereas
other researchers used kits employing Type II TGF-β1 receptor or polyclonal anti-TGFβ1 capturing antibodies to detect the growth factor. These differences may also account
for the higher TGF-β1 yields in our study.
Because there are many methods to prepare PRP, and since forming a PRP gel by
inducing clot formation with Ca2+ and thrombin appears to decrease the amount of TGFβ1 in PRP preparations, the clinical effects of PRP application with and without thrombin
and Ca2+ over time need to be investigated. Future plans include experiments assessing
the neutralizing activity of α2M by combining PRP with PPP in various quantities to
examine whether immunoprecipitation of α2M from PPP allows higher levels of TGF-β1
to persist in PRP. Future studies will also address the in vitro efficacy of PRP on
mesenchymal stem cell differentiation into osteoblasts.

E. Conclusion
This simple and inexpensive procedure for obtaining PRP by the BC method
effectively recovers and concentrates platelets after a 10 minute centrifugation time at
1150 x g. Moreover, this technique did not alter platelet morphology during preparation
of the BC. Platelet morphology did change after 2 hours of bench set time, but the
concentration of GFs (PDGF-BB, EGF, TGF-β1, and VEGF) contained within the
platelets was not altered significantly with bench set time. Therefore, the efficacy of this
preparation condition will be assessed in Study III (in vitro) and Study IV (prospective
clinical study).
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Study II: The Effect of PRP on the Frequency of
Alveolar Osteitis Following Mandibular Tooth
Extraction
A. Introduction
Alveolar osteitis (AO) is a complication that occurs with variable frequency (0.49% –
68.1%) following the removal of permanent teeth (360-368). AO is characterized by
severe throbbing pain that begins within 3 to 5 post-operative days and is usually
refractory to NSAIDs and/or narcotic analgesics (369, 370). The clinical presentation of
AO demonstrates a partial or total disintegration of the intra-alveolar sanguine clot,
resulting in a denuded bony crypt with surrounding debris (371, 372). Suppuration is not
evident but the patient usually complains of an acute throbbing pain emanating from the
extraction site, frequently radiating to the ipsilateral ear and side of the head. Although
rare, AO can affect the jugulodigastric lymph glands on the affected side as well.
A definitive etiology for AO has not been universally accepted, but is commonly
thought to include clot fibrinolysis as a result of bacterial invasion (373). Smoking,
female gender, oral contraceptive use, surgical trauma, operator experience level, poor
oral hygiene, gingivitis, periodontitis, and pericornitis have all been reported in the
literature to be associated with AO formation (374-382). Increased age and systemic
conditions such as diabetes and immunosuppression have also been associated with a
greater incidence of AO (383).
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Treatment for AO is typically preventative in nature, and is based on two theories of
etiology: 1) control of fibrinolysis at the time of extraction and during healing and 2)
control of bacterial populations (371, 384). Due to potential adverse reactions to
antifibrinolytic agents, most treatment has been directed towards control of bacterial
colonization.
More recently, platelet rich plasma (PRP) has been used to facilitate healing in various
oral surgical procedures such as soft and hard tissue grafting (7). PRP has been placed in
the sockets of lower wisdom teeth to decrease the incidence of AO (385). This section of
the dissertation reports on retrospective studies of the effect of PRP on AO incidence and
its relationship with other patient factors.
Platelet-rich plasma was employed as a gelled autologous fibrin clot to enhance postoperative healing in conjunction with the removal of teeth. Anecdotal clinical
observations suggest a decrease in the incidence and severity of AO, compared to the
previous techniques used for tooth removal. The purpose of this study was to examine
the effect of PRP on the incidence of AO following mandibular molar tooth removal.
The study examined the incidence of AO formation and its correlation with immediate
placement of platelet rich plasma gel in the extraction alveolus socket. In addition to the
efficacy of PRP in patients without independent risk factors for AO, the effectiveness of
PRP in patients with potential risk factors was examined. Factors considered included:
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gender
age
smoking status
systemic antibiotic therapy
concurrent use of other oral medications
oral contraceptive use
presence of oral clenching/grinding habits (bruxism)
tooth eruptive state
tooth position, and
concurrent restorative treatments provided at the time of surgery

B. Materials and Methods
Patient Information
This study was reviewed and approved by the Investigational Review Board for the
Protection of Human Subjects in research of Duquesne University. Data were obtained
by retrospective chart reviews of 904 mandibular molar extraction sites from 499
patients. A total of 506 patients had been treated, but 7 patients (all non-PRP treatment)
were excluded because of missing data on one or more variables. All molar tooth
positions and eruptive states (erupted, partially erupted, and complete bone impaction)
were included in the study. Tooth removals done without PRP were performed between
June 1996 and December 2000. Tooth removals done with PRP were performed between
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January 2001 and August 2003. Demographics for the data collection set are presented in
Table 6.
Treatment

Total

Demographic

No-PRP

PRP

Race:
African-American

= 272
7N(2.6%)

= 227
4N(1.8%)

N =11499

Asian

0 (0%)

1 (0.4%)

1

Caucasian

265 (97.4%)

222 (97.8%)

487

15-20

161 (59.2%)

146 (64.3%)

307

21-30

47 (17.3%)

47 (20.7%)

94

31-40

22 (8.0%)

9 (4.0%)

31

41-50

18 (6.6%)

10 (4.4%)

28

51-60

12 (4.4%)

10 (4.4%)

22

61-70

7 (2.6%)

4 (1.8%)

11

71-80

4 (1.5%)

1 (0.4%)

5

80+

1 (0.4%)

0 (0.0%)

1

Age Groups:

Table 6. Demographic Profile of Data Collection
Demographic profile of database used in study by race and age of participants.

Protocol for Obtaining and Applying PRP
The procedure used is similar to that described in the Materials and Methods section
of the Procedure portion of the Preparation and Characterization of PRP study but with 2
differences: 1) whole blood was drawn through a catheter, and 2) the PRP was gelled by
the addition of a calcium chloride/platelet poor plasma (PPP) mixture. The reasons for
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these variations is that whole blood obtained through the catheter eliminated an additional
venipuncture site for the patient and at the time of this study the clinician performing the
surgery preferred to use a gelled form of the BC as it was easier to place in the extraction
site. Steps were performed using aseptic techniques and sterile materials.

Statistical Analysis
Statistical investigation for AO formation by treatment group was chi square analysis.
When analyzing the effect of individual patient factors bivariate tests for independence of
categorical data were performed and when analyzing the combination of factors
multivariate analysis with multiple logistic regressions were performed using SPSS
software (SPSS Inc., Chicago, IL). Values of p < 0.05 were considered significant. The
Mantel-Haenszel test for equality of population odds ratios was used to investigate
interaction effects among factors.

C. Results
The results of this study will provide information that will be of value to clinicians
by revealing the patient factors that have an increased incidence of AO associated with
them and the effect PRP administration has on decreasing that incidence. The 904
extraction sites were assumed to be independent from one another. The test for equality
of proportions revealed a significantly greater proportion of AO cases occurring among
the non-treated sites (n=491) compared with sites in the PRP treatment group (n=413); (p
= .00043). The odds ratio (OR) was 2.81 (95% CI, 1.54 to 5.10), indicating an almost
threefold increase in the odds of AO occurring in the control sites compared to the PRPtreatment group. Figure 20 illustrates the difference in AO formation for non-PRP
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treatment sites and sites receiving PRP treatment at the time of surgery. Table 7 lists a

% AO Formation

comparison of non-PRP treatment and PRP treatment for the various patient factors.

47/491

10.0
7.5

a
5.0

15/413

2.5
0.0
PRP

No PRP

Treatment

Figure 21. Percent AO Formation by Treatment Group

Alveolar Osteitis (AO) formation in extraction sites with or without PRP treatment. All
data were analyzed with a chi square analysis with SPSS software. Significance was
defined as p < .05, where ap < .001.
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population

population

Change in
%
Occurrence
of AO with
PRP

% ↓ in
AO
with
PRP

(%)

(%)

7.00

76.90

5.05

50.50

5.95

61.79

6.06

66.67

Interval

total

95% Confidence

total

formations/

% AO formation

formations/

# of AO
Interval

# of AO

PRP Treated Sites

95 % Confidence

Patient Factor

% AO formation

Non-PRP Treated Sites

Sex (d )
Male

Female

26/260

9.10

10.00

5.4-12.8

21/231

6.4-

4/191

2.10

0.14.1

11/222

4.95

13.6

2.17.8

Age (d)
<40 yrs

42/436

9.63

6.9-

14/380

3.68

12.4
≥40yrs

5/55

9.09

1.85.6

1.5-

1/33

3.03

16.7

-2.88.9

1st molar (d)

0/23

0.00

0.0

0/8

0.00

0.0

NC

NC

2nd molar (d)

1/22

4.55

-4.2-

0/12

0.00

0.0

4.55

100.0

13.3
3rd molar (d)

46/446

10.31

7.5-

0
15/393

3.82

13.1
Erupted (d)

6/93

6.45

6/130

4.62

1.5-

1.0-

6.49

62.95

4.63

71.78

0.62

13.42

5.7
1/55

1.82

11.74
Partially
impacted (d)

1.9-

-1.75.4

4/100

8.2

4.00

0.27.8
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population
Full impaction
(c)

35/268

13.06

9.0-

total
population
10/258

3.88

17.1
Bruxism (a)

24/105

22.86

6/60

10.00

14.8-

6/41

14.63

8/45

Other meds (d)

7/88

17.78

2.4-

1/40

2.50

6.6-

5/49

10.20

10/59

16.95

9.18

70.29

3.8-

8.23

36.00

-2.3-

7.50

75.00

1.7-

7.58

42.63

4.79

60.25

16.95

100.0

18.7

2.3-

3/95

3.16

13.6
Tobacco
Smoking (d)

(%)

7.3

29.0
7.95

(%)

25.4

17.6
Oral
Contraceptives
(b)

% ↓ in
AO
with
PRP

6.5

30.9
Prophylactic
antibiotics (d)

1.6-

Change in
%
Occurrence
of AO with
PRP

Interval

formations/

95% Confidence

total

# of AO

% AO formation

formations/

PRP Treated Sites

Interval

# of AO

95 % Confidence

Patient Factor

% AO formation

Non-PRP Treated Sites

-0.46.7

7.4-

0/37

0.00

0.0

26.5
Other operative
procedures (d)

7/48

14.58

0

4.6-

1/12

24.6

8.33

-7.3-

6.25

42.87

24.0

Table 7. Comparison of Non-PRP Treatment and PRP Treatment
for Each Patient Factor
Table 7 lists all 10 patient factors considered in this study along with the corresponding
proportions experiencing AO for both PRP and non-PRP treated sites. All data were
analyzed with a chi square analysis with SPSS software. Significance was defined as p <
.05, where ap < .001; bp < .01; cp < .05; cp > .05. PRP treatment decreased AO incidence
for all subpopulations in which AO occurred. When examining individual risk factors for
AO formation, significance was found with only 4 factors. Three are listed in this table
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bruxism, oral contraceptive use, and complete impaction. The fourth significant factor
was not using PRP (Figure 21 and 22). AO formation was not observed with first molar
extraction sites and was seen in only one second molar extraction site (which did not
receive PRP treatment). The remaining 61 sites that developed AO formation were all
third molar extraction sites. Note that bruxism and oral contraceptive use display the
greatest likelihood of AO formation for both PRP and non-PRP groups.

Multiple logistic regression (multivariate) analysis revealed four significant risk
factors for AO: complete impaction, oral contraceptive use, bruxism, and failure to use
PRP. Figure 22 lists the expected probability of AO formation for each of these
significant risk factors alone and in combination. The individuals most at risk for AO
were those presenting with a combination of complete impaction, use of oral
contraceptives, bruxism, and no treatment with PRP. With each risk factor combination,
the use of PRP significantly reduced the probability of AO by approximately one half (p
< .05, Figure 22). Multiple logistic regression analysis revealed that when PRP was not
administered the other examined factors (gender, age, tooth position, smoking status,
prophylactic antibiotic use, other operative procedures performed at the same
appointment, and concurrent use of other medications) were not associated with an
increase or decrease in the probability of AO.
Analysis of potential interactions between the use of PRP and identified risk factors
were examined using the Mantel-Haenzel test for OR equality. The results revealed no
significant interactions between PRP and other risk factors for AO. Thus, the
effectiveness of PRP in reducing the incidence of AO is not dependent upon the presence
or absence of other risk factors for this complication.

97

D. Discussion
Multivariate analyses revealed that PRP significantly reduced the incidence of AO,
with the odds of AO formation 2.37 times higher for extraction sites without PRP
treatment (95% CI, 1.3 to 4.4). In addition to the absence of PRP administration, this
multivariate analysis revealed exactly three other significant risk factors for AO: bruxism,
oral contraceptive use, and complete impaction. Figure 22 shows the expected AO
probabilities for patients presenting with any combination of these four significant risk
factors. Notice that when PRP is administered, the AO probability is reduced by roughly
½ for patients in any partition. Therefore, we can conclude that the administration of
PRP following mandibular tooth extraction is beneficial in decreasing the incidence of
AO. PRP use should be considered by the clinician especially for patients who have an
impaction, take oral contraceptives, or brux (grind) their teeth, however all patients
having a mandibular tooth removed would benefit from the application of PRP.

98

Figure 22. Alveolar Osteitis (AO) Formation by Partition
Alveolar osteitis (AO) formation for various partitions found to be significant risk factors
(multivariate analysis). Statistical significance: p < .05 for all of the above combination
of variables. PRP indicates platelet-rich plasma. Complete impaction N=526 (no PRP
N=268; PRP N=258), oral contraceptive use N=94 (no PRP N=45; PRP N=49), bruxism
N=146 (no PRP=105; PRP=41), Non-PRP N=491; PRP N=413). Partition A: N=904;
Partition B: N=526; Partition C: N=94; Partition D: N=146; Partition E: 620; Partition F:
N=672; Partition G: N=240; Partition H: N=766.

Furthermore, this analysis did not find an association between smoking status and the
occurrence of AO (p = 0.3). However, this study did not take into account smoking
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quantity. Moreover, smoking status is subject to a possible response bias. It was
interesting that none of the smoking PRP-treated patients (n=37) experienced AO.
Sorensen et al., (386) showed that smoking induced significant reductions in cutaneous
and subcutaneous tissue blood flow (p < .001), oxygen tension (p < .05), and aerobe
metabolism (p < .01). Sufficient oxygen supply is fundamental for normal healing, and
tissue hypoxia has been shown to impair the reparative processes of wound healing (387),
decrease the neutrophil defense against pathogens (388, 389), and increase the incidence
of wound infection (390) These factors have been implicated in AO formation (391393). Nicotine, a component of cigarette smoke, is known to increases tissue oxygen
(386) and induce angiogenesis (394). The increased oxygen and angiogenesis induced by
nicotine in combination with the growth factors in PRP may explain the 100% remission
in AO formation found with the application of PRP in cigarette smokers.
Patients taking oral contraceptives also had a significant increase (p < .05) in AO
formation. The particular oral contraceptive taken by each of the patients was not
recorded, but a similarity for each of these agents is an estrogen component. A possible
reason for the significant increase in AO formation for patients taking oral contraceptives
is that estrogen is known to induce fibrinolysis (395). Fibrinolysis is thought to be a
mechanism for AO formation (373). A feasible explanation for how PRP reduces the
incidence in AO formation for these patients is the induced angiogenesis and soft tissue
formation by VEGF, PDGF-AB, and PDGFD-BB growth factors found in the platelets of
PRP.
The participants in this study were, overall, young (15 to ≤ 30 years of age, 80.5%)
and white. However, statistical analysis did reveal that the effectiveness of PRP in
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reducing the occurrence of AO was significant and independent of all confounding
factors, including age. Patients younger than 40 years of age and those older than 40
years of age both had AO formation reduced by approximately two thirds. Race was not
considered a variable in the study because of the small number of nonwhite participants.
Placing PRP in surgical sites, particularly in the elderly and/or medically
compromised patient, is a rational approach to treatment. This is supported by the in
vitro work of Cei et al, who found that, irrespective of age, bone marrow stromal cells
responded similarly to platelet-released supernatant and bone morphogenetic protein 6,
both of which are found within PRP (396). Moreover, it is known that TGF-β1 enhances
mineralization on dental implant materials in osteoblast cultures from elderly human
subjects (397).
Mesenchymal stem cells decrease in number early during aging in humans (398).
The stem cells can differentiate into osteoblasts when stimulated by the proper growth
factors contained within platelets. However, the bone marrow microenvironment
changes with maturity and may possibly be unfavorable for mesenchymal stem cell
(MSC) proliferation or may favor MSC maturation toward a different cell lineage such as
adipocytes (399-401). Adipogenesis can be inhibited by TGF-β1, which again is
contained in PRP (402). Therefore, gelled PRP (PGEL) techniques that utilize bovine
thrombin and have decreased TGF- β1 levels (238) could induce hMSCs to go down the
adipogenic pathway and not the osteogenic pathway. This may be an additional reason
for clinicians not witnessing the anticipated bone formation with bovine thrombin PGEL
techniques. Ultimately, since stem cell numbers decrease with age but still retain their
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juvenile potential, it is reasonable to suggest that PRP, with increased concentrations of
growth factors, would be beneficial in treating elderly patients.
Many practitioners prescribe systemic antibiotics to prevent dry socket, but this study
found no significant effect of prophylactic antibiotics on the incidence of AO. This result
supports the position that using prophylactic antibiotics to prevent AO is without benefit,
unless the patient has a systemic pathology that indicates the need for pre-medication
with antibiotics. This study did not examine the effect of localized intra-alveolar postextraction antibiotic administration. Sanchis et al, found that intra-alveolar placement of
tetracycline did not affect the incidence of dry socket (403).
The beneficial effects of PRP for decreasing the incidence of AO may be related to a
number of signaling proteins found in the platelets, including multiple growth factors
such as insulin-like growth factor, vascular endothelial growth factor, epidermal growth
factor, nerve growth factor, transforming growth factors β1 and β2 (TGF-β1,-β2),
platelet-derived growth factors, and cytokines such as angiopoietin-2, and interleukin-1
(404, 405). These factors stimulate cell mitosis and differentiation (406), increase
collagen production, recruit leukocytes and other cells to the surgical site, and initiate
vascular in-growth. Growth factors promote both soft and hard tissue healing and
angiogenesis. In addition, platelets promote clot formation, which is beneficial in
healing. Aside from platelets, PRP also contains white blood cells that can inhibit
bacterial growth. Therefore, PRP application mitigates the currently accepted causes of
AO by facilitation of clot and soft tissue formation and inhibition of bacterial
colonization.
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E. Conclusion
This study found a substantial reduction in the incidence of AO following treatment of
the extraction site with PRP. The results of this study also demonstrated that complete
impaction, oral contraceptive use, and especially bruxism are associated with significant
increases in AO incidence and PRP significantly (p < .05) reduced its incidence. This is
the first time that a simple and cost-effective technique has been reported that provides a
viable methodology by which dental practitioners can decrease the incidence of AO
formation in patients. This study supports the use of PRP in mandibular extraction sites
as a method for reducing patient postoperative discomfort and the need for multiple
postoperative visits that can be associated with AO.
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Study III: Effect of Platelet Rich Plasma on Human
Mesenchymal Stem Cell Growth, Differentiation, and
Gene Expression
A. Introduction
Use of autologous PRP in tooth extractions decreases the incidence of AO (8) and this
benefit may be achieved by facilitating clot formation and decreasing the incidence of
infection. Clinicians have anecdotally found that the use of PRP also seems to stimulate
bone (re)modeling and jawbone density in dental patients prepared for tooth replacement
with a dental implant. Alveolar bone development is fundamental to restoring dental
patients to full function and, therefore is of great interest to clinicians. One way that PRP
might trigger bone formation in these patients is to stimulate the proliferation and
subsequent differentiation of resident hMSCs into osteoblasts.
The most conspicuous function of the osteoblast is the formation of bone.
Clinically, bone formation is a multistep process that begins with the chemotaxis and
attachment of hMSCs (407). Following this initial step, the initiation of bone induction is
primarily regulated by bone morphogenetic proteins, PDGF, TGFβ1, ILGF, and FGF
which are all found in platelets of PRP (407). During phases of active bone formation,
osteoblasts synthesize bone matrix and prime it for subsequent mineralization. Active
osteoblasts in vivo are plump, cuboidal cells rich in organelles involved in the synthesis
and secretion of bone matrix proteins. Osteoblasts are polarized, allowing for the
secretion of matrix onto the underlying bony substratum, which results in bone growth by
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apposition. Some osteoblasts become trapped in matrix during bone formation and are
entombed in lacunae. These cells are referred to as osteocytes and remain in the bone
matrix in a state of low metabolic activity. At the completion of bone formation, those
osteoblasts that avoid entombment in lacunae, lose their important matrix synthesis
function and become bone-lining cells. In mature bone, these bone-lining cells cover
most of the bone surfaces. Osteocytes and bone-lining cells should not be thought of as
senescent, because they play a major role in the regulation of bone modeling and
remodeling in addition to aiding in calcium homeostasis (408).
Bone development is dependent upon the proliferation of hMSCs and the controlled
differentiation of those cells into osteoblasts. Therefore, hMSCs were chosen for this
study because they are known to contribute to bone regeneration (341, 409). They are
also essential for the growth and differentiation of primitive hemopoietic cells within the
bone marrow microenvironment (341, 409-411) and are significant to bone development
and remodeling. Human MSCs are primary cells that can be successfully cultured
through approximately eight passages (412). Techniques are now available to isolate
hMSCs and control their expansion in vitro under controlled culture conditions without
change of phenotype or loss of function (409).
The effect of PRP on hMSCs is of interest because it provides a mechanism for
explaining the clinical effects observed in the previous retrospective study. By studying
the effects of PRP on hMSCs, clinicians may gain greater understanding of the
mechanisms for PRP actions and apply the improved knowledge base to further improve
clinical treatments. Studies have demonstrated the feasibility of transplanting hMSCs
clinically to provide crucial new cellular therapy. The hMSCs are harvested and cultured
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from normal human bone marrow obtained primarily from the posterior iliac crest of the
pelvis (341, 413) and the tibial and femoral marrow compartments (414, 415). These
cells are used in regenerative medicine, immune modulation, and tissue engineering.
Since PRP is thought to induce earlier and enhanced bone formation in the jaw, then
the question arises to “Whether PRP induces earlier and enhanced proliferation of hMSCs
as well as inducing their subsequent differentiation into osteoblasts?”. It is known that
hMSC cultured in growth medium will proliferate (grow in number) (341). This study
examines if hMSC in growth medium with PRP exposure induces earlier and enhanced
proliferation of hMSCs when compared to growth medium alone. Knowing if PRP does
increase proliferation of hMSCs at an earlier time point would provide a partial
mechanistic explanation for what is observed clinically in Studies II and IV of this
dissertation. PRP proliferation effects were assessed by three accepted methods: cell
counts, MTT assay, and total RNA analysis (416-418). We also examined if hMSCs in
osteogenic differentiation medium with PRP exposure induced differentiation into
osteoblasts at an earlier time point when compared to the osteogenic differentiation
medium alone. The PRP differentiation effects were assessed by two known and
accepted methods: alkaline phosphatase assay and examination of key gene expression by
real time RT-PCR that confirm differentiation down the osteoblastic (osteogenic)
pathway (419-422). This molecular study may improve mechanistic understanding of
how PRP improves the bone modeling and remodeling in vivo.
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Materials and Methods
Collection of PRP
PRP was collected as described in the Preparation and Characterization of PRP section
(page 68), except that all Vacutainer™ tubes were centrifuged for 10 minutes at 1150 x
g, and the PRP was used in these studies between a minimum of 3 minutes and a
maximum of 30 minutes after collection from the Vacutainer™ tubes. Three to thirty
minutes is the most typical time that elapses between completion of centrifugation and
PRP application in clinical practice. The protocol for PRP collection in the Preparation
and Characterization of PRP study is also the same protocol that is used in the
prospective clinical study, therefore that protocol is used in this study. A new blood draw
was performed for each cell culture flask. All PRP was collected from the same
individual.

Cell Culture
Human mesenchymal stem cells were purchased from Lonza Biosciences
(Walkersville, MD). Cell purity had been tested by the supplier with flow cytometry and
for their ability to differentiate into osteogenic, chondrogenic and adipogenic lineages.
As per the manufacturer’s specification, these stem cells were positive for CD105,
CD166, CD29, and CD44 expression and were negative for CD14, CD34 and CD45
expression. Upon arrival, cells were initially seeded at a density of approximately 7500
cells/cm2 in a T-75 flask. Human mesenchymal stem cells when assessed by proliferative
ability, morphological appearance, and surface antigen, gene and protein expression have
been found to maintain a stable phenotype through the first 6-8 passages of culture (423).
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Di Girolamo et al. found that early passages of hMSCs would most likely be the most
useful in identifying samples that would provide the consistent and appropriate cell
characterization (413). Therefore, for the experiments in this dissertation cells passaged
3 to 4 times were chosen. For each experiment, cells were seeded at an initial density of
2500 cells/cm2 inT-25 flasks. Cells were cultured in growth medium alone [comprised of
Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum, 2mM L-Glutamine, and 0.5% gentamicin
(10mg/mL)] and incubated at 37°C in a 5% CO2 atmosphere for 24 hours. This initial 24hour incubation was performed so the cells could attach to the flask. After the 24-hour
attachment period all medium was removed and replaced with the appropriate medium
for each experimental group. Cells displayed the typical morphology of growing MSCs
in that they were long, columnar, and spindle-shaped (413, 424) following this initial
attachment period. Growth medium was refreshed every third day. Differentiation
studies relied on the use of supplemented DMEM medium containing 100 nM
dexamethasone, 0.2 mM ascorbic acid, and 10 mM β-glycerophosphate (osteogenic
medium) (425-427). Osteogenic medium will be referred to as differentiation medium in
this manuscript. All differentiation medium supplements were purchased through Sigma
(Sigma Aldrich, St Louis, MO). Cells cultured in differentiation medium displayed the
typical characteristics associated with osteoblastic differentiation, i.e., they became
flattened or broadened in appearance with a much more prominent cytoplasm that
eventually became hardened or dense in appearance after thirty days in culture (424).
Differentiation medium was refreshed every third day. For PRP treatment, PRP (375 µL)
was collected as discussed above and added to the flasks containing 10 mL growth or
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differentiation medium for 24 hours and incubated at 37°C in a 5% CO2 atmosphere, after
which all medium was aspirated and replaced with fresh growth or differentiation
medium as per experimental group. Adding 375 µL of PRP to each flask containing
10mL of medium resulted in a 3.75% v/v concentration. PRP treatment for 24 hours was
chosen because we felt it was more clinically relevant. When placing the BC PRP at the
surgical site, it is uncertain how long it is retained in place, but it is known that when
platelets are present in a blood clot, retraction is thought to occur within hours and
extrudes a very large fraction of serum and its contents (15). Therefore, it seems
reasonable that a 24-hour PRP treatment would be similar to what is occurring in the
body at the surgical site. It should be noted that once the PRP was placed in the culture
flask it would form a clot signifying platelet aggregation and activation. Upon
aggregation and activation, granules within the platelets release their contents (cytokines,
and GFs) (41).
For proliferation studies, cultures of hMSCs were passaged in growth medium until a
sufficient number of flasks were obtained. Cells were then seeded in T-25 flasks at a
density of 2500 cells/cm2 in growth medium. Cells were incubated for 24 hours at 37 oC
in a 5% CO2 atmosphere to allow cells to attach to the flask. After this initial 24 hour
period, all medium was removed and replaced with: either growth medium or growth
medium with 3.75% (v/v) PRP. All media were changed after the initial 24 hours.
Samples cultured in growth + PRP were incubated thereafter in growth medium (no
PRP). Media were changed every 3 days thereafter and cells were incubated for various
times.
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Human MSCs for differentiation studies were cultured as per the following protocols.
For qualitative alkaline phosphatase assays, the cells were seeded on collagen-coated
coverslips (Biocoat® Franklin Lakes NJ) at 2000 cells/cm2 and were placed into each
well. Three mL of growth medium were placed into the wells for 24 hours, after which
all media were changed and replaced with either growth medium only, growth medium
plus PRP 112 µL (3.75% v/v), differentiation medium only, or differentiation medium
plus PRP 112 µL (3.75% v/v). After 24 hours, all medium were removed growth
medium and growth medium + PRP groups had their medium replaced with growth
medium (no PRP), and the differentiation and differentiation + PRP groups had their
medium replaced with differentiation medium (no PRP) for 5 and 15 days. From this
time forward, none of the cells for the experiment were exposed to PRP. All media were
changed every 3 days.
For total RNA and real time reverse-transcriptase polymerase chain reaction (real
time RT-PCR) studies, the cells were cultured in their respective test group medium for
the initial 24 hours to allow cell attachment to the flasks then 3.75% v/v PRP was added
to flasks that were to receive the PRP treatment. Following this 24-hour exposure, all
media were removed from the flasks and replaced with their respective media without
PRP for 5, 10, or 21 days. All media were changed every 3 days.

Cell Counts
Cell counts were performed to evaluate the proliferation effects of a 24-hour exposure
of PRP on hMSCs growth medium in comparison to growth medium alone. Changes in
cell morphology, an indication of differentiation, were also noted. Cell counts were done
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in three microscopic fields for days 1, 3, 4, 5, 7, 10, and 12 using a grid. Days 1, 4, 5,
and 7 were examined in triplicate, while days 3, 10, and 12 were analyzed in duplicate.
MTT Assay
The (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay (R&D Systems, Minneapolis, MN) was carried out as indicated by the
manufacturer’s instructions. The MTT colorimetric assay is well accepted as a measure
of hMSC proliferation (419) and therefore, chosen for this study. This is a colorimetric
assay that determines the ability of viable cells to convert a soluble tetrazolium salt- [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT)- into an insoluble
formazan precipitate. Tetrazolium salts accept electrons from substrates such as NADH
or NAPDH. Specifically, MTT is reduced at the ubiquinone and cytochrome bc 1 sites of
the mitochondrial electron transport system. Figure 23 summarizes the reaction that
transforms the yellow soluble salts to purple or dark blue-colored formazan crystals that
can be dissolved in an organic solvent and concentration can be spectrophotometrically
determined (412).
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Figure 23. Conversion of Soluble MTT Salt to Insoluble MTT
Formazan Crystals (428)
Briefly, cells were trypsinized from the flask and placed in a sterile 15 mL conical
tube. The cells were re-suspended in two volumes of media. From this, 200 µL of cell
suspension were added to each of the wells, five wells in total. Negative controls were
used- three in total- and controls for PRP were used. This plate was placed in a 37° C
incubator at 5% CO2 overnight to allow the cells to reattach. The following day, 10 µL
of the MTT reagent were added to each of the wells and placed in the incubator for 3
hours, until a purple, punctuate precipitate was visible under magnification. When this
condition was visible, 100 µL of detergent were added to each of the wells and the plates
incubated at room temperature for 4 hours. When the crystals had dissolved, the plate
was quantified using a BIO-TEK Kinetic Microplate Reader Model EL312E (Winooski,
VT) at 570 nm.
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RNA Preparation
Total RNA formation can be collected in preparation for use in the subsequent RTPCR experiments. Changes in total RNA production over baseline can be measured and
are reflective of metabolic changes in the hMSC’s functions of proliferation and
differentiation(422).

All cells were cultured in their respective media and grown to a

50% confluent monolayer. The PRP treatment was applied and flasks were placed back in
the incubator for 24 hours. Following the 24-hour incubation, all cell flask media were
aspirated and replaced with new media that was without PRP. At this point all cells,
including PRP treated cells, were grown in their respective medium without PRP for the
set time of 5, 10, and 21 days. All media changes were completed every third day after
this point. The groups examined were (1) growth medium, (2) differentiation medium,
(3) growth medium + PRP treatment for 24 hours followed by growth medium only, and
(4) differentiation medium + PRP treatment for 24 hours followed by differentiation
medium only.
The procedure for the isolation of RNA and reagent preparation was done as specified
by manufacturer’s (Qiagen, Valencia, CA) instructions. Briefly, all media from the cell
culture flasks were completely aspirated and 650 µL of lysis Buffer RTLTM were added
directly to the flask. This flask was then placed on a rotator and periodically visualized
until no cell structures were evident. At this point, the flasks were shaken and the
homogenized cell lysate was placed into a gDNA spin column and spun at 8000 x g for
15 seconds. The spin column was discarded and one volume of 70% ethanol was added
to the flow through and mixed by pipetting. From this, 700 µL were taken and placed
into an RNeasy® spin column and centrifuged at 8000 x g for 15 seconds and the flow
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through was discarded. Seven hundred µL of Buffer RW1TM were added to the spin
column and spun at 8000 x g for 15 seconds and the flow through was discarded. Five
hundred µL of Buffer RPETM were added to the spin column and spun at 8000 x g for 15
seconds and the flow through was discarded. Five hundred µL of Buffer RPETM were
again added to the spin column and spun at 8000 x g for two minutes. The RNeasy® spin
column was placed in a new 1.5 ml collection tube and 100 µL of 37°C RNase-free water
were added to the column and spun for one minute at 8000 x g to elute the RNA. Total
RNA was measured with spectrophotometry at 260nm and quality assessed with 280 nm.

Quantitative Alkaline Phosphatase Assay
The alkaline phosphatase (ALP) assay was chosen as one method to determine
hMSC differentiation. Alkaline phosphatase expression is an early marker of osteoblast
differentiation (429). ALP catalyzes the hydrolysis of phosphate esters found in
nucleotides, proteins, and alkaloids resulting in the formation of an organic moeity and
inorganic phosphate (430). It is known that ALP activity increases during bone
development (431). For this project ALP activity is detected by using p-nitrophenyl
phosphate (pNPP) as an effective chromogenic substrate for alkaline phosphatase. This
assay is highly sensitive with a detection limit that is less than 3 ng with a wide linear
range (432). The assay measures ALP activity as it hydrolyzes pNPP into a yellow
colored product (p-nitrophenol) with a reaction rate that is directly proportional to the
enzyme activity.

ALP

p-nitrophenyl phosphate

p-nitrophenol (yellow) + phosphate
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Alkaline Phosphatase (ALP) assays (Anaspec, San Jose, CA) were performed as per
manufacturer’s directions. Briefly, the p-nitrophenyl phosphate (pNPP) reaction mixture
was diluted 1:100 with dH2O. The ALP dilution buffer was prepared by diluting the 10X
lysis buffer with dH2O and adding 1% bovine serum albumin to yield a 1X working
solution. The ALP standard was diluted 1:25 with dilution buffer. Diminishing serial
dilutions were prepared, with final concentrations ranging from 0.2 to 0 ng/µL. To each
of the wells, 50µL of samples and 50 µL of the serial dilution were added. The plate was
mixed by gentle shaking for 30 seconds. The plate was incubated at room temperature for
30 minutes immediately followed by quantification using a BIO-TEK Kinetic Microplate
Reader Model EL312E (Winooski, VT) at 405nm.

RT-PCR
Real-time RT-PCR has become the preferred method for quantifying changes in gene
expression (433). This project examined two genes (bone sialoprotein and osteocalcin)
that represent hMSC differentiation into osteoblasts. The bone sialoprotein gene (IBSP)
was chosen because it is expressed at 14 days when cells are grown in differentiation
medium (434). IBSP expression occurs prior to the mineralization phase and represents a
functioning osteoblast (287, 435). The osteocalcin gene (BGLAP) expression is a
definitive marker for functioning osteoblasts grown in differentiation medium at 21 days
(276, 277, 279, 434). Two other genes were chosen as control markers. The housekeeper
gene studied was glyceraldehyde-3 phosphate dehydrogenase (GAPDH) (303-306). The
glycoprotein-IIb(GPIIb) gene was chosen because it is expressed in developing
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megakaryocytes and is thought to be found only in platelets and therefore should not be
expressed in the non-PRP treatment groups (294, 300-302). Glycoprotein-IIb gene
expression was examined to assure that all platelet influence was removed following the
medium change after the 24-hour PRP treatment.
The genes of interest were selected based upon their appearance in platelets and
differentiating mesenchymal stem cells (MSCs) (into osteoblasts). The gene for
glyceraldehyde-3 phosphate dehydrogenase (GAPDH) is a well-characterized
housekeeper gene for differentiating MSCs. The gene for bone sialoprotein was chosen
because it is expressed during the differentiation of MSCs, prior to the mineralization
phase, but represents a mature functioning osteoblast. The gene BGLAP (osteocalcin)
was chosen because it is definitive marker for functioning osteoblasts at 21 days in
differentiation medium. The gene for glycoprotein-IIb (GPIIb) was chosen because it is
expressed in developing megakaryocytes and found in platelets. Table 8 lists the forward
and reverse primer sequences used for this study.
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Gene

Forward Primer

Reverse Primer

Glyceraldehyde-3

5’GAGTCAACGGATTTGGTCGT

CATTGATGACAAGCTTCCCG

5’CTATGGAGAGGACGCCACGCCTG

CATAGCCATCGTAGCCTTGTCCT

Osteocalcin(BGLAP)

5’ TACCTGTATCAATGGCTGGG

ATGTGGTCAGCCAACTCGT

Glycoprotein-IIb

5’GTCAGCTGGAGCGACGTCA

CTGAATGCCCAAAATACGACG

phosphate
dehydrogenase
(GAPDH)
Bone sialoprotein
(IBSP)

(GPIIb)

Table 8 Primer Sequences for Genes of Interest
Official abbreviations for the genes are listed in parenthesis in the first column.
The real time RT-PCR reaction protocol was completed in a Bio-Rad Chromo4 Real
Time Detection System using the iScript One-Step RT-PCR Kit (Bio-Rad, Hercules,
CA). Each reaction mixture contained 100 nM RNA. The 50 μL reaction mixture was
placed in the thermal cycler and incubated at 55°C for 10 minutes, 5 minutes at 95°C for
cDNA synthesis and reverse transcriptase inactivation. The PCR cycling was completed
after 45 cycles; 10 seconds at 95°C, 30 seconds at 57°C. A melt curve analysis was
completed; 1 minute at 95°C, 1 minute at 55°C, and 10 seconds at 55°C for 80 cycles,
increasing 0.5°C each cycle. Data were analyzed using MC Opticon ® software.
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Statistical Analysis
Statistical analysis was performed using GraphPad Prism® 3.02. Cell count analyses
and MTT analysis were performed using a two-way ANOVA with Newman Keuls posthoc tests and unpaired two tailed t tests for comparison of growth ± PRP at specific time
points or between time points for a specific medium. Total RNA and ALP were analyzed
using one-way ANOVA with Newman Keuls post-hoc tests. Newman Keuls was chosen
because it will compare between each of the groups. Real time RT-PCR data was
analyzed by a two-tailed paired t test when two sample data sets were analyzed and a
One-way ANOVA with Newman Keuls post-hoc tests were used when more than two
sample data sets were being analyzed.

A. Results
Experimental Rationale:
For proliferation studies, cells cultured in growth medium and growth medium +
PRP were compared. Cells are expected to proliferate when cultured in growth medium
with a limited number of cells undergoing differentiation as the cells reach 100%
confluence (341). When culturing hMSCs in growth medium ± PRP exposure for 24
hours, the effect of PRP on proliferation should be discerned. By culturing cells in
growth medium only, it is possible to determine the rate of cell proliferation and if there
is spontaneous differentiation. If differentiation is occurring in growth medium alone,
differentiation studies will determine the time point that it does occur in growth medium
alone. Cells cultured in growth medium will be compared to cells cultured in growth +
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PRP. If PRP does induce differentiation, it should be observed at an earlier time point or
at an increased level than differentiation seen in growth medium alone.
For differentiation studies, cells were cultured in growth medium, growth medium +
PRP, differentiation medium, and differentiation medium + PRP. Culturing cells in
differentiation medium is a control for known differentiation markers to confirm that
osteoblastic differentiation is occurring (419-422). Culturing hMSCs in differentiation
medium + PRP should determined if PRP has an effect on the normal differentiation
process. PRP may be found to have one of three effects on the normal differentiation
process, PRP may either 1) delay or inhibit normal differentiation 2) enhance
differentiation, that is induce differentiation at an earlier time point, or 3) have no effect
on the normal differentiation process.
It should also be noted that the effects observed in each of these studies is the result
of a 24-hour buffy coat (BC) PRP exposure. Buffy coat PRP contains concentrated
platelets and WBCs therefore; the effects seen are the result of platelets, WBCs, and their
contents.

Proliferation Studies
Cell Microphotographs
To assess proliferation effects of PRP, hMSCs were cultured in either growth
medium alone or growth medium with PRP. Cell counts were performed at 1, 3, 4, 5, 7,
10, and 12 days. Observations from representative photomicrographs are presented in
Figure 24. Photomicrographs were done independently of the cell counts (Figure 25).
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The growth medium control group represents the normal and expected growth patterns
for cultured hMSCs in vitro. After a 24-hour PRP exposure, cells demonstrated an
increase in cell number when compared to cells not exposed to PRP. Some variation
exists between the photomicrographs and the cell counts because they were done
independently of each other. It should be remembered that PRP contains concentrated
platelets and WBCs. When observing the photomicrographs, PRP related cells (platelets
and WBCs) can be observed in the growth + PRP (24-hour exposure) groups up to and
including Day 5. The number of Platelets and WBCs decreases from Day 1 to Day 5
because of medium change after PRP exposure for the initial 24 hours and then again on
Day 4. Medium was changed every 3 days thereafter.

Growth Medium + PRP
Day

Growth Medium
(24 hr. exposure)

1

3
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Growth Medium + PRP
Day

Growth Medium
(24 hr. exposure)
Growth + PRP Day 4

4

5

7
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Growth Medium + PRP
Day

Growth Medium
(24 hr. exposure)

10

12

Figure 24. Photomicrographs of Cell Cultures at Various Time
Points
Representative photomicrographs of cell cultures: Cells were seeded 3 x10 3 cells/cm2 in
a T-25 flask containing 10 mL of growth medium and allowed to attach to the cell flask
for 24 hours. Following this 24-hour attachment period, 375 µL or PRP was added to the
PRP treatment groups. Day 1 represents the cell proliferation after 24 hours of either
growth medium alone or growth + PRP treatment. Several PRP related cells (platelets
and WBCs) can be observed as small round dots in the Day 1 growth + PRP group
photomicrograph. All media were removed and Day 1 photomicrographs taken.
Subsequent microphotographs show the growth of cells in control (growth medium) and
growth medium + PRP treatment for 24 hours. After this 24-hour PRP treatment, all
media were removed from all flasks and replaced with growth media only. Media were
changed every 3 days and replaced with growth media only. Day 3 photomicrographs
demonstrate that both groups had achieved approximately 15% confluence and there are
still several WBCs present in the growth + PRP treated group. On day 4, cells cultured in
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growth medium had reached 25% confluence; growth + PRP had reached 80%
confluence with no morphological changes and several WBCs are present. On day 5,
growth group demonstrated no change in confluence, but the growth + PRP group
increased to 100% confluence with noticeable changes in morphology. Fewer WBCs are
present because this group had gone through two media changes. Day 7 growth group
reached 40% confluence and the growth + PRP group demonstrated further
morphological changes with a slight decrease in number. It is difficult to determine if
any WBCs are still present in the growth + PRP treated group because of the large
number of hMSCs present and morphological changes (cells spreading out and
potentially overlapping). On day 10, the growth group had increased to 45% confluence
with the growth + PRP group demonstrating greater morphological changes (cells are
larger, layered, decreased number and crowding each other out). At Day 10 and beyond,
it is difficult to determine the presence of WBCs in the growth + PRP treatment group.
By day 12, the growth group reached 55% confluence with no changes in morphology,
yet the PRP treated group demonstrated considerable morphological change and a
continual decrease in cell number. Photomicrographs have varying colors due to the use
of different cameras at different time points.

Cell Counts
Human mesenchymal stem cells were counted using phase contrast microscopy at
these specified time points. Several fields were counted and photomicrographs were
obtained. It should be noted that PRP contains concentrated platelets and WBCs.
Therefore, the effects seen here are from PRP and all of its contents, not just the platelets,
or the growth factors contained within them, although platelets and WBCs were not
included in cell counts. Cell counts will be correlated with two other proliferation
studies: MTT assay and total RNA expression.
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Figure 25. Proliferation Confirmation with Cell Counts
hMSC counts per field after exposure to either growth medium (control) or growth
medium with an initial 24-hour exposure to PRP (growth + PRP). Days 1,4,5,and 7 N=3; Days 3, 10, and 12 - N=2. Cells were seeded at a density of 3 x 103 cells/cm2 in a
T-25 flask (represents a 1 to 6 split of an 80% confluent T-25 flask. All cell in this study
were 3rd or 4th passage. Each bar represents the ± S.E.M. of 2 or 3 different tests
performed in triplicate. All data for individual specific time points were analyzed with a
two-tailed paired t test where significance was defined as p < .05, where a = p < .01 for
Days 4, 7, 10, and 12 and b = p < .05 for Day 5. Examination of the actual cell counts at
each individual time point (Days 1, 3, 4, 5,7, 10, and 12) with a two-tailed paired t test
the PRP treatment had a significant effect (p < .01) on cell number for days 4, 7, 10 and
12 in comparison to cells that did not receive the 24-hour PRP treatment. There was also
a significant increase on cell number with the 24-hour PRP treatment on day 5 (p < .05).
Two-way ANOVA revealed that for the entire 12-day time, PRP treatment had a
significant effect (F=583.1, p < .0001) on cell proliferation; total 12 day time elapsed also
have a significant effect (F=206.2, p < .0001) on proliferation; PRP treatment and time
elapsed were related to each other (F=53.68, p < .0001). Therefore, not only does PRP
treatment affect cell proliferation, but also time elapsed from the start of the experiment
has a significant effect on proliferation.
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MTT Analysis
The MTT analysis was used as a measure of cell proliferation. The MTT assay
monitors changes in mitochondrial activity, whereby increases in mitochondrial activity
are associated with increased numbers of cells. Figure 26 illustrates increased
mitochondrial activity with PRP-treated cells up to Day 5, after which the control cells
demonstrated greater activity. Again, it should be noted that PRP contains concentrated
platelets and WBCs. Therefore, the effects observed are from PRP and all of its contents,
not just platelets, or the growth factors contained within them. Platelets and WBCs
contain mitochondrial reductase that may be presenting a confounding factor for
interpretation of the MTT data (15). There was significantly less activity in the PRPtreated cells in comparison to the non PRP-treated cells on Days 6 and 10, which
corresponds to the decrease in platelet and WBC numbers observed in the
photomicrographs (Figure 24). The mitochondrial reductase from the platelets and
WBCs would reduce the soluble tetrazolium salt (MTT) into an insoluble formazan
precipitate and therefore, prevented a portion of the MTT from entering the hMSCs. This
decreased uptake of the soluble tetrazolium salt would mute the actual mitochondrial
reductase activity of the hMSCs. There may have been more hMSCs, but there was
insufficient concentration of the tetrazolium salt to record the true viability (number) of
hMSCs. Figure 26 illustrates that MTT absorbance is significantly greater in the PRPtreated cells for the first 5 days (except Day 2), but these values may be artificially low in
comparison to what should have been observed. Even though muted, significantly
greater MTT activity was seen with PRP-treated cells in comparison to non-PRP-treated
cells. This corresponds with the initial 5day significant increase in cell number observed
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with growth + PRP (Figure 25). The finding of less MTT activity for PRP-treated cells in
comparison to non PRP-treated cells after Day 5 is not surprising when compared with
the cell count data (Figure 25), where the non PRP-treated cells continued to proliferate
and the PRP-treated cells had reached a post-mitotic state. It would appear that after Day
5 the PRP-treated cells are not proliferating at the same rate as the non PRP-treated cells,
possibly because the cells are beginning to become differentiated, and thus post mitotic.
This indicates that the PRP exposure had a significant effect on proliferation in
comparison to non PRP-treated cells for the initial 5 days, but when considering the
entire10-day time, the effect of PRP treatment was lost over the time. Interestingly, the
MTT activity did continue to increase for both non PRP-treated cells and PRP-treated
cells. The significant increase in MTT activity between days 6 and 10 for non PRPtreated cells is due to continued proliferation as which correlates with cell count data
(Figure 25). A possible explanation for the significant increase in MTT activity between
days 6 and 10 for PRP-treated cells may be due to the decreased number of platelets and
WBCs in the flask due to successive media changes that facilitate removal of any PRP
residual PRP cells after the initial 24-hour PRP exposure. There is the possibly a portion
of the tetrazolium salts may have been reduced prematurely by the mitochondrial
reductase present in residual platelets or WBCs mixed in with the hMSCs or osteoblasts
particularly at the earlier time points, therefore, producing an artificially low MTT
absorbance for the initial 5 days. If a portion of the tetrazolium salts had been reduced by
platelet or WBC mitochondrial reductase the full amount of MTT would not have been
available for hMSCs uptake, therefore providing an artificially low MTT absorbance
value for the initial 5 days. There may be other explanations for the increase in MTT
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absorbance observed at Day 10. The Day 10 MTT reported value may be the more
accurate representation of total number of viable hMSCs that received PRP exposure,
than are earlier time point values. From this data, it is now known that a different
methodology to confirm cell viability is necessary for future experiments involving PRP
treated cells.
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Figure 26. MTT Measured Cell Proliferation Effects of
Growth and Growth + PRP Media
Mitochondrial reductase activity in cells cultured in growth medium and cells
cultured in growth medium with an initial 24-hour PRP exposure. All cells in this study
were 3rd or 4th passage. Each bar represents the ± S.E.M. for N=3 with tests performed in
triplicate. All data for individual specific time points were analyzed with a two-tailed
paired t test where significance was defined as p < .05. Where a = p < .0001, PRP-treated
cells had significantly greater activity on day one (p < .001) when compared with cells
not receiving the 24-hour PRP treatment. For b = p < .05, PRP-treated cells had
significantly greater activity on day three when compared with cells not receiving the 24hour PRP treatment. Where c = p < .01, PRP-treated cells had significantly greater
activity on day five when compared with cells not receiving the 24-hour PRP treatment.
Where d = p < .01, non PRP-treated cells had significantly greater activity on day six
when compared with cells receiving the 24-hour PRP treatment. For e = p < .0001, non
PRP-treated cells had significantly greater activity on day ten when compared with cells
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receiving the 24-hour PRP treatment. Where f = p < .0001 as an unpaired two-tailed t
test found a significant difference between Day 6 and Day 10 MTT activity for cells not
treated with PRP. For g = p < .0001 as an unpaired two tailed t test found a significant
difference between Day 6 and Day 10 MTT activity for cells receiving the 24-hour PRP
treatment. Two-way ANOVA analysis for the initial 5 days revealed that both treatment
(F = 832.48, p < .0001) and time (F = 48.33, p < .0001) were significant. The interaction
between treatment and time was significant (F = 5.686, p < .05). However, there was
significantly less MTT activity in the PRP-treated cells on Days 6 and 10 when compared
to non-PRP treated cells. For the entire 10 day period treatment was not significant (F =
0.7060, p > .05), and time was significant (F = 278.9. p < .0001). The interaction
between treatment and time was significant (F = 21.68, p < .0001). This indicates that
the PRP exposure had a significant effect on MTT activity for the initial 5 days, but when
confluence was reached due to contact inhibition, continued benefits of PRP-treatment in
comparison to non-PRP treated cells was not evident.

Total RNA Production
Another indicator of cell proliferation that was examined is global (total) RNA
production on Days 5, 10 and 21. De novo biosynthesis of pyrimidine nucleotides is an
indicator of DNA synthesis, metabolic activity, and cell proliferation (419, 421, 422).
Total RNA evaluation results are shown in Figure 27 A-C.
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Figure 27. Total RNA Yield Days 5, 10, and 21
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RNA yield measured with spectrophotometry at 260:280 ratio demonstrated all RNA
preparations were of good quality. All cells in this study were 3rd or 4th passage. Each
bar represents the ± S.E.M. for N=3 with tests performed in triplicate. All data were
analyzed with a one-way ANOVA with a Newman Keuls post-hoc test where
significance was defined as p < .05, where a = p < .001; b= p < .01. Newman Keuls
analysis represents the comparison between each of the groups. Growth + PRP and Diff
(differentiation) + PRP represent a 24-hour exposure of 3.75% v/v PRP followed by
growth or differentiation medium only. All media was changed every 3 days. Note: Yaxis scale changes between A-C for illustrative purposes. For Day 5 (A) where a = p <
.001 analysis revealed a significant difference between all groups; where b= p < .01 there
was a significant difference between cells cultured in growth medium and cells cultured
in differentiation medium. Growth + PRP and differentiation + PRP groups showed the
greatest yield of total RNA. For Day 10 (B) where a = p < .001 analyses showed a
significant difference between all groups with the PRP treated groups having the greatest
RNA yield. The RNA yield for these two groups is approximately 1/3 of that seen on
Day 5. For Day 21 (C) where a = p < .001 there is a significant difference between all
groups except for cells cultured in growth and differentiation media where there was no
significant difference. Total RNA yield for the growth and differentiation media groups
remained similar to those of Days 5 and 10. PRP-treated groups maintain a signficant
increase in RNA yield over the growth and differentitation media groups. The difference
between the PRP-treated groups is also significant with the Growth + PRP yielding the
most RNA. The total RNA yield for the Growth + PRP group is again highest, but the
level is only 2/3 that of Day 10 and only 1/5 that of Day 5. This again demonstrates that
PRP treatment does have some effect on total RNA yield, but the effect diminishes with
time. This effect may be due to continual removal of residual platelets and WBCs with
media changes every 3 days.

For Day 5 (Figure 27 A), one-way ANOVA with a post-hoc Newman Keuls analysis
revealed a significant difference between all the groups. The growth + PRP group had
the greatest global RNA yield - approximately 5 times that of control and twice that of
differentiation + PRP. Cells cultured in differentiation medium demonstrated the lowest
level of RNA production at day 5. This is expected because in differentiation medium
the total number of cells does not increase significantly. Figure 27 A clearly shows the
PRP-induced positive effect on RNA yield on Day 5. These results correlate with the
MTT data and cell count data offering additional support for the early positive
proliferative effects of PRP on hMSCs. This day 5 specific time point is also the time
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when PRP-treated cells reached 100% confluence. Cell counts for the PRP-treated group
increased by 3.2 fold at day 5 and MTT data had a 2-fold increase, yet the total RNA
yield was increased by 5-fold. This large discrepancy in cell count and total RNA values
may not represent only an increase in hMSC cell number as PRP contains platelets and
WBCs that may be contributing to the RNA levels.
Figure 27 B illustrates the continual PRP-increase in total RNA as seen at day 10.
RNA yield in the PRP-treated groups was again significant (p < .001) when compared to
the non-treated groups. The Growth + PRP group had approximately twice the RNA
level compared to the other 3 groups. It is also noteworthy that the RNA levels from the
PRP-treated groups is about 1/3 that of Day 5 values, possibly due to the reduction in
platelets and WBCs remaining in the culture. RNA yield levels for the non-PRP treated
groups remained similar to those on Day 5 despite an increase in cell number.
Day 21 (Figure 27 C), illustrates that the PRP-treated groups still maintain a
signficant (p < .001) increase in RNA yield over the growth and differentitation media
groups. The difference between the PRP-treated groups is also significant (p < .001) with
the Growth + PRP yielding the most RNA. The non-treated groups have maintained
approximately the same level of RNA production as found on Days 5 and 10, despite
increases in cell number (Figure 25). The total RNA yield for the Growth + PRP group is
again highest, but the level is only 2/3 that of Day 10 and only 1/5 that of Day 5. This
again demonstrates that PRP treatment does have some effect on total RNA yield, but the
effect diminishes with time. This effect may be due to continual removal of residual
platelets and WBCs with media changes every 3 days.
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Differentiation Studies
Differentiation of hMSCs into osteoblasts was measured by the alkaline phosphatase
assay (ALP) and examination of expression of specific mRNAs markers that would
signify osteoblast formation. It should be remembered that these studies were performed
by the application of 375 µL of BC-PRP for 24 hours following an initial cell attachment
to the flask in either growth or differentiation medium. Therefore, the effects seen are for
PRP and its constituents, platelets and WBCs and the cytokines and GFs contained within
them. For growth medium, it is expected that ALP levels would remain unchanged
between Day 5 and 15 because differentiation is not expected. For differentiation
medium, it is anticipated that there will be a significant increase in ALP in comparison to
growth medium alone. If PRP does induce differentiation, it would be expected to
increase ALP expression on either Day 5 or 15 for cells cultured with growth + PRP or
differentiation + PRP media.
The rationale for using growth ± PRP is to determine if PRP can induce
differentiation without the aid of ingredients of differentiation medium, which is known
to induce differentiation. Differentiation ± PRP is examined to determine if PRP alters or
impedes the differentiation that is normally seen with differentiation medium. The in
vivo environment more closely resembles the environment of differentiation medium than
it does growth medium.
When hMSCs differentiate into bone-forming osteoblasts, the intracellular levels of
ALP increase (436). Aubin et al. (431) found that as hMSCs became committed to
mature osteoblasts that these cells became characterized by loss of proliferative capacity
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and sequential increased markers of expression, specifically, alkaline phosphatase,
followed by bone sialoprotein, and osteocalcin. This enzyme is used to dephosphorylate
target proteins at specific sites that induce cellular consequences leading to cellular
differentiation (437). Cells (Figure 28) were incubated in growth medium with and
without PRP, and in differentiation medium with or without PRP as described previously.
PRP treatments occurred in the first 24 hours. ALP was quantified by standard assays as
described in the Materials and Methods section on page 114. ALP evaluation was
performed with N=2 among small coefficients of variation. Since ALP expression was
not normalized with cell number or total protein and there were, varying cell numbers
present depending upon the culture medium of the treatment group, the ALP increases
may reflect increased cell number. For Day 5, the growth medium cells had achieved a
45% confluence, differentiation medium cells had a 20% confluence, differentiation +
PRP medium cells had a 55% confluence, and growth + PRP had achieved a 100%
confluence. At Day 15, growth and growth + PRP media cells had reached 100%
confluence, differentiation medium cells were at 85%, and differentiation + PRP medium
cells had reached 90% confluence. Future examination of ALP levels will use equivalent
cell number or normalize to protein to allow direct comparison to all the groups and
different time points. Different time points will be examined because PRP may shift
differentiation of hMSCs either earlier or later than what is normally observed.
ALP results are reported in Figure 28. It should be noted that with the small sample
size (N=2) and lack of normalization for cell number statistical analysis cannot be
performed on these data (Figure 28 A, B).
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Figure 28. Alkaline Phosphatase Activity on Days 5 and 15
Alkaline Phosphatase activity (µg/mL) was quantified using spectrophotometry at 405nm
for days 5 (A) and 15 (B) in the various media. Cells were seeded on collagen-coated
coverslips (Biocoat ® Franklin Lakes NJ) at 2000 cells/cm2. All cells in this study were
3rd or 4th passage. Growth + PRP and Diff (differentiation) + PRP represent a 24-hour
exposure of 3.75% v/v PRP followed by growth or differentiation medium only. All
media was changed every 3 days. Each bar represents the ± S.E.M. for N=2 with tests
performed in triplicate. Statistical analysis cannot be performed because of the small
sample size. ALP expression is not normalized to cell number or total protein. At Day 5
(A), there is a baseline level of ALP in growth medium. In differentiation ± PRP
medium, the levels increased 4-fold when compared to growth medium. Additionally,
growth + PRP-treated cultures reveal a 3-fold increase at Day 5 when compared to
growth medium alone. This suggests that at Day 5 PRP can induce differentiation in
growth medium that does not contain the differentiation inducing factors dexamethasone,
ascorbic acid, and β-glycerophosphate found in differentiation medium. All cell
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treatment groups began with the same number of cells, but as time progressed each of the
flasks experienced proliferation of cells at individual rates depending on the medium.
Panel B illustrates ALP levels in cultures at day 15. Differentiation medium increased
ALP 3-fold over the growth groups and differentiation medium + PRP induced a 4-fold
increase ALP over the cells receiving growth medium with or without PRP at Day 15. It
should be noted that the ALP levels in differentiation medium alone at Day 5 are higher
than that seen on Day 5 for cells cultured in growth medium + PRP, however, ALP
expression for differentiation medium on Day 15 is similar to that seen on Day 5 for
growth + PRP medium. This suggests that a shift in the time of differentiation may be
occurring with PRP treatment.

Figure 28 A illustrates, as expected, that there is only a baseline level of ALP in
control cells (growth medium) at day 5. In differentiation medium, the levels increased
4-fold with or without PRP. However, PRP-treated cultures in growth medium also show
a 3-fold increase in ALP at 5 days.

There is a substantial difference between

differentiation medium and differentiation + PRP medium at Day 5. This suggests that at
Day 5 PRP can induce differentiation in growth medium that does not contain the
differentiation-inducing factors that differentiation medium contains (dexamethasone,
ascorbic acid, and β-glycerophosphate), therefore PRP contents (platelets and/or WBCs)
contain the factors necessary for the early steps of differentiation. However, the increase
in ALP levels for PRP-treated cells in growth medium is substantially less than that
observed with differentiation or differentiation media. Differentiation + PRP treatment
had substantially less ALP expression than differentiation medium alone, suggesting the
PRP may delay differentiation.
Figure 28 B illustrates ALP levels in cell cultures at day 15. It should again be noted
that the ALP levels in differentiation medium alone at Day 5 are higher than that seen on
Day 5 for cells cultured in growth medium with PRP, however, ALP expression for
differentiation medium on Day 15 is similar to that seen on Day 5 for growth + PRP
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medium. In a study by Jaiswal et al. (438) using the same differentiation media, ALP
activity was present on Day 4, doubled on Day 8, peaked at day 11, and then decreased as
bone sialoprotein and osteocalcin mRNA markers were expressed. Therefore, it appears
that in differentiation medium alone the Day 5 ALP levels may be earlier than ALP’s
normal expression peak and the Day 15 ALP levels may be beyond the peak and
decreasing.

Since, in the differentiation + PRP medium ALP activity is less than

differentiation medium at Day 5, but more than differentiation medium at Day 15, this
suggests that PRP does not stop the differentiation process. However, it may delay
differentiation due to the initial 5 day proliferation period that is seen in cell count
(Figure 25), MTT activity (Figure 26) and total RNA yield (Figure 27).

The

differentiation process appears to be delayed until the proliferation is complete. This
suggestion is supported by Parsons et al. (439) who found that platelet rich concentrate,
when added to the culture medium as a clot, induced an earlier onset of proliferation
followed by a sustained increase in the key osteogenic transcription actor RUNX2.
Figure 29 reflects graphs that correct for the differences in cell density for the various
treatment groups as Days 5 and 15. These data demonstrate that ALP activity is highest
in the differentiation medium on Day 5, which correlates with previous reports (438).
PRP addition to differentiation medium reduced ALP activity, possibly due to an initial
period of proliferation preceeding differentiation. Differentiation + PRP is higher than
growth medium alone suggesting some level of differentiation has begun. On Day 15,
differentiation + PRP is similar to differentiation alone, suggestin that both treatments are
past the peak times for ALP activity (438). Additional time points are also required to
assess whether PRP addition to differentiation medium modifies the differentiation
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capacity of the cultured hMSC cells. However, since cell density was estimated based on
visual inspection and adjustments to ALP activity based on cell density may not be
equivalent at varing levels of confluence, these trends will need to be confirmed in future
studies by quantifying cell number.
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Figure 29. Alkaline Phosphatase Activity Corrected for Cell
Density on Days 5 and 15
Alkaline Phosphatase (ALP) expression observed in Figure 28 is corrected for cell
density variations between media at Day 5 (A) and Day 15 (B). Calculations were made
by taking the actual ALP expression and multiplying it by the recorded cell density
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(percentage confluence) for each medium at the respective time points. These values are
then represented by the bars. This data cannot be analyzed for statistical significance
because the data is corrected by individual interpretations of confluence and not actual
cell counts and the small sample size. Panel A illustrates that as expected differentiation
medium has the greatest ALP expression and growth medium has the least. It also
appears that differentiation + PRP medium decreased the expression of ALP when
compared to differentiation medium at Day 5, but at Day 15, differentiation and
differentiation + PRP are similar. Differentiation medium has ALP expression similar to
that observed with growth + PRP at Day 5 (A). Base on the time points examined this
data suggests that PRP may not have the necessary factors to induce differentiation in
growth media. When PRP is added to differentiation medium, differentiation still occurs,
but it is suppressed at Day 5. It is difficult to say if differentiation is suppressed or if
differentiation is shifted to an earlier or later time point. Most likely it would be to a later
time point because it enhances proliferation at the earlier time point. Differentiation
follows proliferation.
PRP contains the factors necessary to increase proliferation in growth medium
(Figures 25-27).

PRP may not induce differentiation in growth medium; however,

because of the small sample size (N=2) and cell number was not normalized for the ALP
assay, these data cannot be analyzed for statistical significance. Therefore, no definitive
conclusions about PRP’s effects on differentiation are possible from the current study.
However, after normalizing ALP activity by correcting for cell density (Figure 29) there
does not appear to be enhanced ALP activity in growth + PRP medium when compared
to growth medium alone at either Days 5 or 15. Other time points may reveal different
hypothesis, but at Day 5 and 15 enhanced ALP activity with PRP treatment in growth
medium does not appear to occur. The decreased ALP activity with differentiation +
PRP medium when compared to differentiation medium alone at Day 5 suggests that PRP
may affect the differentiation process when differentiation signals are present. At Day
15, differentiation + PRP medium ALP activity is similar to that observed with
differentiation medium. Therefore, at this one specific time point (Day 15) it appears that
PRP did not affect differentiation. However, it cannot be clearly stated if differentiation
+ PRP medium reached the same peak of ALP activity at any time when compared to
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differentiation medium. In addition, this study we cannot conclude when the peak in
ALP activity with differentiation medium occurred. From this data, it can be suggested
that PRP does not stop differentiation. However, it does not effectively address to what
degree it affects differentiation. These data suggest that it may either delay and decrease
differentiation, but this does not match what is seen clinically. Clincally early bone
development occurs; therefore, in the in vivo environment it does not appear to
substantially alter the differentiation process in a negative manner.

Perhaps, the

differentiation process is delayed until after proliferation has ended. Future studies to
examine the effect of PRP on the early differentiation marker ALP will include a larger
sample size and normalization with either cell number or protein levels and additional
time points to determine if a shift in the differentiation process does occur.

Real time RT-PCR
Finally, differentiation was examined by looking at expression of key genes that are
known to be switched on during osteogenesis. These genes are bone sialoprotein (IBSP)
and osteocalcin (BGLAP). As a baseline control, expression of the housekeeper gene for
glyceraldehyde-3 phosphate dehydrogenase (GAPDH) was monitored. The glycoprotein
IIb gene (ITGA2B) was chosen because it is expected to be expressed in platelets
specifically and would serve as a method of monitoring platelet mRNA contribution (59,
60, 294, 300). It was predicted that with a 24-hour PRP exposure and successive medium
changes that all platelets would be removed and, therefore, ITGA2B expression would be
non-existent after Day 5. Unexpectedly, ITGA2B was found expressed in all of the
treatment groups, not just those that had been exposed to PRP (Table 8).
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Real-time RT-PCR experiments were done in triplicate with 3 readings taken for each
sample. For normalizing the tested osteoblast markers, a housekeeper gene, GAPDH,
was also monitored. Gene expression was measured as a threshold cycle (CT) value.
The analysis revealed that the housekeeper gene (GAPDH) was expressed 2-3 cycles
sooner at the 5- and 10-day time points in the cells that had been exposed to PRP versus
cells that had not received PRP treatment (Table 9). For accurate normalization, GAPDH
expression should be consistent across all groups. In the PRP-treated groups, GAPDH
expression is likely higher due to the presence of WBCs and other cellular constituents
present in PRP. Therefore, CT values for the PRP treated groups at Days 5 and 10 may
not reflect effects observed only in hMSCs. However, GAPDH mRNA expression (CT
values) at Day 21were consistent between all groups (growth, growth + PRP,
differentiation, and differentiation + PRP) and therefore analysis could be performed for
all groups at this specific time point. At Days 5 and 10, GAPDH CT values were
consistent for the non-PRP groups; therefore, analysis could be performed for these
groups on Days 5 and 10, unlike the PRP treated groups. Examining the CT values for
the non-PRP-treated groups at these time points provides confirmation that these genes
are expressed as expected and therefore, confirms that differentiation medium does
induce differentiation and growth medium alone results in little expression of these
osteoblast markers.
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Gene

Treatment

GAPDH

Growth

a

Bglap

ITGA2B

Day 10

Day 21

15.35

17.71

19.92

Growth + PRP

b

12.11

14.91

21.13

Differentiation

a

14.94

16.67

21.51

12.17

15.57

22.54

Growth

16.19

15.94

14.77

Growth + PRP

16.44

15.85

14.91

Differentiation

16.24

15.70

14.66

Differentiation + PRP

17.34

15.46

14.92

Growth

25.07

24.02

24.30

Growth + PRP

24.54

23.43

25.03

Differentiation

25.51

23.87

24.90

Differentiation + PRP

23.78

23.40

24.60

Growth

30.37

29.39

29.18

Growth + PRP

30.29

28.87

29.07

Differentiation

30.72

28.79

28.83

Differentiation + PRP

30.69

28.68

29.15

Differentiation + PRP

IBSP

Day 5

b

Table 9. CT Values for Genes of Interest
CT values for the genes of interest with the various treatment conditions. It should be
noted that the lower the CT value the greater the expression of the gene(s) and conversely,
the higher the CT value the lower the expression of the gene(s). The target genes (IBSP,
BGLAP) and the platelet gene (ITGA2B) from the various treatment groups were
normalized to the housekeeping gene found in the same RT preparation for which the
target gene was evaluated. Note a consistency of CT values for GAPDH on Days 5 and 10
(groups not exposed to PRP). Note b consistency of CT value for GAPDH on Days 5 and
10 (groups were exposed to PRP). Note that CT values for other genes in all treatment
groups were consistent within each time point (meaning gene expression began at similar
cycles of the real time RT-PCR process).
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The question of whether differentiation occurred was addressed by the expression of
the IBSP (bone sialoprotein) and BGLAP (osteocalcin) mRNAs for cells cultured in
differentiation media as measured by real time RT-PCR. The IBSP gene expression has
been reported to increase during middle to late stages of differentiation (14-21 days) and
occurs prior to BGLAP gene mRNA expression at 21-28 days for hMSCs cultured in
differentiation medium (275, 282, 287, 288). Table 10 examines the expression of IBSP
and BGLAP mRNAs on Days 10 and 21 relative to Day 5 for growth and differentiation
media.
The relative quantification (fold changes) in expression for the genes of interest
(∆∆CT) for Days 10 and 21 relative to Day 5 in its medium were calculated and
summarized in Table 10. The relative quantification calculation was performed by
examining the gene of interest’s ∆CT expression for Day 10 or 21in medium of interest
(growth or differentiation media) and comparing this value to Day 5 (control) ∆CT
expression for the gene of interest in the same medium. ∆∆CT values were calculated by
subtracting the target gene’s ∆ CT from the medium of interest (growth or differentiation)
on Day 5 (control) from the ∆ CT value for the target gene in the medium of interest on
Day 10 or 21. The final calculation (fold increase in expression) involved raising the
efficiency value (2) to the negative ∆∆CT value for the target gene. Calculations were
done by raising the efficiency (e) of the gene to the negative power of the average target
gene ∆ CT minus the average control gene ∆CT for medium of interest (growth or
differentiation medium). The formula used is: e-(target ∆ CT-control ∆ CT). An efficiency of “2”
was used for all calculations. Table 10 lists the relative fold changes for IBSP and
BGLAP gene expression on Days 10 and 21 compared with Day 5 for medium of interest
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(growth medium or differentiation). These data are of importance because they confirm
that differentiation medium is inducing the hMSCs to induce the expression of
differentiation markers. Therefore, suggesting that osteogenic differentiation is taking
place.

Gene

Treatment

Day 5

Day 10

Day 21

Growth

1

8.09

84.16

Differentiation

1

1.74

413.96

Growth

1

12.91

49.12

Differentiation

1

3.39

188.92

IBSP

BGLAP

Table 10. Relative Quantification of Gene Expression for Days 10
and 21 When Compared with Day 5 for Growth and
Differentiation media Using the Comparative CT Method
The relative quantification of IBSP and BGLAP gene expression over time is shown for
growth and differentiation media. There are 3 CT readings for each sample. N=3 and
each sample was run in triplicate. The average CT was calculated for each day followed
by averaging the three daily averages together. Method of calculation is presented in the
text. IBSP and BGLAP gene expression for Days 10 and 21 relative to Day 5 for growth
and differentiation media illustrate that the relative IBSP gene expression at Day 21in
differentiation medium is 413.96 times that of Day 1. This is expected because the IBSP
mRNA is expressed at 14 to 21 days after initiation of the differentiation process. IBSP
mRNA gene expression also precedes the expression of the BGLAP mRNA that is
normally expressed at 21 to 28 days. BGLAP mRNA gene expression at Day 21 is
188.92 times that of Day 1. For both of these genes the mRNA gene expression of Day
21 exceeds that of Days 1 and 10 by several fold; therefore suggesting that these hMSCs
are differentiation process of becoming osteoblasts.
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Bone sialoprotein gene (IBSP) mRNA ∆ CT values for growth and differentiation
media are illustrated in Figure 30 A-C. ∆ CT values relate to the cycle at which the gene
is expressed after normalization to the housekeeper (GAPDH) for each sample. Because
these are ∆CT values, the more positive or higher the values (bars) represent less
expression of the mRNA for that particular gene. Therefore, the lower, or more negative,
the ∆CT values, the greater the gene mRNA expression. To find the relative expression of
the gene between treatment groups versus the control, one must examine the ∆∆CT value.
To determine the ∆∆CT value, the average ∆CT values for the gene of interest in the
medium of interest is compared to the average ∆CT values for the same gene in the
control (growth) medium. ∆∆CT values are calculated by raising the efficiency of the
primer to the negative power of the growth medium target genes average ∆C T value
minus the target gene average ∆CT value for the medium of interest. The fold changes
between treatment groups for each time point are represented in Table 11. As sample
variation for calculating statistical significance is determined from the ∆C T, these values
and not the ∆∆CT or fold changes are graphed in Figures 30-32.
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Figure 30. Bone Sialoprotein gene (IBSP) ∆CT mRNA Expression
for Days 5, 10, and 21 in Growth and Differentiation Media
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Bone Sialoprotein gene (IBSP) ∆CT expression as determined by real time RT-PCR
reactions. It should be noted that the lower the CT value the greater the expression of the
gene(s) and conversely, the higher the CT value the lower the expression of the gene(s).
The target gene (IBSP) from growth and differentiation media were normalized to the
housekeeper gene found in the same RT preparation for which the target gene was
evaluated. All cells in this study were 3rd or 4th passage. Panels A, B, and C report only
cells cultured in growth and differentiation media due to the interference of the WBCs
with the PRP treated cells. All media was changed every 3 days. Each bar represents the
± S.E.M. for N=3 with tests performed in triplicate. All data for Panels A, B, and C were
analyzed with a two-tailed unpaired t test where significance was defined as p < .05.
Panels A-C shows the relative changes (∆CT) in IBSP expression at days 5, 10, and 21 in
growth and differentiation media. There was no significant difference (p > .05) in IBSP
gene expression at the Days 5 or 10, but there was significantly increased (p < .01) IBSP
gene expression on Day 21.
PRP-induced expression of IBSP at Day 5 was low and not significantly different
between the growth and differentiation media (Figure 30 A). The fold change for IBSP
with differentiation medium was 0.73 times (Table 11) that of IBSP expression in growth
medium. It was expected that IBSP expression in differentiation medium would not be
significantly different from growth medium on Day 5 because IBSP is known to have
middle to late expression during the differentiation process. Day 10 IBSP expression was
not significantly different (p >.05) for differentiation medium when compared to growth
medium. The fold increase for IBSP on Day 10 with differentiation treatment was 0.57
times (Table 11) that of IBSP expression observed in growth medium. Again, this was
expected for Day 10 IBSP expression. For Day 21, there is a significant increase in IBSP
gene expression in differentiation medium when compared to growth medium. IBSP
mRNA expression for differentiation medium was 3.26 times (Table 11) that of growth
medium.
Osteocalcin gene (BGLAP) mRNA expression for growth medium and
differentiation medium is illustrated in Figure 31 Panels A-C.
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Figure 31. Osteocalcin (BGLAP) ∆CT mRNA Expression for Days
5, 10, and 21 in Growth and Differentiation Media
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Osteocalcin (BGLAP) ∆CT expression as determined by real time RT-PCR reactions. It
should be noted that the lower the CT value the greater the expression of the gene(s) and
conversely, the higher the Ct value the lower the expression of the gene(s). The target
gene (BGLAP) from growth and differentiation media were normalized to the
housekeeping gene found in the same RT preparation for which the target gene was
evaluated. All cells in this study were 3rd or 4th passage. Osteocalcin (BGLAP) ∆CT
expression as determined was real time RT-PCR reactions. All cells in this study were
3rd or 4th passage. Panels A, B, and C report only cells cultured in growth and
differentiation media due to the interference of the WBCs with the PRP-treated cells. .
All media was changed every 3 days. Each bar represents the ± S.E.M. for N=3 with
tests performed in triplicate. All data for Panels A, B, and C were analyzed with a twotailed unpaired t test where significance was defined as p < .05. Panel A shows the
relative changes (∆CT) in BGLAP expression at day 5. There was no significant
difference (p > .05) in BGLAP expression between the differentiation and growth
medium group ∆CT values. Expression of BGLAP as measured by ∆CT for either group
at Day 5 was low with the fold change for IBSP with differentiation medium 0.55 times
(Table 11) that of BGLAP expression in growth medium. Day 10 BGLAP expression as
measured by ∆CT and analyzed with a two-tailed unpaired t test was not significantly
different (p > .05) for differentiation medium when compared to growth medium. The
BGLAP fold increase for Day 10 with differentiation treatment was 0.54 times (Table 11)
that of BGLAP expression observed in growth medium. For Day 21, there is no
significant difference between any of the ∆CT values when comparing differentiation
medium to growth medium. Differentiation medium BGLAP gene expression was 2.00
times (Table 11) that of growth medium expression.

Figure 31 A-C illustrates the relative changes in BGLAP gene expression in growth
medium and differentiation medium at days 5, 10, and 21. When using a two-tailed
unpaired t test, there was no significant difference found in BGLAP gene expression at
days 5, 10, or 21 when comparing differentiation medium to growth medium. It was
expected that there would not be a significant difference between differentiation and
growth media at days 5 and 10, because BGLAP gene expression occurs late in the
differentiation cycle (21-28 days). On Day 21, there was a 2-fold increase in BGLAP
expression in differentiation medium when compared to growth medium (Table 11) as
expected for this late stage differentiation marker.
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Figure 32. Bone Sialoprotein (IBSP) and Osteocalcin (BGLAP)
∆CT mRNA Expression for Day 21 in Growth ± PRP and
Differentiation ± PRP Media
Bone sialoprotein (IBSP) and osteocalcin (BGLAP) ∆CT expression as determined by
real time RT-PCR reactions. It should be noted that the lower the CT value the greater
the expression of the gene(s) and conversely, the higher the CT value the lower the
expression of the gene(s). The target genes (IBSP and BGLAP) from growth ± PRP and
differentiation ± PRP media were normalized to the housekeeping gene found in the same
RT preparation for which the target gene was evaluated. All cells in this study were 3rd
or 4th passage. IBSP and BGLAP ∆CT expression were determined by real time RT-PCR
reactions. All cells in this study were 3rd or 4th passage. Panels A and B report both
genes in all media because the interference of the WBCs with the PRP-treated cells
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appears to be removed by Day 21. All media was changed every 3 days. Each bar
represents the ± S.E.M. for N=3 with tests performed in triplicate. All data for Panels A
and B were analyzed with a two-tailed unpaired t test where significance was defined as p
< .05. Panel A shows the relative changes (∆CT) in IBSP expression. There was no
significant difference (p > .05) in IBSP expression between the differentiation ± PRP and
growth medium ± PRP groups ∆CT values. The fold change for IBSP at Day 21 with
differentiation + PRP medium was 4.52 times (Table 11) that of IBSP expression in
growth medium (control). The fold change for IBSP at Day 21 with differentiation
medium was 3.56 times (Table 11) that of IBSP expression in growth medium (control).
Panel B represents Day 21 BGLAP expression as measured by ∆CT and analyzed with a
two-tailed unpaired t test. There was not significantly different (p > .05) between any of
the media groups. The BGLAP fold increase for Day 21 with differentiation + PRP
medium was 4.08 times (Table 11) that of BGLAP expression observed in growth
medium. Differentiation medium BGLAP gene expression was 2.00 times (Table 11)
that of growth medium expression.
The relative quantification (fold changes) in expression for the genes of interest
(∆∆CT) was calculated and summarized in Table 11. ΔΔCT values were calculated by
subtracting target gene’s ΔCT from the medium and day of interest from the ΔCT value
for the target gene in growth medium (control) on the day of interest. The final
calculation (fold increase in expression) involved raising the efficiency value (2) to the
negative ΔΔCT value for the target gene. Table 11 lists the relative fold changes for each
treatment compared with growth medium for each gene and time point.
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Gene
IBSP

BGLAP

Treatment

Day 5 Day 10 Day 21

Growth

1

1

1

Gwth + PRP

n/a

n/a

2.11

Differentiation

0.73

0.57

3.26

Diff + PRP

n/a

n/a

4.52

Growth

1

1

1

Gwth + PRP

n/a

n/a

1.39

Differentiation

0.55

0.54

2.00

Diff + PRP

n/a

n/a

4.08

1

1

1

Gwth + PRP

n/a

n/a

2.50

Differentiation

0.59

0.73

3.85

Diff + PRP

n/a

n/a

5.12

ITGA2B Growth

Table 11. Relative Quantification Using the Comparative CT
Method
The relative quantification calculation for all four genes in the medium of interest relative
to growth medium (control) are presented. There are 3 CT readings for each sample.
N=3 and each sample was run in triplicate. The average CT was calculated for each day
followed by averaging the three daily averages together. Standard Error of Measures is
reported in Figures 30 and 31. Delta CTs were calculated by subtracting the
housekeeping gene average CT value for the gene of interest in growth medium from the
target gene average CT value for the treatment of interest. Delta-delta CT values were
calculated by subtracting the growth medium target genes Delta CT value from the delta
CT value for the target gene in the medium of interest. The final calculation (fold
increase in expression) involved raising the efficiency value (2) to the negative deltadelta CT value for the target gene. Note: n/a= not available, this data was not able to be
calculated because the housekeeper gene (GAPDH) was not consistent across these
groups at Days 5 and 10 due to a possible WBC interference for PRP treated groups at
Days 5 and 10.
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There was no relative increase in IBSP (bone sialoprotein) or BGLAP
(osteocalcin) expression compared to growth medium for Days 5 or 10 with non-PRP
treatments (PRP treatments not reported). By Day 21, IBSP expression had a 2.11 fold
increase for the growth + PRP medium, 3.26 fold increase for the differentiation medium
and a 4.52 fold increase for the differentiation + PRP medium. The results were similar
for Bglap expression with the growth + PRP having the lowest fold increase (1.39),
followed by differentiation (2.00) and differentiation + PRP again having the greatest
fold increase (4.08). However, additional studies will be required to establish if these
PRP-induced increases are significant.
The ITGA2B expression showed the same trend as the IBSP and BGLAP genes.
Differentiation + PRP medium at Day 21 had the greatest fold increase (5.12). The
expression of the ITGA2B gene mRNA in the non PRP treated groups at all time points
and its expression in the PRP treated groups at Day 21 was unexpected as ITGA2B gene
was reported to be expressed only in megakaryocytes and platelets (294, 300-302).

D. Discussion
Based on the premise that PRP will enhance bone formation by stimulating
proliferation of hMSCs (and not interfere with hMSCs differentiation into osteoblasts)
via platelet activation, it is important to consider whether the platelets are activated in the
in vitro conditions. Platelets have several methods of activation in vivo, but a concern
when working with platelets in vitro is, will the platelets be activated? When platelets
become stagnant, the platelets enter a second stage where they rapidly convert into their
active form with filopodia and lamellipodia that derive from a remodeled actin skeleton

152

and a sophisticated assembly of new actin filaments (36). This change in physical state
allows platelets to interact with each other and adhere to each other. Platelet aggregation
or coagulation occurs when platelets adhere to each other by adhesion receptors, with
glycoprotein IIb/IIIa being the most abundant adhesion receptor (15, 59). Once the
glycoprotein IIb/IIIa receptor is activated, it initiates cell-surface signaling, resulting in
activation of the platelet (15). Upon activation, platelets release the contents of their αgranules. Alpha granules contain coagulation factors, platelet activating factors, adhesion
molecules, cell-activating molecules, cytokines, integrins, inflammatory molecules, and
growth factors. Therefore, it is believed that the platelets are activated in vitro.
Another concern is that PRP is processed from whole blood that is collected in
BD Vacutainer™ tubes that contain the anticoagulant trisodium citrate (9:1). The reason
for concern is that trisodium citrate may block the coagulation (aggregation) and
subsequent platelet activation. However, in the BC PRP preparation process the whole
blood in the Vacutainer™ tube undergoes centrifugation at 1150 x g for 10 minutes. The
trisodium citrate is present in an ionic state in the whole blood and would rise to the
supernatant (PPP) portion of the tube with centrifugation. Therefore, the trisodium citrate
would be removed from the BC PRP. This is confirmed by the findings of the Study I:
Preparation and Characterization of PRP (page 67). With bench set time, it became
evident that platelets were aggregating (Figure 18) and therefore activation would follow.
Additionally, when the BC PRP was applied to the culture flask the BC PRP would form
a clot, again signifying aggregation and subsequent platelet activation and release of the
α-granule contents.
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The results of each of the proliferation studies (cell growth photomicrographs/ cell
counts, MTT analysis, and total RNA) appear to correspond with each other. It is readily
apparent that 24-hour PRP exposure does have an early effect on proliferation and that
effect is seen most dramatically within 5 days and then appears to taper off after that time
point. The reason for the decline in proliferation response at this time point may not be
due to a loss of proliferative effects of PRP, but may be due to PRP promoting osteoblast
differentiation into a post mitotic phenotype. At the time of PRP removal, it was noted
there were actually fewer cells present than had been seeded. It appeared that some cells
had been lost with the PRP removal. Cells normally attach to the flask within 24 hours of
placement. PRP administration occurred after this initial 24-hour attachment period. The
cytokines in PRP are known to be chemotactic to hMSCs and therefore, a portion of the
cells may have detached from the flask and attracted to the PRP. The PRP that was
aspirated was placed in a new T-25 flask and cells were found to be growing in these
flasks over the subsequent days (data not reported). This observation further enforces the
proliferative effects of PRP. This finding warrants additional investigation in future
studies. The cell count study is the only proliferation study done in this study that is not
confounded by the constituents of PRP and therefore the most reliable. The MTT assay
may be compromised due to the mitochondrial reductase found in the residual platelets
and WBCs and total RNA yield may be challenged by the presence of WBC RNA.
The MTT results correlate with those of Lucarrelli et al. (106). Lucarrelli found the
PRP-induced increase in MTT values was PRP dose dependent. Stromal stem cells were
exposed to thrombin plus calcium gluconate-activated PRP for 3, 6, and 9 days in a 1% or
10% concentration. Their experimental design differs from our work in that our exposure
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was for 24 hours only and in a 3.75% v/v concentration. Lucarrelli et al. found that at
day 3 (10% concentration) there was a 1.5-fold increase in MTT absorbance. In our
study, there was a 1.34-fold increase. The difference between the two studies is that
platelets in our study were not subjected to exogenous thrombin and calcium gluconate
and we had 1/3 the concentration with 1/3 of the PRP exposure time. Many clinicians
feel that PRP must be activated and in a gel form for PRP benefits to be realized and that
is the thought behind using bovine thrombin and calcium gluconate. However, the BC
PRP technique had a positive effect on proliferation without the addition of bovine
thrombin and calcium gluconate. Future work should include examining similar
concentrations of thrombin/calcium gluconate-activated PRP vs. our buffy coat PRP
technique. With continuous exposure, Lucarrelli et al. found the same fold increase
present at days 6 and 9. Their 1% concentration had a modest 1.1-fold increase at day 6.
In another study, Graziani et al. (328) examined leucodepleted thrombin/calcium
gluconate-activated PRP (via negative-charged Pall™ filter) at various concentrations.
Concentrations for the Graziani study were determined by recording baseline platelet
values and then measuring the platelet count in the PRP samples. These samples were
then diluted to give a range of 100% (PRP1x), 250% (PRP 2.5x), 350% (PRP 3.5x), and
550% (PRP 5.5x - undiluted) PRP concentrations over baseline values. PRP exposure
was for either 24 or 72 hours. MTT measurements were taken for each of these time
points. At the 24-hour time point, the maximal MTT absorbance occurred with the PRP
1x concentration and higher concentrations of PRP resulted in decrease proliferation.
However, at the 72-hour mark, the PRP 2.5x had the highest MTT absorbance with a
70% increase in cell number compared to the negative control. Interestingly, in the
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leucodepleted thrombin/calcium gluconate-activated PRP studies, none of the PRPtreated groups surpassed the control group, which was growth medium (328). In contrast,
in our study, the PRP treated group surpassed growth medium until Day 6. The main
difference in the techniques was the activation of the platelets with thrombin and calcium
gluconate and that their preparation was leucodepleted and therefore may not have the
degree of interference from the WBCs that our MTT assays do. Platelets were
continuously applied in the Graziani study, therefore the platelets may have compromised
their data also. This brings into question if leucodepleted thrombin/calcium gluconateactivated PRP retains the same proliferative qualities as PRP containing WBCs and not
activated with bovine thrombin/calcium gluconate. Future work should include
comparing various concentrations of leucodepleted thrombin/calcium gluconate-activated
PRP with our buffy coat PRP technique.
At day 5, growth + PRP treated groups demonstrated a total RNA increase of 6.5-fold
over growth medium alone (Figure 27). This represents a much greater increase than is
seen with cell counts (3.2 fold increase) (Figure 25) or MTT assay (2-fold increase)
(Figure 26). At day 5, total RNA expression is twice that of the cell count increase. Part
of this excessive total RNA increase may be due to the 24- hour PRP exposure. PRP
contains platelets and white blood cells (WBCs). Platelets contain mRNA carried over
from megakaryocytes, but it cannot synthesize mRNA due to the lack of a nucleus and
with time, mRNA undergoes progressive decay (136-139). Therefore, it is unlikely that
platelet mRNA is responsible for the additional total RNA seen in Figure 27. WBCs
contain ribosomal RNA (440) and this is most likely causing the excessive increase in
total RNA at day 5. This marked increase in total RNA was present in both PRP treated
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groups (growth + PRP and differentiation + PRP). The control groups (growth and
differentiation media) did not display these large increases in total RNA. Differentiation
medium alone had a significant (p < .001) decrease in expression of total RNA in
comparison to growth medium. At Day 10, the total RNA difference between growth
medium and growth + PRP treatment was much less. The growth medium total RNA
was unchanged from day 5 and the differentiation medium total RNA had increased
slightly. Interestingly, on day 10, the growth + PRP and the differentiation + PRP
treatments had approximately 1/4 to 1/3 of the total RNA that these groups had on day 5.
This drop in total RNA may not be due to a proliferation or differentiation effect, but
rather the decreased presence of WBCs in the PRP. The PRP was removed after 24
hours, but WBCs can be adherent to the flask and therefore retained in the flask, even
with successive medium changes every 3 days. The life expectancy of a WBC depends
upon the cell type and can range from hours to weeks (441, 442). The decrease in WBCs
either because of media changes every 3 days or apoptosis of existing WBCs could
explain the drop in total RNA. Since the cell numbers increased by 3.2-fold with growth
+ PRP treatment over growth medium counts, we could take the total RNA value for the
growth medium and multiply it by 3.2 to get the approximate total RNA value for the
growth + PRP treatment effect. The difference would represent the WBC effect beyond
the proliferative effect seen with the MTT assay (Figure 26). The potential WBC effect
appears to be approximately 52% of the total effect seen with the growth + PRP
treatment.
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Figure 33. White Blood Cell Effect on Total RNA Yield - Day 5
Gth (growth) + PRP treatment bar is marked with the proposed effect WBCs may have
upon the total RNA levels. Approximately 52% of the effect seen in this example may be
due to ribosomal RNA from WBCs, 48% of the effect may be due to a true proliferative
effect induced by PRP. Proliferative effect was measured by taking the growth medium
total RNA production and multiplying it by 3.2, which represents the fold increase
growth + PRP treatment cell counts were beyond growth medium alone cell counts.

This potential WBC effect will be reviewed again with the real time RT-PCR discussion.
Despite this WBC effect, it appears that PRP has an enhancing effect on proliferation.
This finding is supported by the cell count and MTT data. At day 10, the RNA
expression for growth + PRP treatment had decreased by 67% of the day 5 level. This
may be due in part to the decrease in the number of WBCs. Even with this drop in
growth + PRP treatment total RNA, the total RNA level is still twice that of growth
medium alone. The effect of PRP on proliferation at day 10 is additive for growth
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medium, but is sub-additive for differentiation medium. It is interesting to note that at
day 10 the total RNA level for differentiation + PRP treatment had decreased by 70%, but
still exceeded the differentiation or growth media. In this case, PRP is sub-additive for
differentiation medium. It is obvious that the PRP effect is decreasing and the nontreatment groups are approaching the PRP treatment groups. At day 21, the growth +
PRP treatment level had diminished by 80% of the total RNA occurring at day 5. Again,
despite this continual drop, it still exceeded all other groups for RNA production by a
significant amount (p <0 .001). At day 21, the differentiation only group had
significantly exceeded the growth medium and differentiation + PRP treatment groups.
This would occur because of the continual hMSC differentiation that is taking place in
this medium. Notwithstanding the WBC effect, there is robust total RNA expression that
may be due to the presence of TGF-β1 in PRP. TGF-β1 is known to control growth in
hMSCs (443). By day 21 PRP is sub-additive for growth medium, but now interferes
slightly with differentiation medium, which may be due to down-regulation of protein
synthesis or differentiation signals.
Figure 34 A and B illustrate the total RNA yield for Days 5, 10, and 21 for growth
medium and differentiation medium.
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Figure 34 Total RNA Yield for Growth and Differentiation Media
Days 5, 10, 21
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RNA yield measured with spectrophotometry at 260nm and quality assessed with 280 nm
for growth medium (Panel A) and differentiation medium (Panel B) expressed as total
RNA yield ng/μL. These graphs are extractions from Figure 27 with all conditions being
the same. All data were analyzed with a one-way ANOVA with a Newman Keuls posthoc test where significance was defined as p < .05, where a = p < 0.05 when compared to
Day 5, b = p < 0.05 when compared to day 10. Newman Keuls analysis represents the
comparison between each of the Days. Panel A (growth medium) analysis revealed that
there was no significant difference (p > .05) in RNA yield between Days 5 and 10. Day
21 did have a significantly greater (p < .01) total RNA yield when compared to Days 5 or
10. Differentiation medium shown in Panel B did have a significant difference (p < .001)
for each of the time points. Total RNA yield in differentiation medium continued to
increase throughout the time span.
For growth medium there was no significant difference (p > .05) between Days 5 or
10 in total RNA yield, but there was a significant increase (p < .01) between Day 21 and
these earlier time points. Neither of the other cell proliferation studies (cell count or
MTT assay) was extended to Day 21. Cell count data (Figure 25) suggests that
proliferation in growth media doubled between Days 5 and 10. MTT data (Figure 26)
suggests that cell proliferation increased three fold in this time for cells cultured in
growth medium. Therefore, total RNA may not be a good indicator of cell proliferation
and the entire total RNA yield effect seen with growth + PRP medium and differentiation
+ PRP medium at Days 5 and 10 may be due to the WBCs.
In the future, proliferation studies should be performed with cell counts and the use
of the CellTiter-Glo® Luminescent Cell Viability Assay that is a homogeneous method of
determining the number of viable cells in culture based on quantification of ATP present
(444, 445).
Total RNA levels will increase with differentiation as well as proliferation. For
differentiation medium, there was a significant increase (p < .001) in RNA yield as time
passed from Day 5 to 21. This most likely signifies that differentiation was taking place
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to account for the increase in total RNA. Proliferation of hMSCs in vivo is of great
importance clinically because there is an age-related decrease in hMSCs and the
generation of osteoblasts. Additionally, the time for doubling of hMSC is increased by
1.7 fold for older patients (446). Therefore, these aging issues may compromise the
healing response and PRP application may help negate these factors.
For the alkaline phosphatase assay our results (Figure 28) for differentiation medium
without PRP correspond with those of Jaiswal et al. (438). Jaiswal et al. used the same
differentiation media and found that on Day 4 ALP, expression was present and at day 8
ALP expression had doubled and peaked at day 11. However, over time there was a
decrease in ALP activity beyond Day 12 that correlated with bone sialoprotein and
osteocalcin mRNA expression and terminal osteogenic cell differentiation as hMSCs
become osteocytes (438). Although our time points varied from Jaiswal et al., there was
a greater ALP expression at Day 5 than at Day 15. For growth + PRP medium, ALP
results suggest that PRP-treatment does induce this early differentiation marker in 5 days.
A valid question is does the presence of WBCs affect these results. The WBCs may not
be causing the increased ALP levels seen with the alkaline phosphatase assay, because
there is not an additive effect with the differentiation + PRP treatment. There was an
enhancing effect of PRP exposure to differentiation medium in the total RNA study for
Days 5 and 10. This same effect was not observed with the ALP assay at Day 5. To
answer the question if this 5-day ALP increase is truly due to platelets and not WBCs, the
study would need to be repeated with a WBC-free PRP treatment in comparison to this
BC method of PRP preparation. At Day 15, the differentiation + PRP treatment had
significantly (p < .001) higher ALP expression than the other groups. At Day 15, PRP
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may interfere with the normal effect of differentiation medium ALP production.
Interestingly Day 15 differentiation medium ALP expression (average 0.07972 µg/mL
±SEM 0.0001383) was similar to that seen at Day 5 for growth + PRP medium (average
0.07194 µg/mL ±SEM 0.0006543). This may suggest that PRP treatment induces ALP
formation, but at a lower level than does differentiation medium. At Day 5,
differentiation medium ALP expression was substantially higher than that of growth +
PRP medium. There was no sizeable difference between differentiation medium and
differentiation + PRP induced expression of ALP. The reason that PRP treatment may
not be as effective for inducing differentiation is that differentiation medium has
signaling mechanisms (dexamethasone, β-glycerophosphate, and ascorbic acid) that are
specific to differentiation, while PRP has signals that appear to enhance proliferation and
differentiation. Owen et al. (447) found that a temporal relationship exists between
proliferation and differentiation; therefore, maybe PRP-treatment must initially perform
proliferation before progressing to differentiation. Since PRP-treatment induces
proliferation initially, this may lead to a shift in the differentiation process to a different
time point than what is normally observed. The Day 5 ALP activity for differentiation +
PRP medium was less than that of differentiation medium alone; however, Day 21 ALP
activity for differentiation + PRP medium was greater than that of differentiation medium
alone. Also the growth + PRP medium had less ALP activity at Day 5 than
differentiation medium, but the Day 15 differentiation medium ALP activity was similar
to that of growth + PRP on Day 5. This suggests that PRP does have the following
effects on differentiation: 1) it does not stop the differentiation process, 2) it may not
have the factors necessary to induce differentiation in growth medium, and 3) it may
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delay the differentiation process when the necessary differentiation signals are present to
a later time point because of its initial influence on proliferation.
Further evaluation of the differentiation effect of PRP was performed by examining
specific genes known to be markers of middle to late differentiation. Cells cultured in
PRP treatment media had approximately a 3 cycle earlier expression of the GAPDH
housekeeping gene at day 5 in comparison to cells cultured in media that did not have
PRP exposure and each cycle represents a doubling in the expression of the gene of
interest. At Day10, this difference had decreased to 1 or 2 cycles. The housekeeper gene
is used as the internal standard and used to normalize and quantify target mRNA
expression. The housekeeper expression should be stable within each cell regardless of
the treatment (448, 449). These differences raised concerns about the validity of using
this housekeeper for the study. The GAPDH expression was very consistent across all
treatment groups with the day 21 samples. It was observed that the other osteoblast
(IBSP) or platelet (BGLAP) specific genes were also consistent in their expression across
all of the treatments. Therefore, the question is what was different about these PRP
groups at the 5 and 10-day time points? As mentioned earlier in the introduction section,
PRP contains platelets and WBCs. The possibility of platelets being the confounding
factor was considered. Platelets were ruled out as the cause for the over expression of
GAPDH in the 5- and 10-day samples because the ITGA2B gene that was thought to be
expressed only in platelets did have consistent expression (albeit at low levels) in all
treatment groups. WBCs express GAPDH that could be increasing the housekeeper gene
expression. This housekeeper gene was selected because it had been reported as the
housekeeper gene by Kanno et al. in a similar semiquantitative RT-PCR study examining
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the differentiating effects of PRP (329). It was also thought that if the PRP were
removed after 24 hours and new medium placed that the effects of PRP and its contents
would be removed and therefore not a confounding factor for these studies.
At Day 21, IBSP expression (Table 11) was at a higher level than BGLAP expression
for all media with differentiation + PRP having the greatest expression. It is expected
that IBSP expression preceded BGLAP mRNA expression (276, 277, 279, 287). Gene
expression for PRP treated groups is reported for the Day 21 samples because the
housekeeper gene was stably expressed. This suggests that influence of the WBCs was
gone by the Day 21 time point. Ingrwoth + PRP at Day 21, PRP may somewhat enhance
differentiation of growth medium alone because, IBSP (2.11 fold) and BGLAP (1.39
fold) expression were higher than growth medium alone and approached that of
differentiation medium. PRP exposure also demonstrated an enhancing effect on
differentiation medium for IBSP (4.52 fold) and BGLAP (4.08 fold) expression at Day
21. Further studies will be required to confirm these proposed effects of PRP.
This dissertation is suggesting that BC PRP enhances hMSC proliferation and
suggests that it may not stop their differentiation into osteoblasts. Proliferation seems to
be occuring in a shorter time than what is normally observed in vitro with growth
medium for proliferation. PRP does not appear to induce differentiation in growth
medium, nor does it stop the differentiation process for cells cultured in differentiation
medium. Parsons et al. (439) found that platelet rich concentrate, when added to the
culture medium as a clot, PRC induced an earlier onset of proliferation and stimulated a
transient enhancement of bone morphogenetic protein-2 mRNA that peaked after 12
hours and induced an earlier and a sustained increase in the key osteogenic transcription
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actor RUNX2. After 3 days of treatment, PRC enhanced alkaline phosphatase activity
more than 2-fold compared to donor-matched serum, and at 23 days, the increase in
osteoblastic commitment translated to enhanced calcified matrix deposition. Our studies
found that cells cultured in growth + PRP medium had ALP activity increased by 2.5 fold
at Day 5 (Figure 28) when compared to growth medium alone, but when ALP activity
was corrected for cell density, there did not appear to be a difference in ALP activity
between cells cultured in growth or growth + PRP media. We also found that by Day 5,
cell counts (Figure 25) were 3.2 fold greater for cells cultured in growth + PRP in
comparison to cells cultured in growth medium alone. It is at Day 5 we also found that
the MTT assay showed a drop in MTT activity (Figure 26), signifying that proliferation
was ending. Therefore, it appears that proliferation discontinues and differentiation
begins immediately thereafter. A possible explanation for this may be found in the work
of Owen et al. (447). They found a relationship existed between fetal rat hMSC growth
and differentiation-related gene expression during the in vitro cultivation of osteoblasts.
They found a temporal, functional relationship between the decline in proliferative
activity and the subsequent induction of genes associated with osteoblast differentiation,
matrix maturation, and mineralization. Initially, proliferating cells express cell cycle and
cell growth regulated genes that lead to the production of a fibronectin/type I collagen
extracellular matrix. Immediately following a sequence of events occurs in which there
is an enhanced expression of ALP and later an increased expression of osteocalcin at the
onset of mineralization. Additionally, it was demonstrated that there is enhanced
expression of the osteoblast markers as a function of ascorbic acid-induced collagen
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deposition. This suggests that the extracellular matrix contributes to both the shutdown
of proliferation and the development of the post mitotic osteoblast phenotype.

E. Conclusion
This molecular-based study examining the effects of the buffy coat method of
preparing PRP supports the hypothesis that PRP obtained by this simple and costeffective method enhances proliferation. It also suggests that BC PRP does not interfere
with hMSC differentiation down the osteogenic pathway. Proliferation was confirmed
with cell count and MTT assays. Evidence of PRP not stopping the differentiation
process was suggested by the unaltered ALP activity at Day 15 for differentain+ PRP
medium when compared to differentiation medium . Additionally, evidence of
differentiation was supported by the increased expression of the bone sialoprotein gene
mRNA and the osteocalcin gene mRNA in differentiation +PRP medium. This study
also supports the concept that PRP initially accelerates proliferation of hMSCs and it
does not stop differentiation with the possibility of inducing differentiation at a late time
point. PRP may induce a shift in the differentiation chronological framework. PRP
causes the hMSCs to proliferate before differentiation into osteoblasts begins. These
effects may promote bone healing and formation. This molecular study provides a
mechanistic basis for the clinical use of PRP in osseous surgery.
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Study IV: The Effect of PRP on Wound Healing
Following Tooth Extraction:
A Prospective Clinical Study
A. Introduction
Immediately following the removal of one or several teeth, a healing process begins
that affects the eventual alveolar bone volume and architecture of the alveolar ridge.
Proper and timely healing are essential in order to obtain the ideal functional
reconstruction for the patient. Improper traumatic removal of a tooth or a poor healing
response may lead to excessive bone loss delaying tooth replacement, may necessitate
expensive and time-consuming alveolar bone reconstructive surgeries, or create a
situation that is impossible to correct, leaving the patient severely compromised (450). If
a cost-effective, simple technique were available that would decrease bone-healing time
and increase the predictability of having a favorable result, patients and clinicians would
benefit. The intent of this study was to determine whether the application of PRP to a
tooth extraction site would facilitate healing.
Following tooth extraction, a cascade of inflammatory reactions begins immediately,
and the extraction socket is temporarily closed by clotting blood. Epithelial tissue
proliferation and migration start within the first week and the disrupted tissue integrity is
quickly restored. Histological evidence of active bone formation in the bottom of the
extraction socket is seen as early as 2 weeks following tooth removal. The socket is
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filled with newly formed bone in about 6 months (451, 452). If the removed tooth is not
replaced by an intraosseous fixture within 6 months of removal, the residual ridge
alveolar bone undergoes a life-long catabolic remodeling (451).
Radiographic techniques have been used to document the gross morphologic changes
of the alveolar processes after the loss of teeth (450, 453-455). A well-established
method for the detection of subtle bone changes is the use of subtraction radiography.
We used a variation of the technique reported by Hildebolt et al. in 1998 (456). To
determine changes in alveolar bone radiodensity through time, homologous regions of
interest (ROIs) were identified and compared (456, 457), with one image subtracted from
the other, the difference representing the change in radiodensity (457-461). The regions
of interest were interpreted using a computer program that examined the pixel number
and converted to grayscale images. In this study, we used a combination of these
techniques and normalized radiographs to an ROI (the adjacent tooth). The extraction
sockets were evaluated by the same method and normalized to the ROI. The grayscale
values of the baseline radiograph were subtracted from the grayscale value for the time
point radiograph.
Macro-structural and micro-structural bone forming information can be acquired with
advanced imaging techniques rather than with conventional radiography or standard bone
densitometry (462). Computerized tomogram scanning technology (CT scan) provides a
three-dimensional representation of the object in any geometry (463) which can provide
information about bone healing and define the skeletal response to innovative therapies
(462, 464-469). Investigators have employed quantitative CT scans to monitor fracture
healing in experimental models and clinical studies (462, 464, 465). Since this
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technology is expensive and requires more radiation exposure than digital radiography, it
was used on only three patients in this study.

B. Materials and Methods
This study was reviewed and approved by the Investigational Review Board (IRB) for
the Protection of Human Subjects at Duquesne University. Funding for this study was
provided for by the American Academy of Implant Dentistry Research Foundation. The
appendix contains forms relevant forms to IRB approval.

Patient Selection
All patients (N=6) selected were between ages 18-40 with a negative medical history
and were non-smokers. Tooth extractions considered in the study were bilateral
mandibular impacted third molars of equal eruptive states. Patients were informed
individually of possible complications and signed study, surgical and IV sedation
informed consent forms. Patients were remunerated $250.00 at the completion of the 25
week evaluation period.

PRP Collection
A venous puncture using a 21 gauge 1.5 inch latex-free needle(EXELINT Int. Co.,
Los Angeles, CA) with an attached vacutainer holder (EXELINT Int. Co., Los Angeles,
CA) in the ante-cubital fossa, or the dorsal surface of the hand contra-lateral to the IV
administration site was performed. Whole blood was drawn using two 4.5 mL BD
Vacutainer™ tubes containing 0.45 mL of the anticoagulant tri-sodium citrate (9:1)
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(Becton Dickinson & Co., Franklin Lakes, NJ). PRP was prepared as described
previously in the Preparation and Characterization of PRP section (Study 1).

Third Molar Surgical Technique and PRP Placement
Intravenous access was obtained using a 22 gauge 1-inch Terumo Surflo™
intravenous catheter (Terumo Medical Corporation, Elkton, MD). The vein was kept
open (KVO) with dextrose 5% in water (Baxter Healcare Corporation, Deerfield, IL).
Patients were monitored via electrocardiogram (EKG), automatic blood pressure, and
percent hemoglobin oxygen saturation with a Criticare Systems model 507 E (Criticare
Systems, Inc. Waukesha WI) anesthesia monitor. All patients were sedated with a
combination of intravenous midazolam HCl, diphenhydramine HCl, and fentanyl citrate
(Ace Surgical, Brockton, MA) as needed to induce a state of conscious sedation. Once
the patient was sedated, the blood draw was performed to acquire the PRP for use after
the teeth were removed. Depending on allergies, patients were administered either
cefazolin 2.0 gram (Baxter Healthcare Co, Deerfield, IL) or clindamycin 600 mg (Ace
Surgical, Brockton, MA) immediately pre-operative via IV. Following sedation and
administration of antibiotics, all patients were administered lidocaine HCl 2% with
epinephrine 1:100,000 (Cook-Waite, Rochester, NY) bilaterally as follows: 1.8 mL (1
unit-dose carpule) as a Gow-Gates inferior alveolar block, 1 unit-dose carpule as a long
buccal, buccal infiltration and lingual block. If anesthesia was deemed to be inadequate,
additional carpules were administered as needed to a total maximum of 11 unit-dose
carpules. Incisions were made in the envelope fashion. The posterior extension of the
incision diverged laterally to avoid injury to the lingual nerve. The incision was brought
anterior in the gingival sulcus to the mesial of the first molar (no vertical releasing
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incision was made). The gingival soft-tissue was reflected exposing bone overlaying the
impacted tooth. Bone was removed by the use of a Elcomed 100 electric handpiece
(W&H Dentalwerk, Burmoos, GMbH, Austria) and a #8 round surgical burr (Henry
Schein Inc. Melville, NY). Teeth were sectioned as needed with a 45° High Impact
handpiece with a #700 Fisher burr (Henry Schein Inc., Melville, NY). The control
extraction site was treated immediately post-extraction as follows:
a. Placement of Gelfoam® (Pharmacia Corporation, Kalamazoo, MI) only (no PRP)
b. Primary closure was achieved with 3-O chromic gut suture material (Henry
Schein Inc., Melville NY 11747 USA).
c. After removal of the tooth, a small periapical digital radiograph (Dentsply
Gendex®, York, PA) was taken using an XCP-DS® mount to determine a
baseline grayscale representing bone density at each extraction site.

The treated site was treated immediately post-extraction as follows:
a. Injection of 200 μL of PRP into the extraction site
b. Placement of Gelfoam®, moistened with 175 µL PRP
c. Primary closure was achieved with 3-O chromic gut suture material (Henry
Schein Inc., Melville NY 11747 USA).
d. After removal of the tooth, a small periapical digital radiograph (Dentsply
Gendex®, York, PA) was taken using an XCP-DS® mount to determine a
baseline grayscale representing bone density at each extraction site.
To help prevent excessive post-operative inflammation, patients were administered
dexamethasone sodium phosphate (Ace Surgical, Brockton, MA) 8 mg IV pre-
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operatively and methylprednisolone suspension Depo-medrol® (Pharmacia & Upjohn Co,
New York, NY) suspension 40 mg IM immediately post-op. Patients were also
administered ketorolac trimethamine 30 mg (Hospira, Lake Forest, IL) IV immediately
post-op. Immediately post-operative bilateral Gow-Gates mandibular block injection
using 1.8 mL of bupivacaine HCl 0.5% with 1:200,000 epinephrine (Hospira, Lake
Forest, IL) was administered to prevent immediate post-op pain. Patients were advised to
take ibuprofen 600 mg every 6 hours for 3 days and then every 6 hours as needed
thereafter. They were advised to take acetaminophen 500 – 1000 mg every six hours if
the ibuprofen did not control the pain. Patients were dismissed with a grade card for
notations every 8-hours for 3 days, then notations every 12 hours for the following 6
days. Each surgical site was graded with a visual analogue scale (VAS) for:
1. Pain
2. Temperature (external feeling of warmth)
3. Facial swelling
4. Bleeding
5. Numbness or altered sensation of tongue, face, lip or chin.
The participants used the instrument in the appendix for post-operative evaluation from
their perspective.
The patients returned post-operatively for observer evaluations plus digital
radiographs using the same protocol for immediate post-operative radiographs. These
evaluations were repeated at the following post-operative time points: 3 days plus weeks-
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1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. Blinded observers used a VAS to evaluate the
following:
1.

Dehiscence (surgical soft tissue opening)

2.

Bleeding

3.

Inflammation

4.

Facial edema

5.

Intra-oral edema

6.

Pain
Three of the patients had a mandibular computerized axial tomography (CT) scan

performed by a local hospital. Each of these three patients had one CT scan taken.
Patient-1 had theirs taken at 18 weeks post-operative, Patient-2 at 14 weeks postoperative, and Patient-3 at 10.5 weeks post-operative. This allowed for verification of the
grayscale from digital radiography with the bone density Hounsfield units (HUs) of the
CT scan and percent bone fill of the extraction sites.

Radiographic Technique and Exposure
Radiographs were taken with a Trophy ETX Dental peri-apical X-ray machine
(Trophy Radiologie, Vincennes, Cedex, France). X-radiation settings were 70 KV, 8
mA, for 0.05 second exposure time. The digital x-ray sensor used was a Gendex GX-S
sensor (Gendex Dental System, Lake Zurich, IL). The radiograph sensor was held by a
Dentsply Sensor Holder XCP-DS® posterior holder and ring (Dentsply International
York, PA). Digital radiographs were formatted by VinWix Pro computer software
(Gendex Dental System, Lake Zurich, IL). Digital radiographs were used for two
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reasons: 1) the technique allows for consistent radiographic opacity and evaluation, and
2) it exposes patients to only 25% of the radiation used with conventional radiography. A
correlation of bone density was confirmed during the study with a CT scan and computer
reformatting for bone density determination via HU for three patients. Because of the
need to evaluate the post-operative bone healing, participants were exposed to 22 digital
periapical radiographs.

CT Scan Technique and Exposure
Mandibles were scanned 1mm inferior to the mandible to the superior surface of the
mandibular teeth. CT specifics were as follows:
•

Image size: 512 x 512 pixels

•

Gantry tilt: 0.0 degrees

•

Scanner slice thickness: 0.5 – 1.0 mm

•

Scanner step increment: 0.5 – 1.0 mm

•

Field of View: typically 150 – 180 mm

Images were taken in uncompressed DICOM 3.0 format. KV and MA were kept as low
as possible with a table pitch 1:1. CT scans were reformatted for quantitative
measurement using Logic VIPTM Data Conversion® software.

X-ray Analysis
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Image J software (downloaded from http://rsb.info.nih.gov/ij/) was used for digital
radiograph analysis. The radiographs were assessed by obtaining the average density of
the third molar extraction socket sites. Three different readings were taken of each
socket and averaged. This average was compared to the average of three density outlines
of the adjacent tooth. When all radiographs for a patient were assessed in this manner,
they were normalized to the original radiograph and the same untouched adjacent tooth.
The baseline socket average was then subtracted from the normalized radiographic
average for each of the tooth extraction sockets at the different time points. This
accounted for minor radiographic exposure and technique variation with each time point.
The final normalized socket value differences for each PRP treated and non-treated sites
for the various time points were compared. Figure 35 illustrates the outline with ImageJ
software for outline of adjacent tooth used for normalization of radiographs and the
outline of the extraction socket.
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Figure 35. Example of ImageJ® Software Outline of Adjacent Tooth
and Extraction Socket
Example of ImageJ® software outline of adjacent tooth (left photo) used for
normalization with the baseline radiograph taken of the same site immediately following
tooth extraction and placement of the Gelfoam® (± PRP) and sutures. Right radiograph
illustrates outline of tooth extraction socket that is compared to the same region of
interest of the baseline radiograph. All radiographs were taken with the same exposure
parameters (KV, mA, and time) and similar angles and distance from x-ray source.

All radiographs were taken by a blinded certified X-ray dental assistant or hygienist.
Radiographs were taken immediately post-op and at the following time points after the
day of surgery: 3 days, 1 wk, 2 wks, 4 wks, 6 wks, 12 wks, 16 wks, 20 wks, and 24 wks.
Radiographs were evaluated by 3-blinded dental professionals.

CT Scan Analysis
CT scans were evaluated concerning percent bone fill, formed bone density, and total
socket formed bone density. CT scans were reformatted with Logic VIPTM Data
Conversion® software, which permitted quantitative measurements at 1mm increments of
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the extraction socket. Percent bone fill was determined by measuring the quantity of
bone that had formed in the socket at that time point and dividing this value by the entire
socket depth and multiplying by 100% . Representative bone fill measurements for
Patient-2 at 14 weeks are shown in Figure 36.
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Figure 36. Example of CT Scan Evaluated Percent Bone Fill
Measurements (mm) for Extraction Sites
Representative CT scan projections of control and PRP-treatment extraction sites are
illustrated by VIPTM Data Conversion® software for Patient-2 at 14 weeks. Each
individual projection represents a 1 mm sagittal cross section slice of the extraction
socket in a anterior to posterior direction. Measurements in millimeters (mm) are shown
using the measuring tool provided by the software. Two measurements are taken, one
that measures from the base of the extraction site to the superior aspect of actual formed
bone (left number in each slice), the second is total socket depth and is measured from
the base of the extraction socket to what would be the most superior aspect of the socket
(right number in each slice). Dividing the actual bone formed bone by the total socket
depth and multiplying this number by 100% provides the percent bone fill for the socket.
All bone fill measurements for the multiple 1 mm slices of the respective extraction site
were averaged together. Each CT scan was evaluated by 3-blinded observers. All three
evaluator average readings were then analyzed by a two-tailed t test.
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Newly formed bone density (NFBD) was measured in Hounsfield units (HU) by the
use of an elliptical drawing tool provided with the software. Areas of new bone
formation were outlined and quantified as HUs. Representative measurements of NFBD
for Patient-2 at 14 weeks are illustrated in Figure 37.
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Figure 37. Example of CT Scan Evaluated Newly Formed Bone
Density (NFBD) in Hounsfield Units for Extraction Sites
Representative CT scan projections of control and PRP-treatment extraction sites are
illustrated by VIPTM Data Conversion® software for Patient-2 at 14 weeks. Each
individual projection represents a 1 mm sagital cross section slice of the extraction socket
in a anterior to posterior direction. Measurements in Hounsfield units (Hus) are shown
with the elliptical measurement tool provided by the software. The elliptical tool was
used to outline actual bone that had formed in the extraction site as is referred to as newly
formed bone. Each measurement provides an average HU that was recorded for each
1mm slice. Average HUs represent averaged bone density, therefore these values would
represent the average newly formed bone density (NFBD) for that 1 mm slice. All HU
measurements obtained for the multiple 1 mm slices of the respective extraction site were
averaged together. Each CT scan was evaluated by 3-blinded observers. All three
evaluator average readings were then analyzed by a two-tailed t test.
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Total socket formed bone density (referred to as total formed bone density - TFBD) was
a measurement of the HUs for the entire socket, regardless of the quantity of bone
formed. Representative measurement of TFBD for Patient-2 at 14 weeks is shown in
Figure 38. This measurement was done in a similar manner to NFBD (Figure 37) but the
difference being that the entire height of the socket was considered, not just the areas that
had actual bone formation. This measurement could more accurately represent the same
areas measured by digital radiographs. Taking this measurement allowed for comparison
of the two measurement tools.
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Figure 38. Example of CT Scan Evaluated Total Formed Bone
Density (TFBD) in Hounsfield Units for Extraction Sites
Representative CT scan projections of control and PRP treatment extraction sites are
illustrated by VIPTM Data Conversion® software for Patient-2 at 14 weeks. Each
individual projection represents a 1 mm sagittal cross section slice of the extraction
socket in an anterior to posterior direction. Measurements in Hounsfield units (HUs) are
shown with the elliptical measurement tool provided by the software. The elliptical tool
was used to outline the entire vertical height of the extraction site as is referred to as total
bone formed. Each measurement provides an average HU that was recorded for each 1
mm slice. Average HUs represent averaged bone density, therefore these values would
represent the average total formed bone density (TFBD) for that 1 mm slice. All HU
measurements obtained for the multiple 1 mm slices of the respective extraction site were
averaged together. Each CT scan was evaluated by 3-blinded observers. All three
evaluator average readings were then analyzed by a two-tailed t test.

Patients 1 and 2 CT scans were measured in 1 mm cross section planes (anterior to
posterior). The CT scan for patient three was measured in panoramic 1 mm sectional
planes. The cross sectional planes were preferred, but the topography of the bone after
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tooth removal for Patient-3 did not permit accurate quantitative measurements with those
projections. CT scans were evaluated by 3-blinded evaluators working independently.

Statistical Analysis
Statistical analysis was performed using GraphPad Prism® 3.0 (GraphPad Software,
Inc., La Jolla, CA). Two-way ANOVA analysis was performed for digital radiographs
taken over a 0 to 2 weeks, 3 to 12 weeks, 3 to 25 weeks, and 0 to 25 weeks time-periods.
Two-tailed paired t-tests were performed for individual time points with digital
radiographs and CT scan analysis.

C. Results
Digital Radiographic Results:
Digital radiographs were used to evaluate changes in radiographic bone density for
each extraction site. Three blinded dental professionals working independently evaluated
all radiographs. All extractions were of bilateral mandibular third molars (wisdom teeth)
that had similar eruptive states prior to removal. Each patient had one extraction site
treated with PRP and the ipsilateral side did not receive PRP treatment. Three patients
received PRP treatment on the right side and three received the PRP treatment on the left
side. Treatment side was predetermined as follows. The first, third, and fifth patients
would receive PRP treatment on the left side and the second, forth, and sixth patients
would receive PRP treatment on the right side. This treatment decision was made prior to
viewing patient radiographs and patient position in the sequence was based on their order
of scheduling.
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Radiographic analysis of the digital radiographs taken for the 6 patients over the 25
week time period show a significant (p < .0001) effect of localized PRP treatment on
bone density. The data represent the percent change in radiographic density for each
socket and each time point from its corresponding baseline value. Baseline values were
determined as the radiographic density of extraction site immediately following tooth
removal and placement of the Gelfoam® and sutures. Figure 39 illustrates the mean
densities for all patients. The two-tailed paired t test was used to analyze each time point,
while two-way ANOVA was used to analyze data representing the span of a time-period.
The two-tailed paired t test showed that there was a significant increase in the
radiographic bone density for PRP treatment sites compared to control sites for each of
the time points 1week (p < .01), and 2 weeks (p < .05). The PRP treatment side had a
positive effect on bone density immediately following tooth extraction. Whereas, the
control side when compared to its corresponding baseline bone density immediately
following tooth removal (baseline density), showed a decrease in bone density for the
initial week and by week 2 returned to baseline. Two-way ANOVA for the initial 2
weeks showed that treatment was significant (F = 32.16, p < .0001), the time elapsed
following surgery was not significant (F = 2.874, p > .05) but there was a significant
interaction between treatment and time (F =7.733, p < .001). For weeks 3-12, treatment
was significant (F=21.97, p < .0001), but time was not (F=1.698, p > .05) and there was
no significant interaction between time and treatment (F=0.1455, p > .05). Weeks 3, 4, 6,
and 8 showed parallel density changes from their respective baseline. The two-tailed
paired t test revealed at week 12 a significant difference (p < .05) between the density
changes between the two groups as did week 20 (p < .05). The intervening week 16 (p >
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.05) did not show a significant difference nor did week 25 (p > .05. The PRP treatment
group had greater bone density changes over baseline immediately following extraction,
but the differences between the groups were not significant at later time points with the
exception of weeks 12 and 20. For weeks 3-25 two-way ANOVA analysis did reveal that
treatment was significant (F = 15.21, p < .0001), time elapsed was also significant (F =
5.924, p < .001), but the interaction between treatment and time was not significant
(F=0.07530, p > .05). When examining the entire 25-week period, treatment was again
significant (F = 37.49, p < .0001), time elapsed following surgery was significant (F =
13.75, p < .0001) but the interaction between treatment and time was not significant
(F=0.6975, p > .05).
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Figure 39.

Percent Radiographic Density Change of Surgical

±PRP Treatment compared to Control Radiograph Taken
Immediately Following Tooth Removal

All 6 patients are represented in this graph with each time point representing the average
values of the patients combined. Percent bone density change on the Y-axis represents
the change in bone density that has occurred at the extraction site in comparison to the
extraction site immediately after tooth removal and placement of the Gelfoam® sponge ±
PRP and suturing. Digital radiographs were normalized to the immediate post-operative
film by comparing the unaltered adjacent tooth on the time point radiograph with the
immediate post-operative radiograph’s corresponding unaltered tooth. Each patient’s
digital radiographs were evaluated by 3-blinded evaluators. Each point on the connecting
bars represents the ± S.E.M. for the six different patients and each treatment group.
Analyses for each treatment site were performed in triplicate by each evaluator. Each
data point was analyzed with a two-tailed paired t-test where significance was defined as
p < .05, where a = p < .01; b = p > .05 for individual time points. For the span of timeperiods, a two-way ANOVA was performed and significance was defined as p < .05. For
the time period 0 to 2 weeks PRP-treatment was significant (p < .0001); time was not
significant (p > .05); but there was a significant interaction (p < .001) between the
benefits of PRP-treatment and time, therefore the beneficial effects of the PRP-treatment
and time were related for the initial 2 week post-operative healing time period. For
weeks 3 though 12 treatment was significant (p < .0001), but time was not (p > .05) and
there was no significant interaction between time and treatment (p > .05). For the time
period 0 to 25 weeks PRP-treatment was significant (p < .0001); time was significant (p <
.0001); but there was not a significant interaction (p > .05) between the benefits of PRPtreatment and time, therefore the effect of the PRP-treatment was independent of time for
the entire 25 week time period.

CT Scan Results
Sample CT scan projections for each of the 3 patients who underwent this analysis are
presented in Figures 40-42. The panoramic, axial and sagital cross-sectional windows
were viewed in one mm slices and sagital cross-sectional views were evaluated for each
patient at their indicated time point. Three-blinded dental personal working
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independently analyzed each of the CT scans. The standard error of the mean (SEM) of
these three measurements is indicated on each of the graphs. There is some subjective
interpretation in outlining areas to evaluate, as there was with the digital radiographs.
Each evaluator recorded three readings for each 1mm slice at each extraction site.
Evaluations were done for 3 criteria: 1) percent bone fill; 2) newly formed bone density
(NFBD); and 3) total bone formed density (TFBD). The three readings for each scan
slice were averaged.

Figure 40. Patient 1 CT Scan 18 Weeks
CT scan panel for Patient 1. A. Panoramic radiographic projection (traditional x-ray);B.
Axial CT section superior to extraction sites; C. Panoramic CT section note: L (left) and
R (right) correspond to each side of the patient; D. CT scan sagittal cross-section 1mm
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slices of left extraction site (PRP treated); E. CT scan sagital cross-section 1 mm slices of
right extraction site (control).

Figure 41. Patient 2 CT Scan 14 Weeks
CT scan panel for Patient 2. A. Panoramic radiographic projection (traditional x-ray);B.
Axial CT section superior to extraction sites; C. Panoramic CT section note: L (left) and
R (right) correspond to each side of the patient; D. CT scan sagital cross-section 1mm
slices of right extraction site (PRP treated); E. CT scan sagital cross-section 1mm slices
of left extraction site (control).
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Figure 42. Patient 3 CT Scan 10.5 Weeks
CT scan panel for Patient 3. A. Panoramic radiographic projection (traditional x-ray);B.
Axial CT section superior to extraction sites; C. Panoramic CT section note: L (left) and
R (right) correspond to each side of the patient; D. CT scan sagital cross-section 1mm
slices of right extraction site (PRP treated); E. CT scan sagital cross-section 1 mm slices
of left extraction site (control).
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Three factors were evaluated for each of the CT scans. The first factor was percent
bone fill that represented the degree to which the bone had developed and filled in the
extraction socket. This was done by measuring the radiographic evidence of bone
formation in the socket from an inferior to superior manner and dividing this value by the
height of the total socket (again inferior to superior measurement). The second factor
analyzed was newly formed bone density (NFBD) which represents the density of the
bone that had actually formed in the socket. This measurement was calculated by the
computer program and was concerned only with actual new bone formation. The third
factor analyzed was Total Formed Bone Density (TFBD). This factor considered the
entire extraction socket bone density. All three factors were analyzed for each individual
patient’s CT scan at a specific time with three readings (averaged) from three blinded
evaluators using the two-tailed paired t test. The data for the three patients’ individual
factors were combined and analyzed with a two-way ANOVA, because three different
time points were considered.
For the first factor percent bone fill of the extraction sockets were examined and
compared.

PRP treated sites were compared with non-PRP treated sites (control).

Percent bone fill for all of the patients (Patient-1 at 18 weeks, Patient-2 at 14 weeks, and
Patient-3 at 10.5 weeks) did not reveal a substantial difference in bone height between the
PRP treatment sites and control sites (Figures 43 A-C). Patient-1 (18 weeks) CT scan
(Figure 43-Panel A) indicated that bone fill for the PRP treated side was 96% in
comparison to the control side at 90%. Patient-2 CT scan (14 weeks) illustrated that the
PRP treated side bone fill was 90% in comparison to the control side at 81% (Figure 43Panel B). Patient-3 (Figure 43-Panel C) had the earliest CT scan (10.5 weeks) indicated
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that the PRP treated side had 55% bone fill while the control side was approximately
42%. The lesser percent bone fill for the earliest CT scan and greater bone fill for the
subsequent later time point CT scan was expected. When using a two-way ANOVA to
compare all 3 patients and their respective time points together, the PRP sites did
show significant (F=19.76, p < .05) greater percent bone fill than the control sites
(Figure 47-Panel D); time was also significant (F=185.3, p < .01).
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Figure 43. Percent Bone Fill of Extraction Sockets Analyzed by
CT Scan
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Panels A-C represents CT scan analyses of percent bone fill for the PRP-treated and
control extraction sites on three different patients at a specific time point. Panel A
represents a patient’s percent bone fill at 18-weeks. Panel B represents a patient’s
percent bone fill at 14-weeks. Panel C represents a patient’s percent bone fill at 10.5weeks. Panel D represents the three patients over the three time points and analyzed by
two-way ANOVA where significance was defined as p < .05. Where a = p < .05 revealed
that PRP-treatment significantly enhanced the percent bone fill when compared to nonPRP-treated sites (control). For b = p < .01 Time elapsed since tooth removal was also
found to be significant.

The second factor examined was bone that had developed since the extraction
had taken place and it is referred to as newly formed bone. PRP treated sites were
compared with non-PRP treated sites (control). New bone that formed was measured in
HUs and illustrated in Figure 44 A-D. It is referred to as newly formed bone density
(NFBD). As expected, the NFBD was greater at the later time points than the earlier
10.5-week time point. Patient -1 (18-weeks) NFBD is presented in Figure 44A. Patient2 (Figure 44 B) had denser bone at the 14-week time point in comparison to Patient-3
(Figure 44-C)at the 18-week time point, but this may be due to individual patient
variation or measurement variables. When comparing all patient treatments together
(Figure 44 D) and the various time points with a two-way ANOVA, the PRP-treated and
control sites did not differ significantly (F=0.01475.134, p > .05) in NFBD, and time was
not a significant (F=13.19, p > .05) factor either.
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Figure 44. Newly Formed Bone Density (NFBD) of Extraction
Sockets Analyzed by CT Scan
Panels A-C represents CT scan analyses of newly formed bone density (NFBD) for the
PRP-treated and control extraction sites on three different patients at a specific time
point. Panel A represents a patient’s NFBD at 18-weeks. Panel B represents a patient’s
NFBD at 14-weeks. Panel C represents a patient’s NFBD at 10.5-weeks. Panel D
represents the three patients over the three time points and analyzed by two-way ANOVA
where NFBD with PRP-treatment was not significant (p > .05) in comparison to the
control sites. Time elapsed was found not a significant (p > .05) factor for NFBD.
The third factor considered was the average bone density for the entire tooth
extraction site. PRP treated sites were compared to non-PRP treated sites (control).
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Total Formed Bone Density (TFBD) represents the density of the complete extraction
socket. This measurement includes new bone that had actually formed in the socket and
areas of the socket where bone had not yet developed. TFBD is measured in HUs and
illustrated in Figures 45 A-D. Again, as expected Patient-3 (10.5-weeks) (Figure 45 C)
with the earliest CT scan had the lowest TFBD, while Patient-2 (14-weeks) (Figure 45 B)
did have a slightly higher value than Patient-1 (18-weeks) (Figure 45 A). When
comparing all of the patients together (Figure 45 D) with a two-way ANOVA analysis,
the PRP-treated sites did not have a significant increase (F = 0.2557, p > .05) in TFBD,
but time elapsed since tooth removal was a significant (F = 96.12, p > .0001) factor.
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Figure 45. Total Formed Bone Density (TFBD) of Extraction
Sockets Analyzed by CT Scan
Panels A-C represents CT scan analyses of total formed bone density (TFBD) for the
PRP-treated and control extraction sites on three different patients at a particular time
point. Panel A represents a patient’s TFBD at 18-weeks. Panel B represents a patient’s
TFBD at 14-weeks. Panel C represents a patient’s TFBD at 10.5-weeks. For each of
these patients there was no substantial difference between PRP-treatment and control
sites. Panel D represents the three patients over the three time points and analyzed by
two-way ANOVA, where TFBD with PRP-treatment was not significant (p > .05) in
comparison to the control sites. Time elapsed did have a significant effect (p <.0001) on
TFBD.
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Next, the TBFD values obtained from the CT scan analysis were compared to the
grayscale digital radiographic analysis. The digital radiograph grayscale values were of
the entire socket (as were the TBFD values) and therefore, represent similar
measurements. Figure 39 shows the normalized percent change in digital radiographic
bone density from the baseline value. Table 12 shows the ratio of the normalized
grayscale value of the PRP treated site to the control site in each of these three patients
who underwent CT scans. To minimize radiation exposure for patients the CT scans
were obtained midway between two digital radiographic time points. This comparison
revealed that the CT scan percent TBFD were similar, but higher than the digital
radiograph grayscale values. The results for the two later time point CT scans had greater
similarity to the digital radiograph grayscale values than for the CT scan taken at the
earlier time point.
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Patient

1
2
3

(A) Digital
Radiograph prior to
CT scan ± S.E.
101.0 ± 3.377 (16
wks)
102.7 ± 1.448 (12
wks)
101.2 ± 2.247 (9.5
wks)

(B) CT scan ± S.E.

(C) Digital Radiograph
after CT scan ± S.E.

106.0± 3.99 (18 wks)

97.25 ± 0.8253 (20 wks)

107.6 ± 7.353 (14 wks)

101.2 ± 0.5452 (16 wks)

115.7± 5.108 (10.5 wks)

105.3 ± 2.717 (11.5 wks)

Table 12. Total Bone Formed Density (TFBD) - Percent Change
Comparisons of Digital Radiographs and CT Scans
These TBFD values compare the percent radiographic density changes observed between digital
radiographs and CT scans. Column A represents the digital radiograph taken 2-4 weeks prior to
the CT scan (column B) and column C represents the digital radiograph taken 1-2 weeks after the
CT scan. Comparison revealed that the CT scan percent TBFD were comparable, but

higher than the both earlier and later digital radiograph grayscale values. The results for
the two later time point CT scans had greater similarity to the digital radiograph grayscale
values than for the CT scan taken at the earlier time point. It is commonly accepted that
CT scan Hounsfield Unit readings are more accurate than digital radiographic grayscale
values; therefore, the digital radiographic analysis may be artificially lower than reality.

Patients’ Evaluation Results
Patients were asked to use a visual analogue scale (VAS) with a 1-10 rating for pain
and a 1-3 rating for bleeding, numbness, facial edema and facial temperature for each
time point. The patient is asked to pick a numerical score on a horizontal line that has a 1
to 10 or 1 to 3 markings to evaluate the severity of the factor being considered. The
higher the numbered response represents a greater the severity of the factor. An example
being a score of “8” signifies greater pain than a score of “2”. Figure 46 provides
illustrations for the patients’ post-operative observations. Patients were blinded to which
side received the PRP treatment.

198

B. Bleeding

A. Pain
30
Control

VAS Rating

VAS Rating

PRP
20

10

0
1

2

3

4

5 6
Day

7

8

1

VAS Rating

PRP
Control

2

3

Control

2

3

4

5 6
Day

7

8

9

D. Facial Edema

9
8
7
6
5
4
3
2
1
0
1

PRP

9

C. Numbness

VAS Rating

9
8
7
6
5
4
3
2
1
0

4

5 6
Day

7

8

9

9
8
7
6
5
4
3
2
1
0

PRP
Control

1

2

3

4

5 6
Day

7

8

9

VAS Rating

E. Facial Temperature
9
8
7
6
5
4
3
2
1
0

PRP
Control

1

2

3

4

5 6
Day

7

8

9

Figure 46. Patient VAS Evaluated Post-Operative Pain, Bleeding,
Numbness, Facial Edema, and Facial Temperature
Visual analogue scale (VAS) ratings by patients for post-operative perceptions of pain
(Panel A, 1-10 scale), bleeding (Panel B, 1-3 scale), numbness (Panel C, 1-3 scale), facial
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edema (Panel D, 1-3 scale), and facial tissue temperature (Panel E, 1-3 scale). Patients
provided ratings for the initial nine post-operative days. Ratings were taken every 8
hours for days 1-3 and scores are reported as a total for the entire 24-hour time period for
a total possible score of 30 points for pain and 9 points for the other factors. Ratings
were reported every 12 hours for days 4 -9 and scores were again reported as a total for
the entire 24-hour time period for a total possible score of 20 points for pain and 6 points
for the other factors. Two-tailed paired t tests revealed that there was no significant
difference (p > .05) for any of these factors at any specific time point. For the entire nine
day time two-way ANOVA analysis demonstrated that time elapsed since the surgical
procedure was significant (p < .0001) for pain, bleeding, numbness, facial edema, and
facial temperature (p < .05). PRP treatment did not have a significant impact on any of
the factors (p > .05). Time and PRP treatment were independent of each other.

Patients were asked to post-operatively rate their perception of pain using a 1-10 visual
analogue scale (VAS) (Figure 46 A). There was a total possible score of 30 for the first 3
days and then 20 for the subsequent days. When using a two-tailed paired t test for each
specific time point there was no statistical difference (p > .05) between the PRP treatment
side and the control side for any of the parameters. Patients were administered
dexamethasone sodium phosphate IV intra-operatively; ketorolac trimethamine IV, and
methylprednisolone suspension IM, and 4% bupivacaine with 1:200,000 epinephrine via
an inferior alveolar block immediately following the procedure. Patients were instructed
to take 600 mg ibuprofen every 6 hours for the first 3 days and thereafter, as needed. The
adjuvant medications most probably reduced the post-operative pain, which may explain
why the patients did not report high pain ratings. The use of bupivacaine local anesthesia
would explain the higher numbness rating for the initial 24 hours. When examining the
entire nine day time with a two-way ANOVA, treatment did not have a significant effect
(F = .003, p > .05), time did have a significant effect (F = 9.01, p < .0001), and there was
no interaction between treatment and time.
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Patients reported minimal post-operative bleeding (Figure 46 B). Two-tailed paired t
test analysis for each specific time point revealed no significant differences between the
PRP treated sides and the control sides (p > 05). Two-way ANOVA analysis for the
entire nine day post-operative period did show that treatment was not significant (F =
.373, p > .05), time was significant (F = 9.47, p < .0001), and there was no interaction (F
= .117, p > .05) between treatment and time. Therefore, PRP treatment and time were
independent of each other.
Patient reports of post-operative numbness (Figure 46 C) was substantial on both
treatment and control sides for the 1st day, thereafter it was very slight. The numbness on
the initial post-operative day is due to the administration of the long-acting local
anesthetic bupivacaine HCl 0.5% with epinephrine 1:200,000. The half-life for soft
tissue anesthesia of this local anesthetic is 7 to 8 hours (470). Subsequent numbness over
the remaining 8 days was minimal and most likely due to the formation of edema. The
two-tailed t test analysis for each time point revealed no significant differences between
the PRP treated sides and the control sides (p > .05). Two-way ANOVA analysis for the
entire post-operative period showed that PRP treatment did not make a difference (F =
0.72, p > .05), time was significant (F = 13.81, p < .0001) and there was no interaction (F
= 0.72, p > .05) between treatment and time.
Facial edema was higher on both the treatment and control sides for each of the first 3
days but the two-tailed t test revealed that there was no significant difference (p > .05)
between sides (Figure 46 D). The administration of glucocorticosteroids and the
patient’s use of ice packs may also have contributed to the lower ratings for edema.
When examining the entire nine day time with a two-way ANOVA, treatment did not
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have a significant effect (F = .076, p > .05), time did have a significant effect (F = 27.71,
p < .0001), and there was no interaction between treatment and time (F = 0.246, p > .05).
At no time did any of the patients report marked increases in tissue temperatures
(Figure 46 E). The two-tailed paired t test for each specific time point revealed that skin
temperature was not significantly different (p > .05) for any of the time points. Two-way
ANOVA for the entire nine day post-operative period showed that tissue temperature was
not affected by PRP treatment (F = .083, p > .05), time was significant (F = 3.176, p <
.05), and there was no significant interaction between treatment and time (F = 1.254, p >
.05).
The patients use of NSAIDs (ketorolac and ibuprofen) may have helped keep
temperature elevations to a minimum. It has been well documented that the use of
glucocorticosteroids and/or NSAIDs may interfere with new bone formation (471, 472),
but this does not appear to be the case here. This is likely because the medications were
administered for only a short time period. Also, the presence of PRP with constituent
multiple growth factors and cytokines could have mitigated the negative effects of these
medications.
A comprehensive listing of patient rated post-operative parameters are presented in Table
13.
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p value

F ratio

No

>.05

.003

Yes
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9.01

No

>.05

.053

Bleeding
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>.05
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9.47
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Numbness
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.72
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>.05
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.>.05
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>.05
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F ratio

F ratio

Significance

Interaction

p value

Significance

Time

Pain

Factor

p value

VAS Rating

Significance

Treatment

Facial
Edema
Temp.

Table 13. Summary Table of Two-way ANOVA Analysis of Patient
Post-operative Observations
Two-way ANOVA statistics summary of the significance, F ratio, and p-values for each
of the patient evaluated post-operative parameters. PRP treatment was not significant for
any of the parameters. Elapsed post-operative time did have a significant impact on all of
the parameters. Time and PRP treatment effects were independent of each other.

Observers’ Evaluation Results
Blinded clinical observers evaluated the degree of tissue opening (dehiscence),
bleeding, inflammation, facial edema, intra-oral edema, and perceived pain using a VAS
(Figure 47 A-F).
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Figure 47. Observer VAS Evaluated Post-Operative Dehiscence,
Bleeding, Inflammation, Facial Edema, Intra-Oral Edema, and
Pain
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Visual analogue scale (VAS) ratings as reported by blinded observers for post-operative
perceptions of dehiscence (Panel A), bleeding (Panel B), inflammation (Panel C), facial
edema (Panel D), intra-oral edema, (Panel E) and pain (Panel F). Dehiscence, bleeding,
inflammation, facial edema, and intra-oral edema evaluations were done on a 1-3 scale,
pain was evaluated on a 1-10 scale. Observers provided evaluations at the following
post-operative time points: days 3 and 7, then weeks 2, 3, 4, 6, 8, 12, 16, 20, and 24.
Two-tailed paired t tests revealed that there was no significant difference (p > .05) for any
of the parameters at specific time points. When analyzing the entire 24-week time with a
two-way ANOVA analysis PRP treatment was significant for reducing facial edema (p <
.05). PRP treatment was not significant for any of the other parameters (p > .05). Twoway ANOVA analysis demonstrated that time elapsed since the surgical procedure was
significant for dehiscence (p < .01), inflammation (p < .0001), facial edema (p < .0001),
intra-oral edema (p < .0001), and pain (p < .0001). Time was not significant for bleeding
(p > .05). Treatment and time were independent of each other (p > .05).

Observers found no dehiscence (Figure 47 A) on day 3 because primary closure was
obtained with sutures. Subsequent ratings did reveal tissue retraction, but this does not
translate to exposed bone. This was the result of the edges of the tissue rolling back, but
the socket was covered initially by a blood clot and later by soft tissue. No patients
experienced exposed bone. The two-tailed paired t test showed that there was no
significant (p > .05) difference between the two treatment sites in regards to dehiscence
for any of the specific time points. The two-way ANOVA did reveal the treatment was
not significant (F = .019, P > .05), time was significant (F = 4.198, p < .01), and there
was no interaction between these two factors (F = .117, p > .05).
Observer’s perception of bleeding (Figure 47 B) was that there was minimal bleeding
from all operative sites. The two-tailed paired t test analysis of the specific time points
showed no significant difference between the PRP treated sides and the control sites (p >
.05). Two-way ANOVA showed that treatment, time, and interaction were not
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significant factors [treatment (F = .617, p > .05), time (F = 1.367, p > .05), and interaction
(F = .277, p > .05)].
Inflammation (Figure 47 C) was not significantly different (p > .05) between PRP
treated sides and the control sides for any of the specific time points when rated by the
observers and analyzed by the two-tailed t test. The two-way ANOVA analysis of the
24-week post-operative period revealed that PRP treatment was not significant (F =
2.577, p > .05), time was significant (F = 13.20, p < .0001), and there was no interaction
between these two factors (F = .339, p > .05).
Observers’ evaluation of facial edema (Figure 47 D) and two tailed paired t test
analysis revealed that PRP treatment provided no significant differences (p > .05)
between treatment and control at any of the specific time points. Two-way ANOVA of
the entire post-operative period did show that treatment was significant (F = 4.416, p <
.05), time was extremely significant (F = 8.986, p < .0001) and there was no interaction
(F = .639, p > .05).
Intra-oral edema (Figure 47 E) was rated by the observers and two-tailed paired t test
analysis revealed that treatment provided no significant differences (p > .05) for any of
the specific post-operative time points. The two-way ANOVA analysis of the entire postoperative time revealed that treatment was not significant (F = 3.843, p > .05), time was
significant (F = 11.4, p < .0001) and these two factors were independent of each other (F
= 0.696, p > .0001).
Observers’ ratings of the patients’ pain (Figure 47 F) analyzed with the two-tailed
paired t test showed that there was no significant difference (p > .05) at any of the
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specific time points. Analysis of the entire post-operative period with two-way ANOVA
revealed that treatment was not significant (F = 1.104, p > .05), time was significant (F =
44.5, p < .0001), and there was not a significant interaction between these two factors (F
= 0.185, p > .05). There were similarities between the pain ratings provided by the
patients (Figure 50-Panel A) and those provided by the observers at day 3 (Figure 51Panel F). Observer ratings were at day 3, week 1, then weekly thereafter, while the
patient ratings were on a daily basis for the initial nine post-operative days following
surgery. Patients rated their pain on day 3 as 10.83 (total - maximum of 30) for the PRP
side and 11.00 for the control side, representing the sum of three readings for the day. If
the patient readings were divided by three to give an average reading for each 8 hour time
period that the patients evaluated it would translate to 3.61 for the PRP side and 3.67 for
the control side. Observers provided only one rating on day 3 resulting in a score of 4.5
for the PRP side and a score of 5 for the control side. The other reading that overlapped
for the observers and patients was day 7. Patients provided an average score of 1.5
(average 12 hour reading) for the PRP side and 1.83 for the control side. Observers
provided scores of 1.8 for the PRP side and 2.2 for the control side. These overlapping
pain ratings were similar, but the observer always rated the pain slightly more severe than
did the patients.
A summary of the statistical analysis of the post-operative parameters evaluated by
the observers are listed in table 14.
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Table 14. Summary Table of Two-way ANOVA Analysis of
Observers Post-operative Observations
Two-way ANOVA statistical summary table of the significance, F-ratio and p-values for
each of the observer evaluated parameters. PRP treatment over the 24-week time was
significant (p < .05) for facial edema. PRP treatment was not significant for any of the
other parameters. Elapsed post-operative time did have a significant impact on all of the
parameters. Time and PRP treatment effects were independent of each other.
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D. Discussion
This prospective blinded third molar pilot study offers insight to what is occurring
clinically when BC-PRP is applied to fresh extraction sites. Third molar extractions are
often used as a measurement tool for comparing treatments because they are usually
performed electively on a younger population that do not present with multiple
confounding factors such as systemic pathologies or multiple medications. Therefore,
data analysis and interpretation from this study applies to healthy 18 to 40 year old
patients.
Intra-oral digital radiographs taken of the individual surgical sites revealed that
the effects of PRP were significantly beneficial (p < .05) for bone density determined by
grayscale analysis. One can make the argument that this significant difference in bone
density suggests a greater volume of new bone formation with PRP treatment. This
increase in bone density (presumed as increased volume of new bone formation) was
found to occur at earlier time points than the non-PRP treated control sites. Figure 48 is
the same as Figure 39, except grid lines that allow for closer interpretation of the data
points.
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Figure 48.

Percent Radiographic Density Change of Surgical

±PRP Treatment compared to Control Radiograph Taken
Immediately Following Tooth Removal

This graph is the same as Figure 43 with the exception that grid lines have been added. .
Grid lines allow for time comparison between PRP treated and control sides. Each data
specific time point was analyzed with a two-tailed paired t-test where significance was
defined as p < .05, where a = p < .01; b= p > .05 for individual time points. The marked
difference in bone density during the initial 2 weeks post-operatively denotes the
accelerated bone formation PRP treatment seems to provide. This immediate increase in
bone density at the PRP treated sites indicates early bone formation in comparison to the
control sites that have a decrease in bone density indicating further bone loss. Note that it
takes 6 weeks to reach the same degree of bone density that the PRP treated sites had
achieved at week 1.
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Of note was the immediate increase in grayscale readings which represents bone
density and therefore early bone formation. This finding corresponds with the results
from the molecular study that demonstrated PRP treatment of hMSCs induced an early
proliferation of these cell types and possibly differentiation into osteoblasts. This
accelerated bone formation is in contrast to the control site that showed a drop in bone
density (representing bone loss) before bone formation began to take place. It took
approximately 6 weeks for the control side to reach the same degree of bone density that
the PRP treated site had reached at week 1 (Figure 48). The PRP induced accelerated
bone formation may be due to the presence of BMPs 2 and 6 in PRP that stimulated the
hMSCs to begin the osteoblast differentiation development and subsequent calcification
(473, 474). The control sites would be dependent upon osteoclast activity to initially
breakdown existing bone so the bone matrix could release these two BMPs and then
stimulate the hMSCs to begin bone development. These findings correspond well with
the known and accepted bone-repair time-line (475). This immediate start of bone
formation is of clinical relevance because, it is the initial two weeks following bonemanipulation oral surgery that is important in preventing infection, loss of the blood clot
and/or AO (dry socket) formation. Moreover, there was a slight drop in grayscale density
at the 1.5 to 2 week period suggesting that the initial direct impact of BC-PRP treatment
might end, or at the minimum decrease, by the 1.5 – 2 week time point.
Further examination of the digital radiographic density changes shows that
subsequent changes in bone density with the PRP treated sites and control sites are
parallel, with no significant differences, except for the 12 and 20-week time points. The
finding of the parallel lines most likely represents that normal healing is now taking place

211

at both sites, but the change in bone density was greater for the PRP treated site because
it had the immediate bone formation, whereas the control site did not. The significant
differences seen at the 12 and 20-week time points may be due to bone remodeling or
inherent variations in the radiographic evaluation technique.
It should also be noted that it takes the control side 16 weeks to reach the same degree
of increased radiographic grayscale for the total extraction socket as the PRP treatment
achieves in 8 weeks. This is of clinical significance because it suggests decreased
healing time. Therefore, patients bone recovers more rapidly to full function or is ready
for the next step in dental reconstruction at an earlier date. Examples of this benefit
include patients who undergo complete arch extractions and are in need of prosthesis for
esthetics and function. The patient may be given an initial temporary denture that is
normally utilized for 6 months prior to constructing the definitive final denture that has
superior esthetics and function. This final denture could be constructed at the 2 to 3
month time point and therefore return the patient to full function in a shorter time-period.
The decrease in bone healing time would also apply to the placement of dental implants
that normally occurs after 4 to 6 months, unless expensive bone-grafting techniques are
utilized which still require a 4-month bone healing time. With PRP treatment at the time
of tooth removal, dental implants can be placed at a 2 to 4 month time, thereby
decreasing the time to implant placement by 50%.
The instrumentation in this portion of the study utilized non-invasive radiographic
techniques. Admittedly, bone histology studies could provide additional information
with greater validity, but that analysis technique would be invasive, requiring surgical
reentry. Individual site digital radiographs were taken and normalized to baseline
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radiographs. The initial radiographs were normalized between the two surgical sites of
the patient. Digital panoramic radiographs may have been a better measurement tool
because the two surgical sites would be represented on one film, thereby eliminating the
need for radiographic normalization between the initial surgical sites. Nonetheless,
normalization between the series of radiographs and baseline radiographs would still
have been necessary. The disadvantage of the digital panoramic radiograph is that these
films have a 20 to 25% distortion factor incorporated into the image because it is an
extra-oral film as opposed to the intra-oral individual (periapical) digital radiographs.
The periapical radiograph was chosen over the panoramic radiograph because the
periapical radiograph has less distortion incorporated into the images than with
panoramic films. There is less distortion because the periapical film is in close proximity
to the oral site being evaluated as opposed to being removed from the immediate site of
interest as is the extra-oral panoramic radiograph is.
The CT scans may have shown greater differences between the PRP treated sites and
the control sites, had they been obtained at earlier time points. Based on these findings
and now knowing the effects of PRP-treatment are greatest during the initial 2 weeks it
would be beneficial to acquire the CT scans at earlier time points. Therefore, future
studies will have the CT scans taken at earlier time points to confirm the early effects of
PRP treatment.
Patients in this study were exposed to medications (dexamethasone sodium phosphate,
methylprednisolone suspension, ketorolac trimethamine, and ibuprofen) that interfere
with inflammation and therefore may have an impact on bone healing. During the early
phase of bone formation there is increased gene expression of pro-inflammatory
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cytokines, mitogenic growth factors, and cell-differentiating factors. Inflammation,
which occurs at the onset of early phase injury- or surgically-induced bone formation, is
hypothesized to provide the initial signaling molecules for continuation of the healing
cascade (476, 477). Cyclooxygenase-2 (COX-2) is important to the course of normal
inflammation (476, 478-480). The rate-limiting step in the synthesis of prostaglandins
from arachidonic acid is catalyzed by COX-2. Prostaglandins are bioactive lipids and are
of significance because they possess pro-inflammatory effects plus other varied
physiological effects (476, 481). COX-2 is responsible for PGE2 and PGF2 formation
and is thought to have a functional role in healing (482).
Glucocorticosteroids (dexamethasone, methylprednisolone) and NSAIDs (ibuprofen,
ketorolac) were used during this clinical study because of their analgesic and antiinflammatory efficacy. The inhibition of cyclooxygenases is the mechanism by which
glucocorticosteroids and NSAIDs achieve their intended effects.

Following the

hypothesis that inflammation is necessary for normal bone healing and formation, postoperative NSAID therapy may potentially delay bone healing. However, PRP may be a
suitable agent to offset this inhibition when NSAIDs are prescribed for a short postoperative course. Figure 49 offers a possible mechanism for the beneficial effects of PRP
that can offset the negative bone healing effects of NSAIDs. PRP contains platelets and
monocytes. Both platelets and monocytes contain the cytokine interleukin-1α (IL-1α)
(483, 484). IL-1α is involved in the local regulation of bone homoeostasis (485). It is
also known that IL-1α stimulates PGE2 formation (485-489).

This IL-1α-induced

stimulation of PGE2 formation would counter the PGE2 inhibition induced by systemic
post-operative NSAID and glucocorticoid steroid administration. Transient IL-1α has
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been shown to have a potent stimulatory effect on bone formation (490, 491). PRP
administration is transient in nature. The platelets in PRP also contain several growth
factors (PDGF-AA, PDGF-BB, ILGF, TGFβ1, VEGF, and OPG) which work in concert
in bone development and repair. Therefore, PRP use most likely would sufficiently
counter any PGE2 inhibition induced by short-term use of NSAID/glucocorticoid.

Figure 49: Effect of NSAIDs on Bone Formation
The use of NSAIDs blocks the formation of PGE2 initiated by the release of arachidonic
acid. The lack of PGE2 formation associated with the inflammatory response interferes
with bone formation. The use of PRP, which contains WBCs that release IL-1α and
platelets, which release IL-1α, TGF-β1, PDGF-BB, VEGF, and OPG, may potentially
medicate the adverse effects that NSAID use has on bone development.
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An alternative to using glucocorticosteroids and NSAIDs would be to use
acetaminophen and/or narcotics for post-operative pain control. Acetaminophen does not
have an anti-inflammatory effect and therefore the patients would experience greater
inflammatory effects, such as edema and pain. Narcotic administration often times are
fraught with unwanted side effects such as decreased mental acuity, lethargy, and GI
disturbance. Therefore, these two analgesics have little advantage over NSAIDs.
When examining the data from this study it appears that PRP does accelerate bone
formation and decreases the time necessary to return to full function. Other factors are
present that would affect the patients’ pain perception, bleeding, and numbness so it is
difficult to confirm the effect PRP has on these factors. Blinded observers did report
significantly less inflammation and facial edema (p < .05) on the sides receiving PRP.
However, a larger study with fewer confounding factors would be necessary to confirm
the effectiveness of PRP on inflammation and subsequent edema.
E. Conclusion
The results of this study validate the use of this simple cost-effective buffy coat (BC)
PRP method with oral surgical procedures. The use of this BC system would be
beneficial for the patient and clinician because it significantly increases the rate of bone
formation early one (initial 2 weeks) and decrease healing time as evidenced by digital
radiographic technology. However, it may not have an effect on pain perception,
bleeding, and numbness. It is possible that PRP decreases inflammation and, therefore,
the discomfort of edema. Having evidence-based support from this and future studies for
the use of this procedure may result in expanded use of PRP with other surgical

216

procedures with improved clinical outcomes. Other surgical procedures requiring
enhanced and predictable bone formation that would benefit from this technology include
orthopedic joint implants, spinal surgeries, and trauma cases involving bone fractures.
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General Discussion
This project contributes directly to evidence based dentistry with a possible
application to orthopedics. There has been a great deal of interest in both of these
disciplines regarding PRP application for enhancing outcomes by decreasing healing time
in surgeries that involve osseous manipulation. A historical review of the literature
reveals that PRP and its various techniques have been used with limited scientific
evidence. Some authors have stated that only complex and expensive techniques for
preparing PRP had clinical validity (10). This project used both in vitro and in vivo
investigations to offer strong support for the use of a simple cost-effective technique for
preparing PRP. Because this technique is inexpensive and simple, its use can be applied
to all osseous surgical procedures, thereby improving the quality of life for more patients.
The Preparation and Characterization of PRP (Study I) confirmed that platelet
recovery and enrichment of PRP using the Cliniseal™ Centrifuge was consistently
optimal with a 10-minute centrifugation time (Figure 16). Moreover, platelet recovery
and enrichment did not change significantly after centrifugation for up to six hours of
bench set time at room temperature (Figure 18). Growth factors of interest were present
at all bench set times and therefore, not affected for up to 6 hours of setting at room
temperature. Platelets did aggregate and possibly undergo activation while undergoing
the bench set, but the GFs that may have been released were not lost as they were most
likely retained in a flexible fibrin junction (Figure 11). The aggregation and activation
process is done slowly so it would most likely mimic the flexible fibrin structure of the
platelet rich fibrin processing technique (page 48) Therefore, the Buffy Coat (BC)
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method of PRP preparation provides platelet concentrations and recoveries that are
adequate for clinical use.
A finding not reported previously in the literature is how platelet morphology changed
with bench set time over a period of six hours at room temperature (Figure 19). At two
hours of bench set time, platelets in the PRP began to appear less normal and formed
small-aggregates that suggest platelet activation and growth factor release. The loss of
GFs with bench set time is a concern for clinicians, because the whole blood is usually
collected at the start of a clinical procedure and the blood centrifuged before coagulation
begins, despite the presence of trisodium citrate anticoagulant in the collection vessel.
Since it is well established that TGF-β1 stimulates osteogenesis, [7, 416, 417] a
significant loss of this factor or the bioactivity of this factor by the various PRP
preparation methods may account for the conflicting reports by clinicians concerning the
osseous generating efficacy of PRP use. ELISA results (Table 5) suggest that PRP bench
set times using our BC method of PRP preparation should not be of consequence up to a
maximum of 6 hours (Table 5). Photomicrographs (Figure 19) did reveal that with the
BC PRP technique platelets do begin to aggregate and possibly becoming activated after
2 hours of bench set time. The ELISA analysis in this study revealed no significant
change (p > .05) in any of the key growth factors examined, including TGF-β1.
Researchers have reported that TGF-β1 activity decreases when prepared using bovine
thrombin. We feel that the decreased TGF-β1 activity experienced by others may be due
to: 1) natural hydrolysis, 2) degradation by proteases or 3) specific irreversible binding by
molecules that may be present in various preparations of PRP. We hypothesize that
bovine thrombin activates latent TGF-β1 and therefore may become subject to all of the
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above. The technique examined here does not use bovine thrombin as an activator for
that reason.
Growth factor levels obtained in our study were generally higher than those reported
by other researchers (238). These findings may result from our analytical method for
treating the platelet lysates with diluted 0.5% Triton X-100 (TX-100) prior to adding the
samples to the ELISA plates. We believe that diluting the TX-100 lysates allowed for
lower binding interference by the detergent and allowed a maximal TGF-β1 signal from
the samples during ELISA analysis. In addition, the ELISA kit for TGF-β1 analysis
utilized a monoclonal capturing antibody, whereas other researchers used kits employing
Type II TGF-β1 receptor or polyclonal anti-TGF-β1 capturing antibodies to detect the
growth factor. We believe these differences, in addition to not adding bovine thrombin,
may account for the higher TGF-β1 yields in our study.
The second investigation of this dissertation was a retrospective analysis of 904
mandibular extraction sites. The study revealed the beneficial effects of PRP in reducing
the incidence of alveolar osteitis (AO). AO is believed to be due to either premature
contraction of the blood clot within the socket or a localized infection. Multivariate
analysis (Figure 22) revealed the odds of AO formation was 2.37 times higher for
extraction sites without PRP treatment (95% CI, 1.3 to 4.4) than those with PRP
treatment were. Bivariate analysis (Figure 21) demonstrated that extraction sockets
treated with the immediate placement of a gelled BC PRP resulted in a significant
decrease (p < .00043) in AO. The beneficial effects of PRP treatment that resulted in a
reduced incidence of AO may be related to the variety of growth factors found in PRP
that stimulate cell mitosis and differentiation [452], increased collagen production,
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recruitment of leukocytes and other cells to the surgical site, and initiation of vascular ingrowth (15). The presence of these growth factors in PRP promotes both soft and hard
tissue healing and angiogenesis, all critical to the prevention of AO. In addition, the
platelets found in PRP promote clot formation and the white blood cells found in PRP
can inhibit bacterial growth. Therefore, PRP application may reduce the currently
accepted causes of AO by facilitating clot and soft tissue formation and inhibiting
bacterial colonization.
Multivariate analysis (Figure 22) also revealed that in addition to the absence of PRP
administration, there were three other significant risk factors for AO: bruxism, oral
contraceptive use, and complete impaction. Oral contraceptive use and complete
impaction had been reported in the literature previously as being risk factors for AO (392,
492). Bruxism had not been reported previously as a causative factor for AO. PRP
treatment reduced the incidence AO formation associated with each of these other factors
by approximately 50% (Figure 22). The reduction was again most likely due to the
variety of growth and other factors found in PRP that promote hard and soft tissue
healing and decreased healing time. As mentioned previously in this dissertation there
are PRP variants that may affect the growth factor content (234, 235, 238). Some of
these variants do not contain WBCs and therefore they may not be as effective in
preventing AO. In addition, if GF concentrations were to decrease below a critical
concentration with some PRP variants, then that particular PRP variant may not
significantly reduce AO formation. Our gelled BC PRP variant contains both WBCs and
GFs; therefore, it is difficult to predict how other PRP variants would affect AO
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formation. We conclude that not using gelled BC PRP following tooth extraction is the
most important risk factor for AO formation.
The molecular study highlighted two important aspects of PRP- first, increased
proliferation of hMSCs and second, PRP does not stop hMSC differentiation into the
terminal osteoblast.
Cell count studies (Figure 25) confirmed the early proliferative effects of a 24-hour
PRP exposure on hMSCs. PRP treated cells had a 3.2 fold increase in cell number over
cells cultured in growth medium alone The BC-PRP technique compared favorably with
(and actually surpassed in some aspects) the results of the MTT proliferation studies of
Lucarrelli et al. (106) and Graziani et al. (328). The Lucarrelli and Graziani studies used
bovine thrombin and calcium gluconate to activate platelets in their PRP. The results of
our study brings into question whether it is in fact necessary, or beneficial, to activate the
platelets through these methods. As discussed in the introduction, there are several
reasons not to use bovine thrombin including: development of antibodies against
thrombin, prothrombin, factor V, cross reactivity with analogous human coagulation
proteins, and decreased PRP TGF-β1 concentrations. It is highly likely that in vivo,
platelets from the BC technique are activated by collagen, thrombin, fibronectin, ADP,
and thromboxane A2 present at the surgical site. Therefore, based on the results of this
study and the drawbacks of bovine thrombin, the addition of bovine thrombin to PRP is a
questionable clinical practice.
The significant (p < .001) increase in cellular total RNA production seen with PRP
treated groups and not with non-PRP treated groups at day 5 (Figure 27 A) strongly
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suggests that the presence of WBCs in PRP may be a confounding factor and therefore
distorting the true increase in total RNA due to increased cellular metabolism. WBCs
have RNA and vital WBCs would be making mRNA that may be inflating what is
thought to be the cellular total RNA concentration. WBCs may have accounted for over
50% of the total RNA increase observed. Further study separating the platelets and
WBCs will help discern the true effect of the platelets on total RNA production. This
could be accomplished by using a Ficoll™ separating gradient to separate the WBCs and
platelets. The project would be greatly improved by using alternate methods to determine
cell proliferation, such as the use of the CellTiter-Glo® Luminescent Cell Viability Assay
that is a homogeneous method of determining the number of viable cells in culture based
on quantification of ATP present (444, 445).
Cell differentiation was measured by two methods: 1) alkaline phosphatase assay
(ALP), an early differentiation marker and 2) examination of the expression of specific
mRNAs signifying osteoblast formation. The ALP assay (Figure 28) suggested that PRP
does not stop differentiation when differentiation signals are present in vitro. When
normalizing for cell number by considering percent confluence of cells (Figure 29), it
appears that PRP does not induce differentiation for hMScs in growth medium. ALP
activity did not increase at either Day 5 or 15 for cells cultured in growth + PRP medium
when compared to growth medium. However, at Day 5 differenentiation + PRP medium
did show ALP activity but it was lower than that seen with differentiation medium. At
Day 15, the ALP activity for differentiation + PRP medium was similar to that seen with
differentiation medium. Therefore, it can be suggested that PRP does not induce
differentiation, but neither does it stop differentiation when the proper differentiation
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signals are present. This study cannot clearly state if differentiation is decreased or if the
level of ALP activity with PRP-treatment of hMSCs meets that of differentiation medium
at any specific time point. Day 5 ALP activity was diminished when compared to
differentiation medium, yet Day 15 ALP activity was similar, it may be suggested that
future studies should include several time points to determine if PRP treated cells express
the same peak ALP activity seen with differentiation medium at a similar or different
time point. It may be suggested that PRP induces proliferation during the initial 5 days
and therefore delays differentiation when differentiation signals are present. Since
proliferation and differentiation of cells cannot occur simultaneously, a question to be
addressed is does the proliferation signals of PRP override the differentiation signals of
differentiation medium, and if so for how long. The clinical use of PRP may be
improved by following PRP treatment with an agent that further enhances differentiation
and shifts it to a shorter time than normally occurs physiologically. The ALP studies may
not reflect consistent findings, because ALP activity was not normalized for cell number
or total protein. The cell number issue that must be corrected in future studies. Another
question to be examined is what effect continuous or intermittent PRP exposure would
have on differentiation.
PRP treatment increased relative mRNA expression at day 21 for two osteoblast
differentiation gene markers, osteocalcin and bone sialoprotein (Table 11). Bone
sialoprotein mRNA relative expression was greater than that of osteocalcin. Bone
sialoprotein is expressed earlier than osteocalcin. Therefore, we may be witnessing the
peak of the bone sialoprotein mRNA expression and the osteocalcin mRNA peak is yet to
appear. Differentiation medium exceeded the relative expression of these two gene
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mRNAs when compared to growth + PRP medium. However, differentiation medium
did not attain the levels of relative expression that the differentiation + PRP treatments
did. Therefore, this data suggests that at Day 21 (Table 11), PRP may induce
differentiation when added to growth medium and it may enhance differentiation when
added to differentiation medium. The expression of these mRNA markers signifies that
differentiation down the osteogenic pathway has occurred, but it does not assure that
functional osteoblasts have been created. We can only assume that the bone sialoprotein
and osteocalcin proteins would be synthesized by these terminally differentiated cells, but
we cannot be certain without doing an assay of these proteins.
The 5- and 10-day time points for evaluating differentiation gene markers (Table 11)
with PRP treatment could not be determined due to the GAPDH levels being elevated,
which are likely due to the WBCs providing additional housekeeper gene (GAPDH)
expression. This finding was surprising and, therefore, future studies may be beneficial
utilizing a gene whose expression is not affected by PRP treatment. The use of a more
appropriate housekeeper gene would provide useable mRNA data. An alternative would
be to use a leucodepleted PRP technique, but then we would lose the ability to confirm
the effect of WBCs and its released factors on hMSC differentiation.
The molecular study confirmed that a 24-hour PRP treatment significantly increased
proliferation and suggests that it does not stop differentiation. Additionally, it provided
evidence that proliferation occurs at a significantly earlier time point than what is
normally found for cells using growth medium (Figure 25).
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The clinical prospective study utilized both digital radiographs and CT scans to
determine the effect of PRP treatment on bone density. The digital radiograph analysis
demonstrated that PRP treatment in mandibular third molar extraction sites did have a
significant effect (p < .001) on changes in bone density in comparison to baseline values
for the first 2 weeks following application at the time of surgery Figure 39). Two-way
ANOVA showed that time and PRP treatment for the entire 25-week study were both
significant and that time and treatment were independent of each other (Figures 39 and
48). Of interest is that bone density in the PRP-treated side was observed to increase
during the initial 3- day post-operative digital radiographic observation, whereas the
control side experienced an initial decrease in bone density before returning to baseline at
the 2-week time point. The control sites did not reach the same change in bone density as
the PRP treated sites at week 1 until approximately weeks 4 to 5. Additionally, in the
long term, it took the control side 16 weeks to reach the same percent change in bone
density that the PRP treated site had achieved by 8 weeks. Based on this result, the
clinician may not have to allow for 6 months healing time prior to initiating implant
placement surgeries, but rather may be able to perform implant placement after 2 to 3
months.
CT scan analyses were performed on three patients at each of the following times:
10.5, 14, and 18 weeks. Three parameters were examined, including total percent bone
fill (Figure 43), newly formed bone density (NFBD) (Figure 44), and total formed bone
density (TFBD) (Figure 45). When comparing averages for the three CT scans the
percent bone fill for PRP-treated sites had significantly greater percent bone fill than the
control sites (p < .05). When examining individual CT scans the total socket bone filled
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bone density and newly formed bone density were not significantly different between
PRP treated and control sites (p > .05). This is not surprising because CT scans were
taken at later time points 10.5-, 14-, and 18-weeks and normal bone modeling takes
approximately 16 weeks. The 10.5-week CT scan had markedly less total formed bone
density and newly formed bone density than later CT scans, but when combining the
three-time point scans together, there was no significant difference between sites. The
results may have been different had the CT scans been obtained at earlier time points.
Therefore, the results of the digital radiographs and the CT scan analysis suggest that
the BC PRP technique does enhance bone formation at an earlier time point than sites not
treated with BC PRP. It can also be recommended that when deciding on time points for
evaluating the effectiveness of PRP treatments that bone formation endpoints should be at
earlier time points (0 to 12 weeks) and not at later time points (14 to 24 weeks).
Patients’ perception of pain, bleeding, numbness, facial swelling and external skin
temperature was not significantly different between PRP treated and control sites.
Moreover, the observers’ perception of patient pain, tissue opening, bleeding,
inflammation, facial edema and intra-oral edema was similar to the patients’ perception.
There was no significant difference between the two treatment sites in dehiscence,
bleeding, intra-oral edema, and perceived pain and there was great similarity between
patients and observers pain perception values, although the observers gave slightly higher
scores. The PRP treated sides did demonstrate significantly less inflammation and facial
edema in comparison to the matched control side (p < .05). The findings that both of
these items were significant are not surprising since edema is a clinical sign of
inflammation.
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The in vitro portions of this study offer a validation of the BC PRP technique and
possible mechanistic explanation as to why the method significantly decreases AO
formation (Figure 21) and significantly enhances radiographic bone density (Figure 39)
and bone fill (Figure 43). Confirmation that platelets and WBCs are concentrated with
the use of the clinical centrifuge (Figures 16 and 17), knowing that platelet morphology
is not disturbed during collection and centrifugation (Figure 24) validates the use of this
centrifuge for BC PRP preparation. The confirmation of the presence of growth factors
(PDGF-BB, TGF-β1, EGF, and VEGF) in the BC PRP preparation (Figure 20 and Table
5) is of importance because each of these GFs are known to play an important role in
healing (102, 104-106, 109-111, 116, 117, 125, 135). The prospective clinical study of
the effects of PRP is consistent with the results from the cell culture study and the
retrospective clinical analysis. The prospective clinical study results of increased
radiographic bone density with PRP treatment at early time points (Figure 39) correlates
well with the in vitro findings of early cell proliferation (Figure 25) followed by possible
differentiation. There was also a correlation between the retrospective clinical AO study
and the prospective clinical study. The increase in bone density during the first 2 weeks
in the prospective study is most likely due to the presence of multiple GFs found in PRP
that stimulate hMSCs to proliferate with eventual differentiation into osteoblasts.
Additionally, GFs contained in PRP facilitate by the formation of soft tissue (493) that
would help preserve thrombus (clot) formation thereby lessening the likelihood of AO.
The application of PRP has great clinical utility because it appears to decrease the risk
of complications by closing the window of vulnerability early during post-operative
healing. There are clinicians who anecdotally claim that PRP does not work and there are
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those who say that it does. They may both be correct. Clinical success with PRP may be
due partially to PRP processing technique and/or the temporal end-point used as a
measurement tool for improved bone formation. If the temporal endpoint for measuring
bone formation is beyond 12 to 14 weeks, there may not be an observable difference
between PRP treatment and control.
The in vivo conditions cannot be duplicated in the in vitro environment. Therefore
these studies focused on the effects of PRP on hMSCs and their differentiation into
osteoblasts. Clinically, PRP may have an effect on osteoclasts in addition to osteoblasts.
In the Preparation and Characterization (Study I) section of this dissertation
osteoprotegerin (OPG) was found(Table 5), but it could not be quantified as it was below
the detectable limits of the standard curve. OPG has been reported in murine platelets
(494),but not human platelets. If OPG were present in human platelets and at effective
concentrations, then PRP would effect osteoclasts as well. OPG is known to inhibit the
maturation of osteoclasts (495). Therefore, an additional explanation for the early
increase in bone density seen in the prospective study with PRP-treatment may be that
OPG (if present) would interfere with the normal bone healing process of initial bone
breakdown by osteoclasts. Osteoclasts free necessary osteoblast stimulating factors from
the bone matrix, therefore beginning the bone healing process (496). This explains the
initial drop in bone density observed at the non-PRP-treated sites in the prospective
study. OPG would block this initial bone breakdown. Therefore, with future studies it
may be determined that hMSC proliferation and possible differentiation is a partial
mechanistic answer and that PRP possibly has an effect on osteoclasts as well.
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Conclusion
This study confirms that a simple and cost-effective technique for concentrating
platelets when performed properly will not alter platelet morphology or growth factor
contents. Additionally, the BC-PRP methodology significantly decreased the formation
of AO when applied immediately to tooth extraction sockets and facilitated the process of
soft and hard tissue healing. This facilitation was most likely due to the enhanced
proliferation and enhanced differentiation of stem cells mediated by growth factors
released by PRP at the surgical site. Since PRP application facilitates healing there is less
opportunity for the occurrence of complications such as AO or delayed bone formation.
Based on our prospective study results the effects of PRP are optimal during the first two
weeks following application. This correlates well with the proliferation of hMSC during
the initial 5 days and enhanced differentiation seen at Day 21following exposure to PRP
treatment. Patients and clinicians would benefit from the use of PRP in oral surgical
procedures. This BC PRP technique may have applications in other types of surgery
requiring bone healing.
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Appendix 1
Institutional Review Board Forms
A. IRB Cover letter
December 1, 2004
Institutional Review Board
403 Administration Building
Duquesne University
600 Forbes Avenue
Pittsburgh, PA 15282
Dear IRB Members:
This Investigational Review Board application is being submitted to permit us to validate
a dental surgical procedure that is currently being done by some dental practitioners.
This clinical research project would provide a scientific examination of the effectiveness
of this procedure. In the procedure, a small quantity of blood is drawn from each subject
and centrifuged to concentrate the patient’s own platelets. This would be done prior to
the surgical removal of bilateral mandibular (lower jaw) third molars. Platelets contain
multiple growth factors that may be beneficial in the healing process. This blood
drawing procedure would be exactly the same as that performed by many hospital
laboratories, medical offices and a few dental practitioners today. Most dentists simply
remove the tooth and do not necessarily place anything into the tooth extraction site,
while some practitioners will place the concentrated platelets and the growth factors
contained within them, into the extraction site to accelerate healing. It may be that postoperative complications are prevented by the addition of these concentrated platelets into
the surgical site. Each patient would be his/her own control. One side would receive the
concentrated platelet treatment while the contra-lateral side would not. There would not
be any new or novel treatments involved in this project. The FDA currently approves the
use of PRP in dental surgical procedures. This project would help provide scientific
validity for providing the additional platelet treatment.
Thank you for your time and consideration with this application. If we can provide any
additional information, please do not hesitate to contact us.
Respectfully,
James L. Rutkowski, D.M.D.
E-Mail: james.rutkowski@verizon.net
Home: 814-226-8691
Office: 814-226-8690

David A. Johnson, Ph.D. (Co-Investigator)
E-Mail: johnsond@duq.edu
Office: 412-396-5952
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B. IRB Submission Form
Research Question:
The research question to be answered is: Does the placement of autogenous platelet rich
plasma (PRP) in the surgical site enhance the soft tissue healing and radiographic density
following the removal of bilateral, mandibular third molars? The radiographic density
would be a measure of bone density and maturity. The purpose of the study is to verify
the validity of obtaining and placing autogenous PRP in recent extraction sites to
decrease post-operative complications and hasten bone formation for future dental
implant placement. If a significant difference is found between a control extraction site
(no treatment) on one side versus a treated PRP contra-lateral side, then it would give a
scientific basis for the continual and possibly expanded use of this technique in other oral
surgical procedures. Currently, extraction sites are often left untreated which may result
in multiple complications such as:
1.
2.
3.
4.

delayed healing of the soft tissue
soft tissue invasion of the extraction site
delayed and/or decreased bone formation
and infection.

Many times, dental implantologists treat extraction sites with allografts (bone from
cadavers), xenografts (bone from another species, such as bovine), or synthetic grafts.
Barriers such as teflon sheets, collagen, or cadaver bone sheets are placed over these
grafts to prevent the invasion of soft tissue into the extraction site. These procedures are
costly, difficult to perform, unpredictable in the presence of an existing infection, and
time consuming. Autogenous PRP is often mixed with these grafting materials. The
literature is divided on the benefits of using PRP with this procedure. Some practioners
have anecdotally place autogenous PRP only in extraction sites and report improved soft
and hard tissue healing. If the PRP treated sites do demonstrate improved healing, then
this would offer a predictable treatment protocol for all extraction sites.
Research Design and Procedures:
This research will be based on the use of a bilateral 3rd molar extraction human model.
The primary investigator, in a private dental office, will perform the clinical procedures.
The following criteria (protocol) will be followed on all patients:
1. Procedures will be done with intravenous (IV) sedation.
2. After sedation, but prior to administration of other medications or
commencement of surgery, the researcher will perform a venous puncture in the
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arm opposite the IV administration site, so that two 4.5 mL tubes of whole
blood can be drawn. These tubes will be drawn via the use of a disposable
VacutainerTM with a 21 gauge 1 ½ inch beveled needle. One tube will be used
for a whole blood platelet count (PC) for baseline values. The other tube will be
centrifuged for 10 minutes in the Clinaseal CentrifugeTM. The PRP will be
removed, from the centrifuged tube, and placed in only one of the extractions
sites after completion of the tooth removal. The contra-lateral extraction site
will be treated by a traditional procedure that does not include the use of PRP.
3. Patients will be administered either AncefTM 2.0 gram or Clindamycin 600 mg.
immediately pre-operative via IV.
4. Adequate local anesthesia will be obtained by the use of mandibular blocks and
local infiltration. This is normally achieved with the use of three to four 1.8
mL. carpules of the lidocaine 2% with epinephrine 1:100,000 for each surgical
site.
5. To help prevent excessive post-operative inflammation, patients will be
administered dexamethasone 4-8 mg. IV pre-operatively and methyprednisolone
acetate suspension 40 mg. IM immediately post-op.
6. Patients will be given ToradolTM 30 mg. IV immediately post-op.
7. Immediate post-operative bilateral Gow-Gates mandibular block injection using
1.8 ml. of bupivacaine 0.5% with 1:200,000 epinephrine will be administered
to prevent immediate post-op pain.
8. Bilateral 3rd molars of a similar eruptive state and angulation will be removed
(both sides must be either impacted or erupted).
9. After removal of the teeth, a periapical (small) digital radiograph (Dentsply
GendexTM) will be taken of each side, using an XCP mount with documented
KVP and time settings to determine a baseline gray scale at each extraction site.
Digital radiographs will be used for two reasons: 1. the technique will allow for
consistent radiograph opacity and evaluation and 2. it exposes patients to only
25% of the radiation used with conventional radiography. A correlation of bone
density will be confirmed during the study with computerized axial tomography
scanning technology (CAT scan) and computer reformatting for bone density
determination via Hounsfield units (HU) on 3 patients. Because of the need to
evaluate the post-operative bone healing, participants in this study will be
exposed to 22 digital peri-apical radiographs, and some participants will also be
required to get a limited CAT scan analysis of the extraction sites. Patients not
involved in this study would not normally receive these radiographs. The
radiation exposure of these 22 digital radiographs is equivalent to that received
with 6 traditional peri-apical dental radiographs.
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10. The control side will be treated immediately post-extaction as follows:
a. Digital radiograph
b. Place GelfoamTM only
c. Primary closure with 3-O chromic gut suture material.
11. The contra-lateral side will be treated immediately post-extraction as follows:
a. Digital radiograph
b. Injection of 200 L of PRP into the extraction site.
c. Placement of GelfoamTM moistened with 100 L PRP.
d. Primary closure with 3-O chromic gut suture material.
12. Dismiss patient with a grade card for notations every 8-hours for 3 days, then
notations every 12 hours for the following 4 days. Each side will be graded for:
a. Visual analogue scale (VAS) for pain
b. Number of and type of analgesic tablets taken
c. Temperature (external feeling of warmth)
d. Facial swelling
e. Bleeding
f. Numbness or altered sensation of tongue, face, lip or chin.
13. Patient will return in 3 days for a post-op grading scale evaluation for each side
by a licensed dental hygienist that is blinded to the study. The PI (who would
not be blinded) will also examine the patient, but will not be involved in the
grading process. The following will be graded:
a. Dehiscence (degree of opening)
b. Inflammation
c. Bleeding
d. Pain
e. Swelling intra-oral and extra-oral
14. Patient will return 7 days post-op for the above evaluations plus
digital radiographs (same protocol as immediate post-op)
15. The above will be repeated at weeks 2, 3, 4, 6, 8, 12, 16, 20, and 24.
16. Starting at 6 weeks post-op periodontal probe readings will be recorded for the
bilateral mandibular 2nd molars.
17. Three of the patients will have mandibular CAT scans performed at a local
hospital at post-op week 12. This would allow for verification of the gray scale
from digital radiography with the bone density HU of the CAT scan.
Sample Selection and Size:
All patients will be between ages 18-40 and with a negative medical history and nonsmokers. Six patients will be included in the study.
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Recruitment of subjects:
Subjects will be recruited from the PI’s private practice. Patients who meet sample
selection criteria and in need of the removal of mandibular third molars, will be asked if
they would like to enroll in the study. After the completion of their radiographic
examinations, subjects will receive a $250.00 remuneration. Risks/benefits will be
explained in detail to all patients. Patients will be given the opportunity to have questions
answered prior to surgery. Attached is a recruitment hand-out that will be given to
potential candidates.
Informed Consent Procedures:
Standard intravenous sedation consent and surgical third molar removal consent forms
will be used (see attached forms). HIPAA acknowledgement consent forms will be used
(see attached form). Subjects will also be informed of the need to have two 4.5 mL tubes
of whole blood drawn prior to surgery. They will also be informed for the need to:
1. complete post-operative questioners
2. permit post-operative digital radiographs and a possible limited CAT scan of
the mandible
3. report for follow up evaluations.
Please see the attached post-operative evaluation forms for the study participants. A
certified dental assistant will explain the sedation and surgical procedures to be
performed. This same dental assistant will go thru the consent forms line by line, as is
normally done with non-study patients. The researcher (Dr. Rutkowski) will be present
and available to clarify any terms and answer questions that subjects may have.
Collection of Data and Method of Data Analysis:
Data will be collected for the following items:
1. Patient self-evaluation for:
a. Visual analogue scale (VAS) for pain
b. Number of and type of analgesic tablets taken
c. Temperature (external feeling of warmth)
d. Facial swelling
e. Bleeding
f. Numbness or altered sensation of tongue, face, lip or chin.
2.

Investigator evaluation of:
a. Dehiscence (degree of opening)
276

b.
c.
d.
e.
f.
g.

Inflammation
Bleeding
Pain
Swelling intra- and extra-orally.
Post-operative digital radiographs at 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24.
CAT scans on 3 of the subjects at week 12.

Data will be analyzed by a paired T-test or Mann-Witney U test. Data will be kept in
a
locked cabinet for 5 years, and then destroyed.
Issues relating to interactions with subjects and subjects’ rights:
Subjects will have the opportunity to ask questions prior to surgery and then decide to
participate or not. Subjects’ needs for pain control, post-operative examinations, further
treatment, and referrals will be the same as those extended to all non-research patients. If
subjects do not wish to partake in the study, they will be given the opportunity to be
treated as routine (non-research) patients. All records or data with names associated will
be stored in a locked cabinet, which only the researcher has access. No name identity will
be made in the data analysis.
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C. Wisdom Tooth Study Announcement

LOWER WISDOM TOOTH SUDY

If you are between the ages of 18 and 40 and need your lower wisdom teeth removed,
you may be eligible to participate in a study that involves the removal of lower wisdom
teeth. The study compares two techniques currently used by dentists when removing
these teeth. Both techniques remove the teeth by the same surgical principles, but upon
closure of the extraction sites one technique utilizes a self-dissolving surgical plug and
sutures, while the other technique utilizes concentrated blood products (platelets and
growth factors) taken from the patient via a standard blood drawing technique. The
method that utilizes the blood drawing technique is believed to enhance the healing
process and decrease post-operative complications. Retrospective studies appear to
support this believe. This project would compare the two techniques in the patient. One
side from the removal of the wisdom teeth would receive the traditionally used technique
of a self-dissolving surgical plug and sutures. The other side would receive the blood
products that had been concentrated, the self-dissolving surgical plug and sutures. We
must emphasize that the blood products are taken from the subject’s own blood. Two
small tubes of blood would be drawn from the patient’s arm just prior to starting the
extractions. The blood would be centrifuged and a layer of concentrated platelets would
be removed and placed in the surgical site. To be eligible for this study you must be:
1.
2.
3.
4.
5.
6.
7.
8.

in need of the removal of two lower wisdom teeth
willing to participate in the study under your own free will
between the ages of 18 and 40
in good health
not taking any medications prior to the removal of the teeth
willing to have 2 small tubes of blood drawn from your arm
willing to be sedated for the tooth removal
willing to have a series of 10 digital radiographs taken over a 6 month period of
time after the surgery
9. the possibility of having a CAT scan at a local hospital 3 months after the
surgery
10. complete a post-surgical evaluation form for pain, swelling, and other
complications for 4 days after the removal of the teeth
11. present for routine post-surgical in-office evaluations by our staff over a 6 month
time period.
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You would be free to leave the study at any time if you should so desire. If you complete
the study you would receive a $250.00 remuneration at the conclusion of the final 6
month radiograph and post-op evaluation.

If you are interested in learning more about the possibility of your involvement in this research
project, please contact: James L. Rutkowski D.M.D.

35 South Second Ave.
Clarion, Pa. 16214
Phone: 814-226-8690
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D. Third Molar Consent Form

THIRD MOLAR/PRP RESEARCH PROJECT
CONSENT FORM

This consent form consists of four (4) parts:

1. Third molar removal consent form that includes possible surgical and
post-operative complications.
2. Intravenous conscious sedation consent form that includes possible
sedation risks.
3. Intravenous conscious sedation patient information sheet.
4. Health Insurance Portability and Accountability Act (HIPAA)
acknowledgment form.

All forms are to be completed and signed by a patient or legal guardian, prior to
participation in the study.
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Appendix 2
Patients’ Post-Surgical Evaluation Form

PARTICIPANTS POST-SURGICAL EVALUATION FORM

Post-surgical grade card for participants of the research project titled: “Effects of Growth
Factors on Cell Proliferation and Differentiation with Radiographic Analysis of Tooth
Extraction Socket Fill Utilizing Autogenous Growth Factors”
(To be completed by the participant. A new form should be completed every 8
hours for the 1st 3 days, then every 12 hours for the next 4 days.)

Patient ID: _______________ (Do not use your name only use the ID # assigned to you)

Date:____________________

Time:____________________

A. Visual analogue scale for pain
(Please place circle the number that represents your perception of the pain you are
currently experiencing. 0 = no pain; 10 = severe pain)

0…….1…….2…….3…….4…….5…….6…….7…….8…….9…….10

B. Please check analgesic tablets and number taken since surgery (if this is your first
report) or since your last report
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Check if any of
the following
were taken

Strength (dose)
Analagesic

Quantity

Advil

200 mg

Alleve

200 mg

Darvocet-N 100

100 mg

Ibuprofen

200 mg

Nuprin

200 mg

Percocet

Percodan

Tylenol regular
strength

325 mg

Tylenol extra
strength

500 mg

Tylenol with
Codeine ½ grain

325/30

Viocodin

500/5

Vicodin ES

750/7.5

Vicodin HP

660/10
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Check if any of
the following
were taken

Strength (dose)
Analagesic

Quantity

Other please
specify

C. Left: Temperature _________oF

Right: Temperature _________oF

D. Swelling (Please circle the best description)

Left: Slight……..Moderate………Severe
Slight……..Moderate………Severe

Right:

E. Bleeding (Please circle the best description)

Left: Slight……..Moderate………Severe
Slight……..Moderate………Severe

Right:

F. Numbness or altered sensation of tongue, face, lip or chin. (Please give location
and circle the best description(s)
Location________________ Slight……..Moderate………Severe

Location________________ Slight……..Moderate………Severe
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Appendix 3
Observers’ Post-Surgical Evaluation Form

OBSERVERS POST-OP EVALUATION FORM
Post-surgical evaluation sheet for participants of the research project titled; “Effects of
Growth Factors on Cell Proliferation and Differentiation with Radiographic Analysis of
Tooth Extraction Socket Fill Utilizing Autogenous Growth Factors”
(To be completed by the blinded Dental Hygienist on post-op days 3 & 7, plus weeks
2,3,4,6,8,12,16,20 & 24.)
Patient ID:_____________________________(Do not use patient’s name)

Date:_________________________________

Time:_________________________________

Dental Hygienist ID:_____________________

A. Dehiscence (degree of opening): Site #17___mm opening; Site #32____mm
B. Inflammation: (degree of)

Circle the best description.

Left side: Slight….Moderate....Severe;

C. Bleeding: (degree of)

Right side: Slight….Moderate....Severe

Circle the best description.

Left side: Slight….Moderate....Severe;
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Right side: Slight….Moderate....Severe

C. Pain (Observers perception of pain at the time of visit)
Circle the number that best describes the observed pain (0 = no pain; 10= severe
pain)

Left side: 0….. 1.….2…….3…….4…….5…….6……..7…….8…….9…….10

Right side: 0…..1.….2…….3…….4…….5…….6……..7…….8…….9…….10

D. Swelling (extra-oral)

Circle the best description.

Left side: Slight….Moderate....Severe;

E. Swelling (intra-oral)

Right side: Slight….Moderate....Severe

Circle the best description.

Left side: Slight….Moderate....Severe;
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Right side: Slight….Moderate....Severe

Appendix 4
Percent Radiographic Density Changes of Surgical ±PRP
Treatment Compared to Control Radiograph Taken Immediately
Following Tooth Removal in Six Trial Patients
In all graphs, percent bone density change on the Y-axis represents the change in bone
density that has occurred at the extraction site in comparison to the extraction site
immediately after tooth removal and placement of the Gelfoam® sponge ± PRP and
suturing. Digital radiographs were normalized to the immediate post-operative film by
comparing the unaltered adjacent tooth on the time point radiograph with the immediate
post-operative radiograph’s corresponding unaltered tooth. Each digital radiograph was
evaluated by 3-blinded evaluators. Patients are coded as Patients 1,2, 5,6, 9, and A.
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Appendix 5

Representative Real Time RT-PCR Results for Day 21 Bone
Sialoprotein Gene (IBSP) Expression in Growth, Growth + PRP,
Differentiation, and Differentiation + PRP media
The reaction protocol was completed in a Bio-Rad Chromo4 Real Time Detection
System® using the iScript One-Step RT-PCR Kit® (Bio-Rad, Hercules, CA). Each
reaction mixture contained 100 nM RNA. The 50 μL reaction mixture was placed in the
thermal cycler and incubated at 55°C for 10 minutes, 5 minutes at 95°C for cDNA
synthesis and reverse transcriptase inactivation. The PCR cycling was completed after 45
cycles; 10 seconds at 95°C, 30 seconds at 57°C. A melt curve analysis was completed; 1
minute at 95°C, 1 minute at 55°C, and 10 seconds at 55°C for 80 cycles, increasing 0.5°C
each cycle. Data were analyzed using MC Opticon® software. Panel A represents the
melt curve for bone sialoprotein gene (IBSP) in growth medium, growth + PRP medium,
differentiation medium, and differentiation + PRP medium. The peaks are all relatively
close over a specific high temperature range indicating amplification of one specific
product in the PCR reaction. The specific, thermodynamically stable product is
represented by the single peak followed by the sharp decrease in fluorescence at the
higher temperature range. Panel B represents cycle expression (C T) for the same gene in
the same media. The CT cycle was defined automatically by the iCycler software.
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